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Stress and Rab35 modulate Alzheimer’s disease-related protein trafficking 
Viktoriya Zhuravleva 
 
 Chronic stress and elevated glucocorticoids (GCs), the major stress hormones, are risk 
factors for Alzheimer’s disease (AD) and promote AD pathomechanisms in animal models. 
These include overproduction of synaptotoxic amyloid-β (Aβ) peptides and intraneuronal 
accumulation of microtubule-associated protein Tau. Tau accumulation is linked to 
downregulation of the small GTPase Rab35, which mediates Tau degradation via the 
endolysosomal pathway. Whether Rab35 is also involved in stress/GC-induced Aβ 
overproduction remains an open question. Here, I find that hippocampal Rab35 levels are 
decreased not only by stress/GCs, but also by aging, another AD risk factor. Moreover, I show 
that Rab35 negatively regulates Aβ production by sorting amyloid precursor protein (APP) and 
β-secretase (BACE1) out of the endosomal network, where they interact to produce Aβ. 
Interestingly, Rab35 coordinates distinct intracellular trafficking events for BACE1 and APP, 
mediated by its effectors OCRL and ACAP2, respectively. Additionally, I show that Rab35 
overexpression prevents the amyloidogenic trafficking of APP and BACE1 induced by GCs. 
Finally, I begin to investigate how GCs and/or Rab35 affect the intercellular spread of Aβ and 
Tau through exosomes. I describe methods for purifying exosomes and measuring their secretion 
from neurons, astrocytes, and microglial cells in order to determine the effects of stress/GCs and 
Rab35 on this process. These studies identify Rab35 as a key regulator of Alzheimer’s disease-




Table of Contents 
 
List of Figures ............................................................................................................................ vi 
List of Tables .......................................................................................................................... viii 
Acknowledgments ..................................................................................................................... ix 
Chapter 1: General Introduction .................................................................................................. 1 
1.1. Stress and organismal homeostasis ................................................................................... 1 
1.1.1. Stress and glucocorticoid signaling ............................................................................ 1 
1.1.2. Chronic stress contributes to brain pathology ............................................................. 3 
1.2. Alzheimer’s Disease ......................................................................................................... 4 
1.2.1. Alzheimer’s disease pathology ................................................................................... 4 
1.2.2. Environmental risk factors for AD ............................................................................. 5 
1.2.3. Genetic risk factors for AD: Early-Onset Alzheimer’s Disease .................................. 6 
1.2.4. Genetic risk factors for AD: Late-Onset Alzheimer’s Disease .................................... 7 
1.3. Cellular mechanisms of Alzheimer’s Disease ................................................................... 8 
1.3.1. Aβ functions at the synapse ....................................................................................... 8 
1.3.2. Role of Tau in the neuron ........................................................................................ 11 
1.3.3. APP and BACE1 trafficking pathways lead to Aβ production .................................. 12 
1.3.4. Rab35 – a master regulator of intracellular trafficking ............................................. 14 
Chapter 2: Materials and Methods ............................................................................................. 18 
2.1. Methods used for Rab35-mediated endosomal trafficking experiments in chapters 3 and 4
 ............................................................................................................................................. 18 
ii 
 
2.1.1. Primary neurons and cell lines ................................................................................. 18 
2.1.2. Pharmacological treatments ..................................................................................... 18 
2.1.3. Lentivirus production, transduction, and DNA transfection ...................................... 19 
2.1.4. Flow cytometry........................................................................................................ 19 
2.1.5. Immunofluorescence microscopy ............................................................................. 20 
2.1.6. Proximity ligation assay ........................................................................................... 21 
2.1.7. Neuronal image analysis .......................................................................................... 21 
2.1.8. Aβ Measurements .................................................................................................... 22 
2.1.9. Animals ................................................................................................................... 22 
2.1.10. Immunoblotting ..................................................................................................... 23 
2.1.11. Retrograde trafficking assay................................................................................... 25 
2.1.12. Recycling assay ..................................................................................................... 25 
2.1.13. Steady-state surface protein measurement .............................................................. 26 
2.1.14. Bioinformatics analysis .......................................................................................... 27 
2.1.15. Statistical analysis.................................................................................................. 27 
2.2. Methods used for exosome experiments in Chapter 5 ..................................................... 28 
2.2.1. Primary neurons and cell lines ................................................................................. 28 
2.2.2. DNA transfection..................................................................................................... 29 
2.2.3. Dexamethasone treatments ...................................................................................... 29 
2.2.4. Exosome purification: Ultracentrifugation ............................................................... 31 
2.2.5. Exosome purification: Size-exclusion chromatography ............................................ 31 
2.2.6. Immunoblotting ....................................................................................................... 31 
2.2.7. Exosome measurements: Nanoparticle tracking analysis (NTA)............................... 32 
iii 
 
2.2.8. Exosome measurements: ExoView on-chip interferometry and antibody-based 
tetraspanin detection .......................................................................................................... 32 
2.2.9. Live Total Internal Reflection Fluorescence (TIRF) imaging ................................... 33 
2.2.10. Live imaging analysis ............................................................................................ 33 
2.2.11. Statistical analysis.................................................................................................. 34 
Chapter 3: Glucocorticoids reduce Rab35 expression, which impacts Aβ production................. 35 
3.1. Rationale ........................................................................................................................ 35 
3.2. Results ........................................................................................................................... 36 
3.2.1. Rab35 levels are decreased under conditions associated with Aβ overproduction ..... 36 
3.2.2. Rab35 is a negative regulator of APP-BACE1 interaction and Aβ production .......... 41 
3.3. Summary ........................................................................................................................ 51 
Chapter 4: Rab35 sorts APP and BACE1 into distinct trafficking pathways, which may be 
disrupted by stress/GCs ............................................................................................................. 53 
4.1. Rationale ........................................................................................................................ 53 
4.2. Results ........................................................................................................................... 54 
4.2.1. Rab35 promotes BACE1 trafficking through the retrograde pathway ....................... 54 
4.2.2. Rab35 stimulates APP recycling to the plasma membrane ....................................... 67 
4.2.3. Rab35 counteracts GC-induced pro-amyloidogenic trafficking of APP and BACE1 78 
4.3. Summary ........................................................................................................................ 83 
Chapter 5: Methods for isolating and measuring exosomes ....................................................... 85 
5.1. Rationale ........................................................................................................................ 85 
iv 
 
5.1.1. Aβ and Tau spread during AD progression .............................................................. 85 
5.1.2. Astrocytes and microglia impact AD pathology ....................................................... 86 
5.1.3. Exosome generation and secretion ........................................................................... 89 
5.2. Results ........................................................................................................................... 93 
5.2.1. Size-exclusion chromatography yields more EVs than serial ultracentrifugation ...... 93 
5.2.2. On-chip interferometry counts EVs and antibody binding reveals tetraspanin profiles
 .......................................................................................................................................... 96 
5.2.3. Microglia may secrete more exosomes than other cell types ..................................... 97 
5.2.4. pHluorin-tagged CD63 and CD81 allow for the monitoring of exosome release in real 
time ................................................................................................................................. 101 
5.2.5. GCs may increase exosome secretion..................................................................... 102 
5.3. Summary ...................................................................................................................... 106 
Chapter 6: Discussion and Future Directions ........................................................................... 108 
6.1. Discussion .................................................................................................................... 108 
6.1.1. Rab35 expression is reduced by stress and conditions associated with AD ............. 109 
6.1.2. Rab GTPases are associated with AD and amyloidogenic APP cleavage ................ 113 
6.1.3. Rab35 sorts APP and BACE1 into distinct trafficking pathways, respectively 
mediated by the effectors ACAP2 and OCRL .................................................................. 117 
6.1.4. Rab35-mediated APP and BACE1 trafficking – implications for Arf6-mediated 
pathways ......................................................................................................................... 121 
6.1.5. Stress/GCs disrupt Rab35-mediated trafficking pathways ...................................... 123 
6.2. Future Directions .......................................................................................................... 124 
v 
 
6.2.1. Stress/GCs and Rab35 in glial contributions to AD ................................................ 124 
6.2.2. Stress/GC effects on exosome secretion ................................................................. 125 
6.2.3. Exosomes as biomarkers ........................................................................................ 128 
Conclusion .............................................................................................................................. 131 





List of Figures 
Chapter 1 
 
Figure 1. Cleavage of APP through the amyloidogenic and non-amyloidogenic pathways. ....... 13 
Figure 2. APP and BACE1 intracellular trafficking. ................................................................. 14 
Figure 3. Rab35 activation cycle. ............................................................................................. 15 
Figure 4. Rab35 mediates endosomal trafficking pathways. ...................................................... 16 
Figure 5. Working model of Tau degradation through the Rab35/ESCRT pathway, and its 




Figure 6. Hippocampal Rab35 levels decrease under stress, Aβ infusion, and aging in rats. ...... 38 
Figure 7. Hippocampal Rab35 levels decrease under conditions associated with amyloidogenesis 
in humans. ................................................................................................................................ 40 
Figure 8. Rab35 overexpression in aged rat hippocampi reduces APP cleavage. ....................... 42 
Figure 9. Rab35 overexpression reduces APP cleavage in N2a cells.  ....................................... 43 
Figure 10. Rab35 overexpression suppresses amyloidogenic processing of APP in iPSC-derived 
cortical neurons. ........................................................................................................................ 44 
Figure 11. Rab35 reduces APP-BACE1 interaction in a screen using Venus Bi-Molecular 
Fluorescence complementation. ................................................................................................ 45 
Figure 12. Rab35 is a negative regulator of APP-BACE1 interaction in N2a cells. ................... 47 
Figure 13. Rab35 is a negative regulator of APP-BACE1 interaction in hippocampal neurons. . 48 




Figure 15. Rab35 does not alter degradation of APP, CTFs, or BACE1 in hippocampal neurons.
 ................................................................................................................................................. 55 
Figure 16. Retrograde trafficking assay timecourse for APP and BACE1. ................................ 58 
Figure 17. Rab35 does not affect APP retrograde trafficking in N2a cells. ................................ 59 
Figure 18. Colocalization between APP N- and C-terminus does not change throughout 
timecourse. ............................................................................................................................... 61 
Figure 19. Rab35 stimulates the retrograde trafficking of BACE1. ........................................... 63 
Figure 20. Rab35-mediated retrograde trafficking of BACE1 is mediated by the effector OCRL.
 ................................................................................................................................................. 64 
Figure 21. Rab35 regulates BACE1 endosomal distribution in hippocampal neurons. .............. 67 
Figure 22. Recycling assay timecourse for APP and BACE1. ................................................... 69 
Figure 23. Rab35 stimulates APP recycling to the plasma membrane. ...................................... 70 
vii 
 
Figure 24. Rab35 does not mediate BACE1 recycling. ............................................................. 71 
Figure 25. Rab35 effector OCRL does not mediate APP recycling. .......................................... 73 
Figure 26. Rab35 effector ACAP2 mediates APP recycling to the plasma membrane. .............. 76 
Figure 27. ACAP2 does not mediate the retrograde trafficking of BACE1. ............................... 77 
Figure 28. GC-induced APP-BACE1 interaction is blocked by Rab35 overexpression. ............ 79 
Figure 29. GCs do not affect BACE1 retrograde trafficking in N2a cells. ................................. 80 
Figure 30. GC-induced pro-amyloidogenic APP trafficking is reversed by Rab35 
overexpression. ......................................................................................................................... 81 
Figure 31. GC-induced pro-amyloidogenic BACE1 trafficking is blocked by Rab35 




Figure 32. MVB biogenesis machineries. ................................................................................. 90 
Figure 33. Putative role of Rab35 in exosome formation and secretion. .................................... 92 
Figure 34. Techniques used for purifying and measuring EVs. ................................................. 94 
Figure 35. Verification of exosome purification and comparison of ultracentrifugation versus 
size exclusion chromatography techniques. ............................................................................... 96 
Figure 36. ExoView on-chip interferometry and tetraspanin colocalization workflow............... 97 
Figure 37. IMG cells produce more EVs than primary cortical neurons, astrocytes, and N2a 
cells. ......................................................................................................................................... 99 
Figure 38. Exosomes from IMG cells are enriched in CD9. .................................................... 100 
Figure 39. Total Internal Reflection Fluorescence imaging of N2a cells expressing mCherry-
pHluorin-CD63. ...................................................................................................................... 102 
Figure 40. GC treatment does not affect total CD9+ and CD81+ exosome secretion or 
tetraspanin profiles in primary mouse cortical neurons. ........................................................... 104 









List of Tables 
Chapter 2 
 
Table 1. List of primary antibodies used for western blotting. ................................................... 24 








I could never have completed my Ph.D. without the support and constant mentorship 
from Dr. Clarissa Waites. Thank you for always being available to help with anything, from 
troubleshooting experiments to writing grants and preparing me for the next step in my career.  
I would like to thank Dr. João Vaz-Silva for beginning this project, being available for 
advice years after graduating, and always sending me files from experiments completed years 
ago so that I could pick representative images. I am also grateful for the collaboration with Dr. 
Ioannis Sotiropoulos and his lab, which contributed several experiments to this work, and aided 
in writing our manuscript. 
I would also like to thank the Neurobiology and Behavior program co-directors for 
helping me navigate the Ph.D, and my thesis committee members, Drs. Franck Polleux, Ai 
Yamamoto, and Ulrich Hengst, for the insightful questions that guided my research, and for 
telling me that I’m ready to graduate when I wasn’t even sure myself. 
To past and present members of the Waites, Hengst, and Israely Labs, thank you for 
everything I’ve learned from you, for the help you have provided, and for making our lab space a 
pleasant work environment over the years. 
Finally, a profound thank you to my friends and family for supporting me during my 
Ph.D. and not asking when I will be finishing my degree or what I’m planning to do with my life 
afterward. In particular, I would like to thank Lilian Coie, Remery A. Camacho, Eren Cameron, 
and Lisa Randolph for being my New York family throughout this journey, and especially during 





Financial support for the work presented in this thesis was provided by NIH grants 
R01NS080967 and R56AG057560 to Dr. Waites, and NIH/NINDS research supplement grant 
NS080967-2 to Viktoriya Zhuravleva. All animal treatments and preparations were conducted 
with grant support from Portuguese and European sources for Dr. Ioannis Sotiropoulos’s lab 
(University of Minho, Portugal). Drs. Cristina Mota, João Cerqueira and Fernanda Marques 
(University of Minho) provided hippocampal tissue. Dr. Subhojit Roy (University of California, 
San Diego, USA) provided APP:VN and BACE1:VC plasmids, and Dr. Andrew Sproul (Stem 
Cell and Cellular Models Platform, Taub Institute for Research on Alzheimer’s Disease, and the 
Aging Brain, Columbia University) provided iPSC-derived cortical neurons. The human aging 
RNAseq data were obtained from the Genotype-Tissue Expression (GTEx) Project, supported by 
the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, 
NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used in this manuscript were obtained 
from the GTEx Portal on 04/15/20 (dbGaP accession number phs000424.vN.pN). The human 
control vs. AD RNAseq data were obtained using a search of the NCBI GEO DataSets database 
(GEO accession number GSE159699; Nativio et al., 2020). Images for APP/BACE1 trafficking 
studies were collected on the confocal microscope in the Taub Institute Shared Resource 
microscopy center (Taub Institute for Research on Alzheimer’s Disease, and the Aging Brain, 
Columbia University), and TIRF images for exosome studies were collected in the Confocal and 
Specialized Microscopy Shared Resource Center of the Herbert Irving Comprehensive Cancer 
Center at Columbia University, supported by NIH grant #P30 CA013696 (National Cancer 
Institute). Schematics in figures 1-4, 7, 33, 34, 36-40, and 42 were made with BioRender.  
1 
 
Chapter 1: General Introduction 
1.1. Stress and organismal homeostasis 
1.1.1. Stress and glucocorticoid signaling 
Stress is an adaptive response to events that disrupt organismal homeostasis. In response 
to a stressor, glucocorticoids (GCs), the major stress hormones, are released by the adrenal 
glands. This process is regulated by the hypothalamic-pituitary-adrenal axis (McEwen, 2007), in 
which corticotropin-releasing hormone is released from the paraventricular nucleus of the 
hypothalamus, leading to adrenocorticotropic hormone release from the pituitary, and resulting 
in the release of GCs from adrenal gland cortices (Lupien et al., 2009). When GCs bind to 
receptors in the hypothalamus and pituitary, they inhibit the HPA axis, producing a negative 
feedback loop to prevent the continuous release of stress hormones (Lupien et al., 2009). 
In the brain, GCs are recognized by the glucocorticoid receptor (GR), which is expressed 
ubiquitously, and the mineralocorticoid receptor (MR), which is expressed in the hippocampus, 
prefrontal cortex, and amygdala, along with a few other select areas (Sotiropoulos et al., 2019). 
GCs have a ten-fold higher affinity for the MR, activating it at low concentrations, whereas the 
GR becomes increasingly activated with increasing levels of GCs (Joels & Baram, 2009; 
Sotiropoulos et al., 2019). MRs are therefore primarily responsible for initiation of the stress 
response and the immediate, non-genomic effects of GCs, as well as some gene-mediated 
processes. GRs, on the other hand, primarily contribute to slower, gene-mediated stress 
responses and to the termination of the stress response. They are involved in stress regulation and 
chronic stress response through their negative feedback on the HPA axis (De Kloet et al., 2008). 
The GR also serves as a transcription factor, activating or repressing genes by binding to DNA 
directly through glucocorticoid response elements, or indirectly through tethered binding by 
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other transcription factors (Meijsing, 2015). GRs are most densely expressed in the hippocampus 
(Ruel & De Kloet, 1985), and their prolonged activation under chronic stress dysregulates 
cellular processes, which can lead to synapse loss, altered glial function, and the progression of 
neurodegenerative diseases (Harris & Seckl, 2011; McEwen et al., 1986; McEwen et al., 2016; 
Sousa & Almeida, 2012; Veldhuis et al., 1982; Vyas et al., 2016). 
In the short term, stress responses are beneficial for modulating the transcription, 
translation, and degradation of specific proteins in cells, allowing organisms to deal with 
stressors and quickly return to homeostasis. However, long-term stress can disrupt cellular 
protein trafficking and maintenance processes (De Kloet et al. 2005). In neurons, proteins are 
primarily synthesized in the cell body and trafficked to the destinations where they perform their 
functions. Because neurons are morphologically complex, long-lived cells, it is of utmost 
importance that the protein trafficking machinery, itself made of proteins, works efficiently to 
transport each protein to its proper destination. Healthy cells are able to maintain their trafficking 
networks, but under stress, they must shut down or activate specific pathways to adapt and 
survive (Gundamaraju et al., 2018). For example, glucocorticoids regulate the transcription of 
genes encoding key proteins for synaptic vesicle recycling, such as synaptosomal-associated 
protein 25 (SNAP-25) (Datson et al., 2008). These processes allow cells to appropriately 
modulate neurotransmitter release at synapses under stress. Modifications to cellular pathways 
protect the brain in the short-term, but they can become dysregulated by chronic stress (De Kloet 
et al., 2005), though at the level of individual organisms, responses to stress challenges vary in 





1.1.2. Chronic stress contributes to brain pathology  
Chronic stress elevates GC levels and generates maladaptive cellular coping mechanisms 
that can produce neuronal damage. GR expression has been linked to stress susceptibility, 
indicating that brain GRs drive neuronal changes in response to chronic stress (Molteni et al., 
2010; Ridder et al., 2005). For example, reduced GR expression was found to dysregulate the 
HPA axis and to increase helplessness following stress exposure in mice (Ridder et al., 2005). 
Decreased GR levels also reduced the effects of stress on the expression of Brain-Derived 
Neurotrophic Factor (BDNF) and Arc (Molteni et al., 2010), proteins essential for synaptic 
plasticity. These data suggest that GRs drive stress-induced changes in the brain, and that stress 
affects synaptic plasticity. Indeed, neuronal remodeling under stress has been well-documented, 
with acute and chronic stress producing opposite effects in the hippocampus and pre-frontal 
cortex (McEwen et al., 2016). In the hippocampus, acute stress was found to enhance long-term 
potentiation and to be reversible, while repeated stress lead to dendritic atrophy and memory 
deficits (Brunson et al., 2005; McEwen, 1999). In the pre-frontal cortex, acute stress induced the 
expression of cell-surface NMDA and AMPA receptors, while chronic stress reduced their 
expression (Yuen et al., 2011). Chronic stress and high GC levels were also shown to promote 
dendritic shrinkage in the medial pre-frontal cortex of rodents (Cook & Wellman, 2004; Liston et 
al., 2006; Radley et al., 2004; Radley et al., 2005). This shrinkage was reversible in young 
animals, but less so in middle aged and older animals (Bloss et al., 2010), suggesting that aging 
limits the ability to recover from stress-induced synaptic changes. The combination of greater 
density of GRs in the hippocampus (Ruel & De Kloet, 1985) and reduced stress recovery in aged 
neurons (Bloss et al., 2010) suggests that the hippocampus is particularly susceptible to stress-
induced pathology during aging. These findings also indicate that stress may accelerate the 
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progression of age-related neurodegenerative diseases such as Alzheimer’s disease, whose onset 
is characterized by hippocampal synapse loss. 
 
1.2. Alzheimer’s Disease 
1.2.1. Alzheimer’s disease pathology 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that currently 
affects 55 million people worldwide, and is projected to affect 152 million by 2050 (Livingston 
et al., 2020; Yiannopoulou & Papageorgiou, 2020). Globally, the societal cost of AD and 
dementia is over $800 billion (www.who.int, 2020), and there are currently no cures or methods 
to slow AD progression (Yiannopoulou & Papageorgiou, 2020). AD is characterized 
neuropathologically by amyloid plaques, extracellular aggregates composed of amyloid-beta 
(Aβ) peptides, as well as neurofibrillary tangles, intracellular aggregates composed of Tau 
protein. The symptoms associated with AD, including memory loss, sleep disturbance, difficulty 
completing daily tasks, and changes in mood or behavior, are due to the progressive loss of 
synapses between neurons in the hippocampus, entorhinal cortex, and frontal cortex (Breijyeh & 
Karaman, 2020; Kashyap et al., 2019; Nelson et al., 2012; Scheff et al., 2006; Selkoe, 2002). 
The causes of AD are multifactorial, including age, genetics, and environmental risk factors, 
though the single greatest AD risk factor is age. Ten percent of people aged 65 and older have 
AD, and the risk of developing AD doubles every five years thereafter (nia.nih.gov, 2019). These 
data indicate that aging renders our brains less capable of protein clearance through normal 
trafficking and degradative pathways, resulting in Aβ and Tau accumulation. Environmental 




1.2.2. Environmental risk factors for AD 
Lifetime stress and high circulating levels of glucocorticoids have been suggested as 
critical precipitating factors of AD (Csernansky et al., 2006; Elgh et al., 2006; Silva et al., 2019; 
Vyas et al., 2016). AD risk increases with mid-life stress (Johansson et al., 2010), as well as with 
high stress-associated factors like depression, anxiety, and sleep disturbance (Burke et al., 2018; 
Mejia et al., 2003). Stress may also accelerate AD progression, as higher plasma cortisol levels 
correlate with more rapidly progressing dementia in humans (Csernansky et al., 2006). 
Mechanistically, stress/GCs have been shown to induce Tau accumulation, amyloid precursor 
protein (APP) processing into Aβ, and Aβ production in cell culture and animal models (Catania 
et al., 2009; Green et al., 2006; Jeong et al., 2006; Sotiropoulos et al., 2011; Srivareerat et al., 
2009), suggesting that stress promotes the cellular pathomechanisms that drive AD. In rodents, 
GC administration increases Aβ production by inducing the expression of APP and its protease 
β-site APP cleaving enzyme-1 (BACE1) (Green et al., 2006), as well as by shifting APP 
metabolism towards the amyloidogenic pathway (Sotiropoulos et al., 2008). In a triple-transgenic 
rodent model of AD (3xTg-AD), even short-term stress increased Aβ generation and synapse 
loss (Baglietto-Vargas et al., 2015), indicating that stress exacerbates AD pathology. 
Interestingly, blocking GRs reduced hippocampal Aβ40, Aβ42, and BACE1 levels in an 
APP/presenilin double transgenic AD mouse model (APPswe/PS1) subjected to early life stress 
(Lesuis et al., 2018). These studies indicate that stress promotes cellular pathways associated 
with AD, and that these effects are largely driven by the effects of GRs.  
Viral infections and brain trauma, including ischemic stroke or traumatic brain injury, can 
also increase the risk of developing AD (Mckee & Daneshvar, 2015; Sochocka et al., 2017; 
Vijayan & Reddy, 2016). Recent studies have found that Aβ acts as an antimicrobial agent in the 
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brain by aggregating around microbes (Gosztyla et al., 2018; Sochocka et al., 2017), which can 
lead to increased Aβ generation following infection. Furthermore, both brain trauma and 
infection activate the immune cells of the brain to repair damage and rid the brain of microbes. 
This immune system activity increases the likelihood of neuroinflammation, which has been 
identified as a major contributor to AD progression (Kinney et al., 2018; Ni Chasaide & Lynch, 
2020) and a primary driver of Tau fibril formation (Newcombe et al., 2018). Interestingly, stress 
and GCs can stimulate the immune system in the brain (Bellezza et al., 2014; Drake, 2015; 
Logsdon et al., 2016; Sprenkle, et al., 2017), providing another avenue by which stress acts as a 
precipitating factor for AD.  
 
1.2.3. Genetic risk factors for AD: Early-Onset Alzheimer’s Disease 
Several genes have been identified as determinants of familial, early-onset AD (EOAD; 
developing in patients in their 40s through mid-50s). Although mutations in these genes are rare, 
accounting for only one percent of Alzheimer’s cases, they have revealed some of the causes of 
AD. AD-causative mutations in the APP gene surround its secretase cleavage site and increase 
Aβ generation; conversely, a mutation that reduces Aβ production is protective against AD (Li et 
al., 2019; Tcw & Goate, 2017). Additionally, mutations in the 𝛾-secretase subunits presenilin-1 
(PSEN-1) and presenilin-2 (PSEN-2) are also linked to EOAD. These mutations increase the 
ratio of Aβ42/Aβ40, producing more hydrophobic, aggregate-prone Aβ42 monomers (Bi et al., 
2019; Breijyeh & Karaman, 2020; Dai et al., 2018; Zhao et al., 2020). All of these AD-causative 
genes affect APP processing and the production of Aβ, providing evidence that Aβ is a major 




1.2.4. Genetic risk factors for AD: Late-Onset Alzheimer’s Disease 
The majority of AD cases are late-onset and sporadic, and many of the risk genes 
associated with late-onset AD (LOAD) encode proteins that drive cellular trafficking 
mechanisms. Around 40-65% of people diagnosed with AD have the APOEε4 gene, encoding a 
protein that serves as a ligand for receptor-mediated endocytosis of lipoproteins such as 
cholesterol, which are essential for normal brain function (Kim et al., 2009; Liu et al., 2013). 
The gene encoding the sorting protein-related receptor-1 (SORL1) has also been linked to AD 
(Yin et al., 2015). SORL1 is a member of the APOE receptor family, mediating the uptake of 
APOE-rich lipoproteins (Taira et al., 2001; Yin et al., 2015), further underscoring the importance 
of lipoprotein trafficking in AD. Additionally, SORL1 has been implicated in the retention of 
APP in the Trans-Golgi Network, and the trafficking of Aβ toward lysosomes (Yin et al., 2015), 
suggesting that disrupted endosomal trafficking of APP and Aβ can lead to AD. 
Bridging integrator 1 (BIN1) is the second-most significant locus associated with LOAD, 
and it functions in clathrin-mediated endocytic pathways (Andrew et al., 2019; Holler et al., 
2014), and extracellular vesicle secretion (Crotti et al., 2019). Interestingly, large genome-wide 
association studies have identified another clathrin-associated gene as a risk factor for AD: 
phosphatidylinositol-binding clathrin assembly protein (PICALM) (Xu et al., 2015). It is yet 
unclear precisely which PICALM-mediated processes are responsible for AD risk, but it has 
been implicated in the endocytosis of APP (Xu et al., 2015). Both BIN1 and PICALM are linked 
to clathrin-mediated endocytosis, suggesting the importance of this pathway in AD.  
The third most significant genetic risk factor for LOAD is the gene encoding clusterin 
(CLU). Clusterin is an extracellular chaperone protein, which has been found intracellularly 
under stress and Aβ treatment (Humphreys et al., 1999; Killick et al., 2014; Nizard et al., 2007; 
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Foster et al., 2019), suggesting a relationship between cellular stressors and clusterin trafficking. 
Clusterin’s role in Aβ accumulation is yet unclear, as it has been shown to both increase and 
decrease Aβ clearance (Foster et al., 2019); however, the relationship between clusterin and Aβ 
may be dependent on the clusterin/Aβ ratio (Yerbury et al., 2007). Clusterin is primarily 
generated by astrocytes, and while its expression increases with injury, inflammation, and AD 
(Foster et al., 2019), recent research indicates that this may be protective rather than pathological 
(Chen et al., 2021). Though the underlying mechanisms of these AD risk factors have yet to be 
identified, they indicate that dysregulated trafficking pathways contribute to AD.  
Many of the genetic risk factors associated with LOAD lead to malfunctions in the 
endosomal pathway, which transports proteins to the plasma membrane and functions in protein 
internalization and recycling. The endosomal pathway is disrupted early in AD, suggesting that 
buildup of Aβ and/or Tau clogs these trafficking mechanisms, further contributing to protein 
aggregation (Xu et al., 2016). Indeed, Aβ can accumulate in multivesicular bodies as it is taken 
up by neurons. This impairs the endolysosomal pathway, reducing degradation of other proteins 
(Almeida et al., 2006). Similarly, APP and PSEN1 mutant neurons, which enhance 
amyloidogenic cleavage of APP, have deficits in lysosome proteolysis, which can be rescued by 
BACE1 inhibition, indicating that increased Aβ generation is driving these defects (Hung & 
Livesey, 2018). APP mutations increase total and phosphorylated Tau as well (Moore et al., 
2015), further complicating the trafficking problem in AD.  
 
1.3. Cellular mechanisms of Alzheimer’s Disease 
1.3.1. Aβ functions at the synapse 
While the detrimental effects of amyloid plaques remain controversial, considerable 
evidence shows that elevated levels of Aβ peptides are synaptotoxic, supporting the ‘amyloid 
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cascade’ hypothesis that AD is initiated by Aβ production (Mucke & Selkoe, 2012). For 
instance, full-length APP promotes synapse formation (Hoe et al., 2012), and its non-
amyloidogenic cleavage into sAPP⍺ modulates synaptic transmission in the hippocampus, 
rescuing synaptic defects in APP knockout mice (Rice et al., 2019). However, increased 
amyloidogenic cleavage of APP into Aβ has deleterious effects on synapses (Rajmohan & 
Reddy, 2017). In APP transgenic mice, synapse loss was greatest near Aβ plaques and 
oligomers, and lessened in a radial fashion away from them (Koffie et al., 2009; Spires-Jones et 
al., 2007), suggesting that Aβ can disrupt synapses. Likewise, in rat hippocampal cultures, 
prolonged Aβ exposure reduced dendritic spine density and produced abnormal spines (Lacor et 
al., 2007). Aβ has also been shown to weaken synaptic transmission by decreasing synaptic 
vesicle endocytosis and reducing presynaptic protein levels (Park et al., 2013; Reddy et al., 
2005). Furthermore, Aβ blocks long-term potentiation and induces long-term depression, as well 
as dendritic spine pruning, through its effect on glutamate receptors, as it has been shown to 
block glutamate reuptake and hyperactivate type 5 metabotropic glutamate receptors (mGluR5) 
(Li et al., 2009; Shankar et al., 2008; Zhang et al., 2015). 
Surprisingly, one of the best-characterized roles of Aβ is promoting synaptic function and 
plasticity. Studies show that deletion of either APP or BACE1 in transgenic mice reduces long 
term potentiation in hippocampal slices (Dawson et al., 1999; Laird et al., 2005), and Aβ 
monomers promote the survival of developing cultured cortical neurons deprived of trophic 
factors (Giuffrida et al., 2009), indicating Aβ’s beneficial roles at the synapse. Indeed, Aβ has 
been shown to regulate the recycling of synaptic vesicles and promote long term potentiation 
when expressed at picomolar concentrations (Lazarevic et al., 2017; Puzzo et al., 2011, 2008), 
which have been characterized as endogenous, non-pathogenic levels of Aβ (Cirrito et al., 2003; 
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Parihar & Brewer, 2010; Seubert et al., 1992). In line with these findings, picomolar 
concentrations of Aβ were shown to enhance LTP and spatial learning, as well as fear memory 
formation and consolidation in rodents (Finnie & Nader, 2020; Garcia-Osta & Alberini, 2009; 
Gulisano et al., 2018). On the other hand, nanomolar concentrations of Aβ reduced plasticity 
(Puzzo et al., 2011), providing evidence that excessive Aβ production is harmful to synapses. 
Together, these data indicate that non-amyloidogenic APP cleavage, and endogenous levels of 
amyloidogenic APP cleavage, are beneficial to the synapse, but that increased APP processing 
into Aβ peptides leads to neuronal damage by reducing synaptic transmission and inducing 
synapse loss.  
Interestingly, synaptic activity increases APP endocytosis and BACE1-mediated Aβ 
production to promote synaptic function (Cirrito et al., 2008, 2003; Kamenetz et al., 2003). Since 
high concentrations of Aβ induce LTD, it has been proposed that Aβ may control a tightly-
regulated negative feedback loop modulating neuronal activity and preventing excess Aβ 
generation and subsequent neuronal hyperactivation (Kamenetz et al., 2003). Mouse models and 
human patient data have revealed that neuronal circuits are hyperactive in the early stages of AD, 
suggesting a dysregulation of this feedback loop. In APP-PS1 double transgenic mice and human 
APP-expressing J20 mice, neurons in the hippocampus and frontal cortex were found to be 
hyperactive and to exhibit reduced dendritic spine density (Busche & Konnerth, 2015). 
Similarly, in humans monitored by blood-oxygen-level dependent (BOLD) fMRI, asymptomatic 
individuals with high Aβ burden exhibited increased activation in the medial prefrontal cortex, 
and patients in the pre-dementia stages of AD had elevated resting-state activity in the 
hippocampus (Busche & Konnerth, 2015). Together, these studies suggest that elevated neuronal 
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activity is a symptom of prodromal and early-stage AD, and indicate a dysregulation of the 
feedback loop between neuronal activity and Aβ generation. 
 
1.3.2. Role of Tau in the neuron  
The microtubule-binding protein Tau is primarily localized to axons, where it serves to 
stabilize microtubules and maintain axonal transport. Hyperphosphorylation of Tau under 
pathological conditions leads to its dissociation from microtubules, reducing their stability and 
disrupting transport mechanisms. Furthermore, hyperphosphorylated Tau becomes mislocalized 
at synapses and in the somatodendritic compartment, where it gains new functions (Hoover et 
al., 2010). For instance, phosphorylated Tau is prone to aggregation, and these aggregates inhibit 
proteasome function (Myeku et al., 2016) and autophagy (Caballero et al., 2021; Feng et al., 
2020), thereby disrupting neuronal proteostasis. At presynaptic terminals, pathogenic Tau binds 
to synaptic vesicles and inhibits their release (Largo-Barrientos et al., 2021; McInnes et al., 
2018; Zhou et al., 2017), while in the postsynaptic compartment Tau impairs AMPA and NMDA 
receptor anchoring and signaling (Hoover et al., 2010; Ittner et al., 2010; Li et al., 2019; Liao et 
al., 2014; Miyamoto et al., 2017; Pallas-Bazarra et al., 2019). These studies reveal that Tau 
hyperphosphorylation leads to neuronal dysfunction as a result of reduced microtubule stability, 
impaired protein degradation, and altered synaptic transmission. 
Hyperphosphorylated Tau also becomes misfolded and aggregates into fibrils, which can 
serve as “seeds” to recruit soluble Tau, inducing further aggregation and the formation of 
neurofibrillary tangles (NFTs) (Guo & Lee, 2011). Tau propagation in the AD patient brain 
closely matches symptomatic progression of the disease (Braak & Braak, 1991). This 
propagation requires the secretion and reuptake of pathogenic Tau species (Braak & Del Tredici, 
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2016) and is mediated by exosomes, extracellular vesicles derived from the endolysosomal 
system (DeLeo & Ikezu, 2018; Ledreux et al., 2021; Perez et al., 2019; Ruan et al., 2021; Xiao 
et al., 2017). Interestingly, the presence of NTFs correlates with cognitive decline and synapse 
loss in AD, implicating Tau as a critical driver of disease progression. However, Tau aggregation 
in the absence of Aβ pathology causes frontotemporal dementia, not AD (Goedert & Jakes, 2005; 
Mufson et al., 2014; Vana et al., 2011), indicating that AD is a result of both Tau 
aggregation/mislocalization and APP misprocessing. Because both of these processes are 
dependent on intracellular trafficking mechanisms, it is important to illuminate the cellular 
trafficking pathways responsible for Tau and Aβ accumulation. 
 
1.3.3. APP and BACE1 trafficking pathways lead to Aβ production  
Amyloid-beta (Aβ) is generated by the cleavage of Amyloid Precursor Protein (APP), 
which can undergo cleavage by two pathways: amyloidogenic and non-amyloidogenic (Fig. 1). 
In the amyloidogenic pathway, APP is cleaved first by the β-secretase BACE1, producing 
extracellular, soluble sAPPβ and the β C-terminal fragment (β-CTF; C99). Secondary cleavage 
by the 𝛾-secretase produces an intracellular AICD (APP intracellular domain) fragment, which 
may function in nuclear signaling, as well as Aβ, which is prone to aggregation (Haass et al., 
2012). This cleavage produces Aβ monomers of varying peptide lengths: Aβ40 is the most 
common, and Aβ42 is the most prone to fibril formation. In the non-amyloidogenic cleavage 
pathway, APP is first cleaved by the ⍺-secretase, metalloprotease ADAM10, producing 
extracellular, soluble sAPP⍺ and the ⍺-C-terminal fragment (⍺-CTF; C83). Secondary cleavage 
by the 𝛾-secretase creates the intracellular AICD fragment, and non-aggregating, extracellular p3 




Figure 1. Cleavage of APP through the amyloidogenic and non-amyloidogenic pathways. In the amyloidogenic 
pathway, APP is cleaved by the β-secretase BACE1 and a 𝛾-secretase, yielding the pathogenic β-C-terminal fragment 
(C99) and aggregate-prone Aβ. In the non-amyloidogenic pathway, APP is cleaved by ⍺- and 𝛾-secretases, yielding 
non-toxic, soluble products. 
 
The generation of Aβ requires interaction between APP and BACE1, which is determined 
by their intracellular trafficking pathways. APP and BACE1 are membrane proteins that are 
transported from the endoplasmic reticulum (ER) through the trans-Golgi network (TGN), to the 
plasma membrane. From the plasma membrane, they can be internalized, entering the endosomal 
system. Either protein can then be recycled to the surface through recycling endosomes, 
trafficked back to the TGN through the retrograde pathway, degraded in lysosomes, or secreted 




Figure 2. APP and BACE1 intracellular trafficking. Newly synthesized APP and BACE1 proteins travel from the 
endoplasmic reticulum to the Trans-Golgi Network (1) and to the plasma membrane (2). APP and BACE1 are 
internalized into endocytic compartments (endosomes) (3), where the acidic pH is optimal for BACE1 activity. Here, 
APP and BACE1 may interact to produce Aβ. From the early endosome, APP or BACE1 can be recycled (4) to the 
plasma membrane (5), or trafficked through the retrograde pathway to the Trans-Golgi Network (6). Alternatively, 
they can be sorted into late endosomes (7) and degraded when fused with lysosomes (8), or secreted as exosomes 
when fused with the plasma membrane (9). 
 
1.3.4. Rab35 – a master regulator of intracellular trafficking 
Intriguingly, many of the recently-identified genetic risk factors for late-onset AD 
(LOAD) are linked to endosomal protein trafficking, and have been shown to induce endosomal 
dysfunction and to prolong the residence times of APP and/or BACE1 in endosomes (Small et 
al., 2017; Ubelmann et al., 2017). Indeed, entry of APP and BACE1 into the endosomal network 
is an essential step in Aβ production (Cirrito et al., 2005; Zou et al., 2007), as endosomes contain 
the optimal acidic pH for BACE1 activity and have been identified as major sites of Aβ 
generation (Haass et al., 2012).  
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Rab35 is a member of the Rab family of GTPases, which regulate endosomal protein 
trafficking by cycling between active (GTP-bound) and inactive (GDP-bound) states (Fig. 3), 
and recruiting effectors that catalyze downstream events such as membrane fusion and vesicle 
transport (Stenmark, 2009). 
 
Figure 3. Rab35 activation cycle. Rab35 switches from an inactive (GDP-bound) state to an active (GTP-bound) 
state when a guanine exchange factor (GEF) exchanges GDP for GTP. Active Rab35 interacts with effectors, driving 
trafficking events. GTP-hydrolysis activating proteins (GAPs) return Rab35 to an inactive state by facilitating the 
removal of a phosphate group, generating GDP from GTP. 
 
Rab35 is considered a ‘master regulator’ of endosomal protein trafficking due to its role 
in multiple cellular trafficking pathways (Fig. 4). These include an endosomal sorting complex 
required for transport (ESCRT)-mediated pathway for protein degradation (Sheehan et al., 2016; 
Vaz-Silva et al., 2018), the retrograde trafficking pathway to the trans-Golgi Network (Cauvin et 
al., 2016), and a fast recycling pathway between endosomes and the plasma membrane 
(Kobayashi & Fukuda, 2013; Patino-Lopez et al., 2008). Furthermore, Rab35 is a central 
regulator of phosphoinositide synthesis and F-actin dynamics during endocytic recycling 
(Klinkert & Echard, 2016), important for sorting cargo internalized by clathrin-mediated 
endocytosis (Dutta & Donaldson, 2015). Rab35 is also involved in neurite outgrowth and 
synapse formation (Kobayashi & Fukuda, 2012; Patino-Lopez et al., 2008), as well as cell 
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adhesion and migration  (Allaire et al., 2013), and exosome secretion (Hsu et al., 2010; Yang et 
al., 2019). As a regulator of multiple cellular trafficking pathways, Rab35 is in a prime position 
to influence the trafficking of AD-related proteins. 
 
Figure 4. Rab35 mediates endosomal trafficking pathways. Rab35 has been shown to control protein sorting 
following clathrin-mediated endocytosis, as well as pathways involved in protein recycling, degradation, and 
retrograde trafficking, as well as exosome secretion. 
 
Indeed, in our previous study, we demonstrated that Rab35 promotes the degradation of 
ubiquitylated Tau by sorting it into the ESCRT pathway. Interestingly, we found that 
glucocorticoids (GCs) downregulate Rab35, leading to intraneuronal Tau accumulation (Fig. 5) 
and downstream Tau-dependent pathology (i.e. synaptic and dendritic loss) in the rat 
hippocampus. AAV-mediated Rab35 overexpression rescued these deficits (Vaz-Silva et al., 
2018), underscoring its role in Tau trafficking and degradation in glutamatergic neurons. 
However, the role of Rab35 in stress/GC-mediated Ab overproduction has not been explored, 
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although Rab35 has been identified as a negative regulator of Aβ production (Udayar et al., 
2013). 
 
Figure 5. Working model of Tau degradation through the Rab35/ESCRT pathway, and its inhibition by 
glucocorticoids (GC). Rab35 mediates Tau clearance via the endolysosomal pathway by recruiting the initial ESCRT 
component Hrs, which recognizes and sorts ubiquitylated Tau into early endosomes for packaging into MVBs. GC 
suppress transcription of Rab35, which in turn decreases Tau sorting into MVBs and its subsequent degradation by 
lysosomes, leading to Tau accumulation and related neuronal atrophy. Copyright © 2018 The Authors, published by 
John Wiley & Sons, all rights reserved. Figure and caption reprinted from Vaz-Silva, et al., 2018, with permission 
under the terms of the granted license, provided as-is with no warranties or liabilities concerning this material. 
 
In this thesis, I identify Rab35 as a molecular substrate through which stress/GCs could 
increase Aβ production, a hallmark of AD. I show that Rab35 levels are significantly decreased 
with stress, Aβ infusion, and aging, all conditions associated with AD. Furthermore, I find that 
Rab35 is an important negative regulator of APP and BACE1 interaction in the endosomal 
network, promoting APP recycling to the cell surface and BACE1 retrograde trafficking to the 
TGN to reduce Aβ generation in endosomes. Finally, I describe methods for assessing exosome 
secretion in neurons, astrocytes, and microglia to determine how GCs and Rab35 affect 
exosome-mediated intercellular spreading of AD-associated proteins.  
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Chapter 2: Materials and Methods 
2.1. Methods used for Rab35-mediated endosomal trafficking experiments in 
chapters 3 and 4 
2.1.1. Primary neurons and cell lines 
Primary neuronal cultures were prepared from E18 Sprague Dawley rat embryos and 
maintained in Neurobasal with GlutaMAX (Invitrogen) and N21 supplement (R&D systems) for 
14 days in vitro (DIV) before use, as described previously (Sheehan et al., 2016). Neuro2a (N2a) 
neuroblastoma cells (ATCC CCL-131) were grown in DMEM-GlutaMAX (ThermoFisher) with 
10% FBS (Atlanta Biological) and 1% Anti-Anti (ThermoFisher) and kept at 37°C in 5% CO2. 
During dexamethasone treatment in N2a cells, FBS in the growth media was reduced to 3%. 
Human iPSC-derived neuronal primary cultures were generated using manual rosette selection 
and maintained on Matrigel (Corning) (Topol et al., 2015). Concentrated lentiviruses expressing 
control-sgRNA or hu-APP-sgRNA were made using Lenti-X concentrator (Clontech). The iPSC-
derived neuronal cultures were transduced with either control-sgRNA or hu-APP-sgRNA after 
Accutase splitting, and were submitted to puromycin selection the subsequent day. Polyclonal 
lines were expanded and treated with puromycin for 5 more days before banking. Neuronal 
differentiations were carried out by plating 165,000 cells/well (12-well plate) in N2/B27 media 
(DMEM/F12 base) supplemented with BDNF (20 ng/ml) and laminin (1 µg/ml). 
 
2.1.2. Pharmacological treatments 
Pharmacological agents were used in the following concentrations and time courses: 





2.1.3. Lentivirus production, transduction, and DNA transfection 
DNA constructs were described previously (Sheehan et al., 2016; Vaz-Silva et al., 2018). 
APP:VN and BACE:VC constructs were a gift from Dr. Subhojit Roy (University of Wisconsin, 
USA). Briefly, Rab GTPases were subcloned into pKH3 vector at the EcoRI site to create HA-
tagged Rabs. Lentivirus was produced as previously described (Sheehan et al., 2016). Neurons 
were transduced with 50–150 µL of lentiviral supernatant per well (12-well plates) or 10–40 µL 
per coverslip (24-well plates) either at 3 DIV for shRNA transduction or 10 DIV in gain-of-
function experiments. Respective controls were transduced on the same day for all experimental 
conditions. Primary neuronal cultures were collected for immunoblotting or 
immunocytochemistry at 14 DIV. N2a cells were transfected using Lipofectamine 3000 
approximately 24h after plating, according to the manufacturer’s instructions. For the 
bimolecular fluorescence complementation assay, double transfection of APP:VN and 
BACE1:VC constructs was performed 48h after transfection with HA-Rab GTPases, to allow 
longer expression of the Rabs. Cells were then fixed and analyzed 18h after the APP:VN and 
BACE1:VC transfection. 
 
2.1.4. Flow cytometry 
N2a cells were detached using TrypLE Express (Life Technologies) for 5 min at 37ºC, 
resuspended in culture medium, and centrifuged (3,000 rpm, 5 minutes, 4oC). The pellet was 
washed once with 0.2 mM EDTA and 0.02% BSA in 1X PBS (Flow buffer), centrifuged again, 
resuspended in 100 µL of flow buffer, then fixed with 4% paraformaldehyde solution for 15 min 
at room temperature. Cells were washed (1X PBS) and resuspended in 1.5% FBS and 0.05% 
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saponin in 1X PBS (permeabilization solution), then placed on a shaker for 30 min at RT. 
Following centrifugation, the supernatant was discarded, and the cell pellet resuspended in 
permeabilization solution with anti-HA-tag Alexa(R)-647 (Cell Signaling Technologies) for 
immunostaining, then placed on a shaker for 90 minutes at 4ºC. After washing twice with flow 
buffer, cells were resuspended in ice-cold Flow Buffer (0.2% FBS, 0.5mM EDTA in 1X PBS), 
strained through a 35µm nylon mesh to promote single cell suspensions, and kept on ice. Cells 
and fluorescence were analyzed by BD Fortessa Cell Analyser and BD FACSDiva software (BD 
Biosciences). Unstained cells were used as a control for background fluorescence. Far-red (APC) 
and green (FITC) fluorescence were analyzed, as they marked the HA-tag and Venus 
fluorescence (APP-BACE1 interaction), respectively. 50,000 events were recorded for each 
sample, with two samples for each condition per experiment. Flow Cytometry data were 
analyzed using FCS Express 6 (DeNovo Software). Median fluorescence intensity of the Venus 
(APP-BACE1) signal was calculated for the HA+ cells only, thus in double positive cells. The 
median Venus fluorescence intensity of each sample was compared to the median Venus 
fluorescence of all samples, thus comparing each condition to the average of the whole 
population.  
 
2.1.5. Immunofluorescence microscopy 
Immunofluorescence staining in neurons and N2a cells was performed as previously 
described (Sheehan et al., 2016). Briefly, cells were fixed with Lorene’s Fix (60 mM PIPES, 25 
mM HEPES, 10 mM EGTA, 2 mM MgCl2, 0.12 M sucrose, 4% formaldehyde) for 15 min, and 
primary and secondary antibody incubations were performed in blocking buffer (2% glycine, 2% 
BSA, 0.2% gelatin, 50 mM NH4Cl in 1X PBS) for 1h at room temperature. Coverslips were 
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mounted using Aqua Poly/Mount (Polysciences, Inc.). Images were acquired using a Zeiss LSM 
800 confocal microscope equipped with Airyscan module, using a 63X objective (Plan-
Apochromat, NA 1.4). 
 
2.1.6. Proximity ligation assay 
Proximity ligation assay (PLA) was performed in primary hippocampal neurons and N2a 
cells according to the manufacturer’s instructions (Duolink, Sigma). Until the PLA probe 
incubation step, all manipulations were performed as detailed in the immunocytochemistry 
procedure. PLA probes were diluted in blocking solution. The primary antibody pairs used were 
C1/6.1 (anti-APP, Mouse; Biolegend) and anti-BACE1 (Rabbit, Cell Signaling Technology). All 
protocol steps were performed at 37°C in a humidity chamber, except for the washing steps. 
Coverslips were then mounted using Duolink In situ Mounting Media with DAPI, and imaged 
using a 40X objective (Plan-Apochromat, NA 1.4). 
 
2.1.7. Neuronal image analysis 
Images were analyzed and processed using Fiji/ImageJ software. PLA puncta were 
counted using the Multi-point tool, and cell area was measured with the Polygon selection tool. 
Colocalization analysis between APP (22C11, Millipore) or BACE1 (Cell Signaling) and 
intracellular compartments (Rab11, Cell Signaling; Syntaxin-6, Synaptic Systems) in neurons 
was determined using the JACoP plugin, in order to obtain the Mander’s coefficient 






2.1.8. Aβ Measurements 
Human iPSC-derived neuronal cultures were kept for 3 days post-transduction, after 
which 50% of the media was changed. Then, conditioned media was collected after 72h, 
centrifuged at 2,000 rcf for 5 min and stored at –80ºC. Aβ42 and Aβ40 levels were measured 
using V-PLEX Aβ Peptide Panel 1 (4G8) Kit (MesoScaleDiscovery, MSD) following the 
manufacturer’s protocol and their concentration was presented as percentage of control levels, 
after normalization to total protein in the conditioned media (measured using ThermoFisher 
Scientific BCA assay kit). 
 
2.1.9. Animals 
Male Wistar rats (Charles River Laboratories, France) were maintained under standard 
laboratory environmental conditions (lights on from 8 a.m to 8 p.m, room temperature 22°C, 
relative humidity 55%, ad libitum access to food and water). All experimental procedures were 
approved by the local ethical committee of the University of Minho and the national authority for 
animal experimentation (DGV9457); all experiments were in accordance with the guidelines for 
the care and handling of laboratory animals, as described in the Directive 2010/63/EU. Twelve-
month-old animals were randomly divided into the below three groups: control, stressed, Aβ-
infused animals (n = 8-10 per group). For stressed animals, the chronic unpredictable stress 
paradigm lasted for 4 weeks and consisted of random application of one of the following 
stressors (one stressor per day): (i) rocking platform, (ii) air dryer, (iii) cold water, and (iv) 
overcrowding, as previously described (Catania et al., 2009). Control, non-stressed animals 
remained in their home cages during the stress period. At the end of the stress paradigm, all 
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animals were implanted with Alzet miniosmotic pumps for i.c.v. delivery of Aβ1-40 
(Eurogentec; 25 µg/200 µl, 0.5µl per hour) or saline for 14 days (Prediger et al., 2007). For the 
Aβ1-40 or saline infusion, mini-osmotic pumps (Alzet. Osmotic Pumps, DURECT, 2002 model) 
and cannulae (Alzet Brain Infusion Kit) were implanted in the left lateral ventricle using the 
following coordinates from Bregma: -0.6mm anteroposterior, -1.4mm mediolateral, -3.5mm 
dorsoventral according to Paxinos and Watson (Paxinos & Watson, 1986). Pump and cannula 
implantation were done under anaesthesia [75 mg/kg ketamine (Imalgene, Merial) and 1mg/kg 
medatomidine (Dorbene, Cymedica)]. For the aged rat study, young (4 month-old) and aged (22-
24 month-old) male Wistar rats were used (n = 4-8 per group). For the Rab35 overexpression 
experiment, another set of male Wistar rats (17 month-old; Charles River Laboratories, Spain) 
were randomly divided into two groups (n = 2–6 per group) and were bilaterally injected into the 
dorsal hippocampus with AAV8-GFP or AAV8-Rab-GFP virus [coordinates from Bregma, 
according to Paxinos and Watson 50: -3.0 mm anteroposterior (AP), ±1.6 mm mediolateral 
(ML), and -3.3 mm dorsoventral (DV)]  under anesthesia with 75 mg/ kg ketamine (Imalgene, 
Merial) and 0.5 mg/kg medetomidine (Dorbene, Cymedica), as previously described (Vaz-Silva, 
et al., 2018).  
 
2.1.10. Immunoblotting 
For immunoblotting experiments, human iPSC-derived neuronal cultures were collected 
in Lysis Buffer (50 mm Tris-Base, 150 mm NaCl, 1% Triton X-100, 0.5% deoxycholic acid) 
with protease inhibitor (Roche) and phosphatase inhibitor cocktails II and III (Sigma) and 
clarified by centrifugation at high speed (10 min, 20,000 g). Rat hippocampi were homogenized 
in lysis buffer (50 mm Tris-Base, 150 mm NaCl, 1% Triton X-100, 0.5% deoxycholic acid) with 
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10mM MgCl2 and clarified by centrifugation at high speed (15 min, 20,000 g). Protein 
concentration was determined using the BCA protein assay kit (ThermoFisher Scientific) and the 
same amount of protein was used for each condition, which was diluted and denatured in 2X 
SDS sample buffer with beta-mercaptoethanol (Bio-Rad; prepared per the manufacturer’s 
instructions). N2a cells were collected in 2X SDS sample buffer with beta-mercaptoethanol. 
Samples were subject to SDS–PAGE, transferred to nitrocellulose membranes using wet transfer 
(Mini Trans-Blot Cell, Bio-Rad), and probed with primary antibody in 5% BSA/PBS + 0.1% 
Tween-20, followed by DyLight 680 or 800 anti-rabbit, anti-mouse (Thermo Scientific) or by 
HRP-conjugated secondaries (Bio-Rad). Primary antibodies used for western blotting are listed 
in Table 1. Membranes were imaged using an Odyssey Infrared Imager (model 9120, LI-COR 
Biosciences), and protein intensity was measured using Image Studio Lite software (LI-COR 
Biosciences).  
Antibody Manufacturer Concentration 
Actin Abcam (#8224) 1:1000 
ACAP2 ProteinTech (#14029-1-AP) 1:1000 
APP & CTFs Biolegend (APP C1/6.1; #802801) 1:1000 
BACE1 Cell Signaling (D10E5; #5606) 1:1000 
GFP Invitrogen (#A6455) 1:1000 
mCherry Abcam (#ab125096) Biovision (#5993) 1:1000 
OCRL ProteinTech (#17695-1-AP) 1:1000 
Rab5 Synaptic Systems (#108011) 1:1000 
Rab7 Abcam (#ab50533) 1:1000 
Rab8 ProteinTech (#55296-1-AP) 1:1000 
Rab11 Cell Signaling (D4F5; #5589) 1:1000 
Rab14 Santa Cruz (#sc-98610) 1:500 
Rab35 ProteinTech (#11329-2-AP) 1:1000 
Tubulin Abcam (#ab4074) Sigma (#T9026) 1:5000 
Table 1. List of primary antibodies used for western blotting. 
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2.1.11. Retrograde trafficking assay 
N2a cells were co-transfected with APP-GFP or FLAG-BACE1 and HA or HA-Rab35 
constructs. Approximately 48 hours after transfection, cells were starved in serum-free DMEM 
for 30 minutes. Cells were then incubated for 30 min at 4oC with 22C11 antibody (anti-N-
terminus of APP, Millipore) or anti-FLAG (Millipore). Antibodies were diluted 1:100 in 
complete medium + 1M HEPES. Following antibody incubation, cells were washed with 
complete medium + HEPES and either immediately fixed with Lorene’s fixative for 15 min, or 
incubated at 37oC for 10, 30, or 60 min and then fixed, followed by washing with 1X PBS. For 
immunostaining, cells were permeabilized using Triton X-100, and coverslips were 
immunostained with the following primary + secondary antibody pairs: internalized anti-22C11 
or anti-FLAG + goat-anti-mouse Alexa(R)-568 to tag internalized APP or BACE1; anti-
Syntaxin-6 (Synaptic Systems) + Alexa(R)-647 to tag the trans-Golgi network (TGN); and anti-
BACE1 (for BACE1-transfected conditions only; Cell Signaling) + Alexa(R)-488 to tag total 
BACE1. Cells overexpressing Rab35 were detected using an anti-HA primary antibody (Rabbit, 
Cell Signaling; Mouse, Biolegend) + Alexa(R)-405 secondary antibody (data not shown). For 
analysis, Fiji/ImageJ was used to outline each transfected cell and clear the background. 
Colocalization between APP or BACE1 and the TGN was determined using the JACoP plugin, 
and the Mander’s coefficient was used for reporting the fraction of APP or BACE1 colocalized 
with the TGN.  
 
2.1.12. Recycling assay 
N2a cells were co-transfected with APP-GFP or FLAG-BACE1 and HA or HA-Rab35 
constructs. Approximately 48 hours after transfection, cells were starved in serum-free DMEM 
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for 30 minutes and then incubated for 30 min at 4oC with 22C11 antibody (anti-N-terminus of 
APP, Millipore) or anti-FLAG (Millipore) as in the retrograde trafficking assay. Following 
antibody pulse, coverslips were washed with complete medium + HEPES and incubated with 
goat-anti-mouse unconjugated antibody (1:50; Invitrogen) for 30 min at 4oC to allow for APP or 
BACE1 internalization while blocking any primary antibody on the surface that is not 
internalized. Antibodies were diluted in complete medium + 1M HEPES. Coverslips were 
washed with complete medium + HEPES and fixed with Lorene’s fixative for 15 min or 
incubated at 37oC for 10, 30, or 60 min and then fixed, followed by washing with 1X PBS. 
Coverslips were immunostained with goat-anti-mouse Alexa(R)-568 for 1hr at RT prior to cell 
permeabilization to mark recycled 22C11 or FLAG antibodies, and any remaining surface 
antibody was blocked using goat-anti-mouse unconjugated antibody (1:50, 30 min at RT). 
Following cell permeabilization, internalized 22C11 or FLAG was marked using goat-anti-
mouse Alexa(R)-647 secondary antibody. Total BACE1 and HA were tagged as in the retrograde 
trafficking assay. Internalization and recycling of APP and BACE1 were determined using 
Fiji/ImageJ by outlining each cell and normalizing the fluorescence of (1) internalized APP or 
BACE1 and (2) recycled APP or BACE1 to total APP or BACE1. These values were then 
normalized to the first control timepoint for APP or BACE1 to determine change over time.  
 
2.1.13. Steady-state surface protein measurement  
N2a cells were co-transfected as in the retrograde trafficking and recycling assays. 
Approximately 48 hours after transfection, surface APP and BACE1 were labeled with anti-
22C11 or anti-FLAG antibodies prior to cell permeabilization, as in the recycling assay. 
Following permeabilization, coverslips were immunostained for HA (APP-GFP transfected cells) 
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or HA and BACE1 as described for the retrograde trafficking assay. Fiji/ImageJ software was 
used to determine surface APP and BACE1 by outlining each transfected cell and normalizing 
the fluorescence of surface APP or BACE1 to total APP or BACE1.  
 
2.1.14. Bioinformatics analysis 
RNA sequencing data across age groups were collected and produced by the Genotype-
Tissue Expression (GTEx) project (https://gtexportal.org/home/). Rab35 transcripts per million 
were normalized to IPO8 transcripts per million for each sample using Microsoft Excel. RNA 
sequencing data for Control vs. AD were collected and produced by Nativio, et. al. (Nativio et 
al., 2020) by aligning RNA-seq reads with STAR v.e.3.0e and annotating them with 
FeatureCounts v.1.6.2. Data were processed using R to obtain Rab35 and IPO8 transcripts per 
million. Rab35 transcripts per million were normalized to IPO8 transcripts per million using 
Microsoft Excel. IPO8 was chosen as a refence gene because it was the most stable gene tested 
from the GTEx and Nativio et al. datasets, using RefFinder (Xie et al., 2012). 
 
2.1.15. Statistical analysis 
Graphing and statistics analysis were performed using Prism (GraphPad). Shapiro–Wilk 
normality test was used to determine whether data sets were modeled by a normal distribution. 
Unpaired, two-tailed t-tests, one-way ANOVA, or two-way ANOVAs were used with values of 
P < 0.05 being considered as significantly different. 
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2.2. Methods used for exosome experiments in Chapter 5 
2.2.1. Primary neurons and cell lines 
Primary cortical neuron cultures were prepared from E18 C57/BL6 mouse embryos or 
E18 Sprague Dawley rat embryos of either sex using a modified Banker culture protocol (Banker 
& Goslin, 1998), as described above in the primary neurons and cell lines section for Chapters 3 
and 4. Neurons were plated in Neurobasal medium with GlutaMAX (Invitrogen) and N21 
supplement (R&D Systems) at a density of 3 million cells per 10 cm dish (dishes treated with 
Poly-L-Lysine, Sigma). Rat neurons were maintained for 14 DIV, undergoing half-media 
exchanges at 2 DIV and 7 DIV. Mouse neurons treated with dexamethasone were maintained for 
14 DIV, undergoing a full media exchange and dexamethasone treatment at 12 DIV.  
Primary cortical astrocyte cultures were prepared from P1-P3 C57/BL6 mouse pups or 
P1-P3 Sprague Dawley rat pups of either sex using the same dissection techniques as for cortical 
neurons. Glia were dissociated in TrypLE Express (Invitrogen) for 30 min, washed with Hanks 
Balanced Salt Solution (Sigma), and centrifuged at 1000 rcf for 15 min. Supernatant containing 
neurons was aspirated, and the remaining glia were resuspended in DMEM-GlutaMAX 
(ThermoFisher) with 10% FBS (Atlanta Biological) and 1% Anti-Anti (ThermoFisher). Glia 
were plated in T75 flasks pre-treated with Poly-L-Lysine (1.5 rat or 3 mouse pups’ cortices per 
flask). Microglia were shaken off of the flask surface at 2 and 7 days after dissection by placing 
flasks on a vortex (Southwest Science) for 1 min at medium speed. Medium containing microglia 
was aspirated and replaced with fresh DMEM-GlutaMAX + 10% FBS + Anti/Anti. Rat and 
mouse embryos were used at separate times because our initial NTA studies were conducted with 
rat primary cultures, and our updated protocol using ExoView on-chip exosome analysis requires 
the use of anti-mouse antibodies, for which we use mouse primary cultures. 
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Neuro2a (N2a) neuroblastoma cells (ATCC CCL-131) and Immortalized mouse 
MicroGlial (IMG, Millipore) cells were grown and maintained as described above (Chapters 3 
and 4 section). Immediately prior to dexamethasone treatment, medium was exchanged to 
DMEM-GlutaMAX with 10% Exosome-Depleted FBS (Gibco) and Anti-Anti.  
 
2.2.2. DNA transfection 
CD63 and CD81 tagged with pHluorin (Table 2) were subcloned from the pUC57-GW-
Kan vector (Genewiz) into pmCherry-C2 vector (Addgene) at KpnI and BamHI sites to create 
mCh-pHluorin-CD63 and mCh-pHluorin-CD81. Approximately 1h after plating, N2a and IMG 
cells were transfected using Lipofectamine 3000, according to the manufacturer’s instructions. 
 
2.2.3. Dexamethasone treatments 
Primary cortical neurons and astrocytes were treated with dexamethasone (Invivogen, 
20uM) for 48h, starting on 12 DIV. N2a and IMG cells were treated with dexamethasone 




























































Table 2. pHluorin-CD63 and pHluorin-CD81 sequences generated by GeneWiz. The tetraspanin proteins CD63 
and CD81 were tagged with the pH-sensitive fluorophore pHluorin (highlighted in green) to detect exosome release 





2.2.4. Exosome purification: Ultracentrifugation 
Extracellular vesicles were isolated from conditioned medium by serial 
ultracentrifugation at 4oC using an established protocol (Perez-Gonzalez et al., 2017; Thery et 
al., 2006). Medium was collected and centrifuged at 3220 x g for 20 min to discard any pelleted 
cell debris. The remaining medium was centrifuged at 20000 x g for 70 min to discard pelleted 
larger extracellular components. Medium was then centrifuged at 100000 x g for 70 min to pellet 
extracellular vesicles. Finally, pellets were washed with 1X PBS, centrifuged again at 100000 x 
g for 70 min, resuspended in 1 mL of 1X PBS, and stored at -80oC. 
 
2.2.5. Exosome purification: Size-exclusion chromatography 
First, medium was collected and centrifuged at 3220 x g for 20 min to discard any 
pelleted cell debris. The remaining supernatant was concentrated to a volume of 0.50 – 1.0 mL 
by centrifugation (3220 x g for 10 min) in Amicon Ultra centrifugal filters (100,000 NMWL; 
Millipore). Extracellular vesicles were isolated from conditioned medium by size exclusion 
chromatography (Koh et al., 2018; Lobb & Moller, 2017) using an IZON Automatic Fraction 
Collector and qEVoriginal columns (35nm; IZON), per the manufacturer’s instructions. 
Extracellular vesicle fractions were collected in 1mL 1X PBS and stored at -80oC. 
 
2.2.6. Immunoblotting 
For immunoblotting experiments, 3 ultracentrifugation-purified extracellular vesicle 
samples per cell type were concentrated to 15µL using Amicon Ultra centrifugal filters (100,000 
NMWL; Millipore) by centrifuging at 3220 x g for 10 min. Samples were diluted and denatured 
in 2X SDS sample buffer with beta-mercaptoethanol (Bio-Rad) and subject to SDS–PAGE, 
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transferred to nitrocellulose membranes using wet transfer (Mini Trans-Blot Cell, Bio-Rad), and 
probed with primary antibody in 5% BSA/PBS + 0.1% Tween-20, followed by DyLight 680 or 
800 (anti-rabbit, anti-mouse; Thermo Scientific). Primary antibodies used for western blotting 
were ALIX (ProteinTech) and TSG101 (Santa Cruz). Membranes were imaged using an Odyssey 
Infrared Imager (model 9120, LI-COR Biosciences). 
 
2.2.7. Exosome measurements: Nanoparticle tracking analysis (NTA) 
Concentrated extracellular vesicle samples were diluted 1:8 for samples collected from 
primary cultures, and 1:100 for samples collected from cell lines, for a total volume of 1.3mL per 
sample. Exosome size and concentration were measured by nanoparticle tracking of Brownian 
motion using ZetaView Nanoparticle Tracking Analyzer (ParticleMetrix). At the time of medium 
collection, cells were trypsinized and counted to estimate the number of exosomes per cell by 
dividing the total number of nanoparticles (determined by ZetaView) by the total number of 
cells. 
 
2.2.8. Exosome measurements: ExoView on-chip interferometry and antibody-based tetraspanin 
detection 
Microarray chips were pre-scanned for particles using ExoView R100 and ExoView 
Scanner software. Conditioned medium or purified exosome samples were diluted in Solution A 
(1:5 dilution for primary cultures, 1:100 for cell lines); 35µL of diluted samples were loaded onto 
microarray chips containing the tetraspanin antibodies CD9 and CD81, and incubated overnight 
(16h) at room temperature. After several washes with Solutions A and B, samples were 
incubated with anti-CD9 CF488a, anti-CD81 CF555, and anti-CD63 CF647 antibodies at a final 
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concentration of 1:1000. Following washes with solutions A and B, microarray chips were 
placed on a sample chuck and measured by interferometry and fluorescence imaging using 
ExoView R100 and ExoView Scanner software. Exosome size, number, and tetraspanin profiles 
were recorded for each sample using ExoView Analyzer; the RIgG and HIgG spots served as 
negative controls, and only fluorescence values exceeding the baseline RIgG and HIgG 
fluorescence were counted. All solutions, antibodies, microarray chips, and software were 
prepared and used per the manufacturer’s instructions (ExoView Biosciences). 
 
2.2.9. Live Total Internal Reflection Fluorescence (TIRF) imaging 
N2a cells were plated on #1.5 (170µm) Poly-L-Lysine-treated glass-bottom MatTek 
dishes and maintained in complete medium at 37oC with 5% CO2. Cells were transfected with 
mCh-pHluorin-CD63 and mCh-pHluorin-CD81 approximately 1hr after plating, treated with 
dexamethasone 48hr after transfection, and imaged 24hr after dexamethasone treatment. 
Immediately prior to imaging, cell medium was exchanged to normal Tyrode’s solution (2 mM 
CaCl2, 2.5 mM KCl, 119 mM NaCl, 2 mM MgCl2, 20 mM glucose, and 25 mM Hepes, pH 7.4). 
At least three fields of view were imaged per dish while cells were maintained in a humidity 
chamber (Tokai Hit) at 37oC with 5% CO2. Timelapse images were acquired at 500ms intervals 
for 3 min using an inverted Nikon Ti Eclipse microscope equipped with piezo Z and electron-
multiplying charge-coupled device camera (Andor DU-897). A 100X CFI Apochromat TIRF 
objective (1.49/0.12 mm, a/0.17 differential interference contrast objective; Nikon) and NIS-
Elements software (Nikon) were used for image capture. 
 
2.2.10. Live imaging analysis 
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Exosome release was measured using Fiji/ImageJ Particle Tracker 2D/3D analysis 
(Mosaic plugin package) for images taken in the pHluorin channel. Total number of particles per 
imaging field detected by the plugin were normalized to the total number of cells in the imaging 
field using Microsoft Excel. 
 
2.2.11. Statistical analysis 
Graphing and statistics analyses were performed using Prism (GraphPad). Shapiro–Wilk 
normality test was used to determine whether data sets were modeled by a normal distribution. 
Unpaired, two-tailed t-tests, one-way ANOVA, or two-way ANOVAs were used with values of 
P < 0.05 being considered as significantly different.  
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Chapter 3: Glucocorticoids reduce Rab35 expression, which impacts 
Aβ production 
3.1. Rationale 
Chronic stress and elevated glucocorticoids (GCs) increase the risk for Alzheimer’s 
disease (AD), and accelerate its progression (Burke et al., 2018; Csernansky et al., 2006; 
Johansson et al., 2010; Mejia et al., 2003; Sotiropoulos et al., 2019; Vyas et al., 2016). The 
pathological hallmarks of AD are the presence of cerebral Tau tangles and amyloid plaques, 
composed of aggregated amyloid-β (Aβ) peptides that accumulate following the proteolytic 
cleavage of amyloid precursor protein (APP) (Querfurth & LaFerla, 2010). Elevated levels of Aβ 
peptides are synaptotoxic, and AD may be initiated by Aβ production (Mucke & Selkoe, 2012). 
Indeed, familial early-onset forms of AD are caused by autosomal dominant mutations in APP or 
presenilin genes that promote amyloidogenic processing of APP into Aβ. However, 95% of AD 
cases are sporadic and late-onset, precipitated by a complex interplay of environmental and 
genetic risk factors.  
In addition to aging, which constitutes the highest risk factor for AD, stress and 
glucocorticoids have been suggested as precipitating factors of disease (Csernansky et al., 2006; 
Elgh et al., 2006; Silva et al., 2019; Vyas et al., 2016), increasing Tau accumulation, APP 
misprocessing and Aβ production (Catania et al., 2009; Green et al., 2006; Sotiropoulos et al., 
2011). Interestingly, GC treatment can shift APP metabolism towards the amyloidogenic 
pathway (Sotiropoulos et al. 2008), suggesting that it promotes APP and BACE1 interaction.  
Many of the genetic risk factors for late-onset AD (LOAD) are associated with 
endosomal protein trafficking dysfunction, prolonging the presence of APP and/or BACE1 in 
endosomes (Small et al., 2017; Ubelmann et al., 2017). The acidic pH of endosomes is optimal 
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for BACE1 activity (Haass et al., 2012), which leads to Aβ production when APP and BACE1 
interact in the endosomal network (Cirrito et al., 2005; Lin Zou et al., 2007).  
The GTPase Rab35 is a master regulator of endosomal protein trafficking, and in a 
previous study, we showed that Rab35 recruits Hrs to initiate ESCRT pathway-mediated 
degradation of ubiquitylated Tau. We also found that high levels of glucocorticoids 
downregulated Rab35 in hippocampal neurons, leading to Tau accumulation (Vaz-Silva et al., 
2018). These findings demonstrate that GCs precipitate Tau pathology by disrupting Rab35-
mediated endolysosomal trafficking. In addition to its role in Tau degradation, Rab35 has also 
been identified as a negative regulator of Aβ production in a loss-of-function screen of Rab 
GTPases (Udayar et al., 2013), suggesting that it controls trafficking pathways involved in Aβ 
generation. However, the mechanisms by which Rab35 reduces Aβ production are yet unclear. 
In this chapter, we discover that hippocampal Rab35 GTPase levels are decreased under 
conditions associated with amyloidogenesis in both rats and humans, and that Rab35 regulates 




3.2.1. Rab35 levels are decreased under conditions associated with Aβ overproduction  
Our previous study showed that treatment with glucocorticoids (GCs) suppresses Rab35 
expression in hippocampal neurons in vivo (Vaz-Silva et al., 2018). To test whether chronic 
stress has a similar effect, I monitored the levels of Rabs associated with endocytic protein 
trafficking (Rabs 5, 7, 8, 11, 14, and 35), in the hippocampi of rats subjected to four weeks of a 
chronic unpredictable stress paradigm by our collaborators in the Sotiropoulos Lab. The chronic 
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unpredictable stress consisted of one randomly assigned stressor per day: air dryer, rocking 
platform, cold water, or overcrowding. I found that hippocampal Rab35 levels were decreased by 
~60% in stressed rats compared to controls (Fig. 6A-B), and that this decrease was not observed 
for other Rabs associated with endocytic protein trafficking (Fig. 6A-B), in line with our 
previous findings (Vaz-Silva et al., 2018). In parallel, I monitored hippocampal Rab levels in 
animals infused with Aβ peptides by our collaborators – a procedure that is widely used to model 
early AD neuropathology in rodents and primates (Fraustchy et al., 1996; Geula et al., 1998; 
Stephan & Phillips, 2005). Infused Aβ peptides interact with full-length APP to further stimulate 
Aβ production (Catania et al., 2009; Davis-salinas et al., 1995; Heredia et al., 2004; Lorenzo et 
al., 2000) and circumvent the need to overexpress human APP containing mutation(s) that 
impact its localization and trafficking. Importantly, levels of Rab14 and Rab35, but not most 
other endocytic Rabs, were similarly decreased in Aβ-infused hippocampi (Fig. 6A-B).  
Since aging is the greatest risk factor for AD, and previous studies report increased APP 
misprocessing in the aged brain (Cisternas et al., 2018; Jiang et al., 2010; Kimura et al., 2016), 
my colleague João Vaz-Silva also compared Rab35 expression levels in hippocampi of young (4 
month old) versus aged (22-24 month old) rats. Again, we observed a significant (~25%) 
decrease in hippocampal Rab35 levels in the aged animals (Fig. 6C-D), suggesting 




Figure 6. Hippocampal Rab35 levels decrease under stress, Aβ infusion, and aging in rats. A-B) Representative 
immunoblots and quantification of Rabs 5, 7, 8, 11, 14, and 35 levels in the hippocampus of control (Ctrl), stressed, 
and Aβ-infused rats. Blots were probed for the noted Rabs and tubulin, with values normalized to tubulin and 
expressed as percent of the control condition (dotted line). Rab14 and Rab35 levels are reduced by Aβ, but only Rab35 
is significantly reduced by both chronic stress and Aβ (**PCON vs. stressed=0.0075, *PCON vs. Aβ-infused=0.0228, **PCON vs. Aβ-
infused=0.0069, one-way ANOVA with Dunnet’s post hoc analysis, n=8–10/condition). C-D) Representative 
immunoblots and quantification of Rab35 levels in the hippocampus of young (4-month-old) and aged (22- to 24-
month-old) rats. Blots were probed for Rab35 and actin, with values normalized to actin and expressed as percent of 
young animals. Rab35 levels are decreased in aged animals (**P=0.0056, unpaired t-test, n=13-17/condition). 
 
To investigate whether aging similarly impacts Rab35 levels in humans, I analyzed gene 
expression data from the Genotype-Tissue Expression (GTEx) Portal, a collection of data from 
non-diseased human tissue (https://gtexportal.org/home/). Hippocampal mRNA transcript levels 







































































































et al., 2012) as the most stable gene across ages and brain regions of this data set. Intriguingly, I 
found that Rab11 and Rab35 transcripts were decreased in the hippocampi of individuals 60-79 
years of age compared to those who are 20-39, while mRNA expression levels for Rabs 5, 7, 8, 
and 14 were not altered by aging (Fig. 7A-B). Among the endocytic Rab GTPases tested in our 
rat tissue and the human tissue database, Rab35 was the only Rab GTPase to show a consistent 
decrease in expression with stress, Aβ infusion, and aging. I therefore probed whether Rab35 
levels decrease with age in various brain areas and found that Rab35 mRNA expression is 
reduced in the hippocampus and frontal cortex of aged individuals, but not in basal ganglia or 
cervical spinal cord, which are tissues less implicated in stress- and AD-related pathological 
changes (Fig. 7C-D). To  determine whether Rab35 levels are similarly altered in the AD brain, 
my colleague Caroline Magalhaes de Toledo analyzed RNA-Seq data from high quality 
hippocampal tissue obtained from AD patients and age-matched controls (Nativio et al., 2020). 
Transcript levels were again normalized to IPO8, and we found that Rab35 transcripts were 
reduced in the AD vs. control tissue (Fig. 7E-F). Together, these findings suggest that Rab35 




Figure 7. Hippocampal Rab35 levels decrease under conditions associated with amyloidogenesis in humans. A) 
Schematic diagram of human hippocampus, used for analysis of transcriptome data from the Genotype-Tissue 
Expression (GTEx) project. B) Quantification of hippocampal mRNA transcripts for Rabs 5, 7, 8, 11, 14, and 35 from 
individuals ages 20-39 years and 60-79 years, normalized to IPO8. Rab11 and Rab35 mRNA expression is decreased 
in the aged group (**P=0.0026; ***P=0.0003, Mann-Whitney test, n=10-114 samples/condition). C) Schematic 
diagram of human brain areas used for analysis of transcriptome data from the Genotype-Tissue Expression (GTEx) 
project: hippocampus, frontal cortex, caudate basal ganglia, and the cervical spinal cord. D) Quantification of Rab35 
mRNA transcripts from individuals ages 20-39 years and 60-79 years, normalized to IPO8 (*P=0.0155, ***P=0.0003, 
Mann-Whitney test, n=6-135 samples/condition). E) Schematic of control and AD human brain. F)  Rab35 
hippocampal RNA expression in age-matched Control (CTRL) vs. Alzheimer’s (AD) tissue samples, normalized 
against IPO8 and displayed as a fraction of control samples, from data collected by Nativio et al.  (*P=0.03, Mann-
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3.2.2. Rab35 is a negative regulator of APP-BACE1 interaction and Aβ production 
A previous study identified Rab35 as a negative regulator of Aβ production in a loss-of-
function screen of Rab GTPases in non-neuronal cells (Udayar et al., 2013), though the 
mechanism for this is yet unclear. To confirm these findings, I first determined whether boosting 
hippocampal Rab35 levels could inhibit APP processing in aged animals. Our collaborating lab 
injected 17-19 month-old rats with AAV8 to express GFP or GFP-Rab35 in the dorsal 
hippocampus (see Fig. 8A), and I measured the protein levels of APP C-terminal fragments 
(CTFs) compared to full-length APP. Intriguingly, I found that Rab35 overexpression decreased 
the levels of both α- and β- CTFs relative to full-length APP (Fig. 8B-E). These results suggest 
that Rab35 inhibits APP processing, and that its reduction during aging and/or stress could 
















































































































Figure 8. Rab35 overexpression in aged rat hippocampi reduces APP cleavage. A) Schematic of bilateral 
hippocampal injection of AAV-GFP control or AAV-GFP-Rab35 constructs into aged (22-24 months old) rats. 
Separate cohorts were used for each condition. B-E) Representative immunoblots and quantification of ⍺- and β-APP 
C-terminal fragments (CTFs) relative to full-length APP in the dorsal hippocampus of aged rats. Blots were probed 
for APP, Rab35, and tubulin with values normalized to tubulin and expressed as percent of the GFP control condition. 
Rab35 expression significantly decreases the ratio of CTFs to full-length APP (*P=0.017, **P=0.0048; Welch’s 
unpaired, two-tailed t-test, n=4-8 samples/condition). All numeric data represent mean ± SEM. 
 
To verify that Rab35 impacts APP processing in vitro, I measured levels of APP cleavage 
products in N2a cells co-transfected with APP-GFP and either mCherry alone, mCh-Rab35, or 
mCh + siRNAs to knock down Rab35 (siRab35; see Fig. 9A-B). Here, overexpression of Rab35 
significantly decreased (by ~70%) the levels of APP C-terminal fragments (CTFs) relative to 








































































































Figure 9. Rab35 overexpression reduces APP cleavage in N2a cells. A-B) Representative immunoblots and 
quantification of Rab35 knockdown in N2a cells expressing APP-GFP (APP) or FLAG-BACE1 (BACE1), HA 
control, and a control siRNA (siCtrl) or siRNA to knock down Rab35 (siRab35). Blots were probed for Rab35 and 
tubulin; values were normalized to tubulin and expressed as a fraction of the siCtrl condition. Cells transfected with 
siRab35 show a ~55% reduction in Rab35 expression, regardless of whether they co-express APP-GFP or FLAG-
BACE1 (**P=0.0059, unpaired two-tailed t-test, n=3 samples/condition). C-D) Representative immunoblots and 
quantification of APP C-terminal fragments (CTFs) from N2a cells expressing mCherry, mCh-Rab35, or mCh + 
siRab35; blots were probed for GFP, tubulin, and Rab35, with values normalized to tubulin and expressed as percent 
of mCh control. Overexpression of Rab35 decreases CTFs relative to full-length APP (**P=0.0029, ***P =0.0006, 
Brown-Forsythe ANOVA with Welch’s correction n=9 independent samples/condition). All numeric data represent 
mean ± SEM.  
 
A decrease in CTFs was also observed in lysates from human induced pluripotent stem 
cell (iPSC)-derived cortical neurons lentivirally transduced with mCh or mCh-Rab35 (Fig. 10A-
B). To determine whether levels of APP CTFs corresponded to Aβ production, we measured the 
concentration of Aβ40 and Aβ42 peptides in medium collected from these human-derived 
neurons. Indeed, Rab35 overexpression decreased the levels of both Aβ40 and Aβ42 by 20% 
(Fig. 10C-D). Together, these results indicate that Rab35 inhibits APP cleavage and the 





Figure 10. Rab35 overexpression suppresses amyloidogenic processing of APP in iPSC-derived cortical 
neurons. A-C) Representative immunoblots and quantification of APP C-terminal fragments (CTFs) from iPSC-
derived cortical neurons expressing mCherry or mCh-Rab35. Blots were probed for APP/CTFs, tubulin, and mCherry, 
with values normalized to tubulin and expressed as percent of mCh control. Overexpression of Rab35 does not affect 
full-length APP expression but decreases CTFs relative to full-length APP (*P=0.017, unpaired t-test, n=19-21 
samples/condition). D-E) Measurement of Aβ peptides secreted by iPSC-derived human neurons transduced with 
mCherry or mCh-Rab35. Values are normalized to total secreted protein and expressed as percent of mCh control. 
Rab35 overexpression decreases the levels of both Aβ40 (D) and Aβ42 peptides (E) (**PAβ40=0.008, **PAβ42=0.009, 
unpaired t-test, n=19-20 samples/condition, 4 independent cultures). All numeric data represent mean ± SEM.  
 
To understand how Rab35 regulates APP processing at the subcellular level, we 
examined its effect on the interaction between APP and BACE1, required for the rate-limiting 
cleavage step of APP into Aβ. As a readout of APP-BACE1 interaction, we utilized a 
previously-published bimolecular fluorescence complementation (BiFC) assay in which APP is 













































































































the complementary C-terminal fragment (BACE:VC) (Das et al., 2015) (see Fig. 11A). I used 
flow cytometry to analyze the mean Venus fluorescence intensity in mouse neuroblastoma (N2a) 
cells co-expressing APP:VN, BACE:VC, and HA-tagged Rab GTPases (for Rab gain-of-
function), with Alexa(R)-647-labeled HA antibody identifying the Rab-expressing cells in which 
Venus fluorescence was measured (Fig. 11B). Compared to average Venus fluorescence across 
the 16 Rab GTPases investigated (Fig. 11C), I found that Rab35 gain-of-function decreased the 
Venus signal by 25% (Fig. 11C).  
 
 
Figure 11. Rab35 reduces APP-BACE1 interaction in a screen using Venus Bi-Molecular Fluorescence 
complementation. A) Schematic diagram of bimolecular fluorescence complementation assay, in which APP and 
BACE1 are tagged with complementary fragments of Venus fluorescent protein (VN and VC, respectively). 
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Representative fluorescence activated cell sorting (FACS) plot of N2a cells co-expressing HA-Rab35 (HA-Rab35+), 
APP:VN, and BACE:VC (Venus+), as used for analyses in C. The number of HA-Rab35+ cells expressing low or no 
Venus fluorescence (top left quadrant) is greater than the number of HA-Rab35+ cells expressing high Venus 
fluorescence (top right quadrant). C) Quantification of Venus fluorescent protein (VFP) intensity in N2a cells 
overexpressing the indicated Rab GTPases. Venus fluorescence for each Rab is normalized to average VFP 
fluorescence of the entire Rab-expressing cell population (Mean). Rab35 is a negative regulator, and Rabs 6, 15, and 
26 are positive regulators of APP-BACE1 interaction (*PRab6=0.0385, *PRab15=0.0135, *PRab26=0.0371, 
*PRab35=0.0468; one-way ANOVA, with Dunnet’s post-hoc analysis; n=4 independent samples across 2 experiments, 
approximately 80,000 cells/condition). All numeric data represent mean ± SEM. 
 
To confirm these findings, João Vaz-Silva performed quantitative fluorescence 
microscopy of N2a cells co-transfected with APP:VN and BACE:VC together with mCh, mCh-
Rab35, or mCh co-expressed with an shRNA previously shown to knockdown Rab35 (shRab35; 
Sheehan et al., 2016). Here, Rab35 overexpression again decreased Venus fluorescence by 70% 
compared to mCh control, suggesting reduced APP-BACE1 interaction, while Rab35 
knockdown increased Venus fluorescence by 200% (Fig. 12A-B). Rab35 overexpression and 
knockdown had similar effects on the size of Venus puncta, with overexpression decreasing 






Figure 12. Rab35 is a negative regulator of APP-BACE1 interaction in N2a cells. A-C) Representative images 
and quantification of Venus fluorescence in N2a cells expressing APP:VN, BACE:VC, and either mCh, mCh-Rab35, 
or shRab35. B) Rab35 overexpression significantly decreases, and knockdown increases, Venus fluorescence intensity 
compared to mCh control (*P=0.042, ***P=0.0001, one-way ANOVA, with Dunnet’s post-hoc analysis, n=21-27 
cells/condition, 2 experiments). C) Venus puncta size in N2a cells expressing mCh, mCh-Rab35, or shRab35. Rab35 
overexpression decreases, and knockdown increases, puncta size (*P=0.0142, **P=0.0077, ****P<0.0001, by one-
way ANOVA with Tukey’s multiple comparisons test, n=17-43 cells/condition, 2 experiments). Scale bar: 10 µm. All 
numeric data represent mean ± SEM. 
 
We further assessed the impact of Rab35 on endogenous APP-BACE1 interaction in 
primary rat hippocampal neurons, using the proximity ligation assay (PLA) in neurons 
transduced either with mCh, mCh-Rab35, or mCh + shRab35 (see Fig. 13A). Though it is 
possible that Rab35 interferes with Venus reconstitution in the BiFC experiments in N2a cells, 
our PLA data was consistent with the BiFC experiments, revealing that Rab35 overexpression in 
primary hippocampal neurons significantly decreased the number of PLA puncta in cell bodies 
(from 6 to 4.5 puncta/250 µm2), representing colocalized APP and BACE1 (Fig. 13B-C). Rab35 



































































enough to detect increases in this interaction (Fig. 13B-C). Overall, these findings demonstrate 
that Rab35 is an important regulator of APP-BACE1 interaction in neurons.  
 
 
Figure 13. Rab35 is a negative regulator of APP-BACE1 interaction in hippocampal neurons. A) Schematic 
diagram of the proximity ligation assay (PLA). APP (orange) and BACE1 (purple) are tagged with primary antibodies, 
which are then recognized by anti-mouse and anti-rabbit PLA probes. When the probes are in close proximity, they 
produce a signal marking protein-protein interaction. B-C) Images and quantification for proximity ligation assay 
(PLA) to detect endogenous APP-BACE1 interaction in primary hippocampal neurons expressing mCh, mCh-Rab35, 
or shRab35. Overexpression of Rab35 decreases PLA puncta density in neuronal cell bodies compared to mCh control, 
while knockdown has no effect (**P=0.001, unpaired two-tailed t-test, n=43-44 cells/condition, 2 independent 
cultures). Scale bar: 10 µm. All numeric data represent mean ± SEM. 
 
Given that APP is cleaved by BACE1 primarily in endosomes (Haass et al., 2012), our 
findings suggest that Rab35 impacts APP and/or BACE1 trafficking and localization in the 
endosomal network. We therefore examined the effects of Rab35 overexpression and knockdown 
on endogenous APP and BACE1 colocalization with Rab11-positive recycling endosomes in 
hippocampal neurons (see Fig. 14A, D), a common site of APP cleavage by BACE1 (Bera et al., 
2020; Buggia-Prevot et al., 2014; Chia et al., 2013; Das et al., 2015; Tan & Gleeson, 2019). 
Indeed, my colleague Mei Zhu found that Rab35 overexpression decreased both APP and 
BACE1 colocalization with Rab11 in the somatodendritic compartment by nearly one fourth 
(18% for APP and 25% for BACE1), while Rab35 knockdown increased colocalization by a 






































overexpression decreased the density of Rab11 endosomes (Fig. 14H), I found that its gain- and 
loss-of-function had no effect on endosome size (Fig. 14H), indicating that the observed changes 
in colocalization were not due to gross effects of Rab35 on the morphology of Rab11 





Figure 14. Rab35 regulates APP and BACE1 endosomal distribution in hippocampal neurons. A) Schematic 
representing colocalization between anti-APP antibody (blue) and Rab11-positive recycling endosomes (red) in 
primary hippocampal neurons. B-C) Representative images and quantification of APP colocalization with Rab11-
positive recycling endosomes in 14 DIV hippocampal neurons expressing mCh, mCh-Rab35, or shRNA to knockdown 
Rab35 (shRab35). Compared to mCh control, Rab35 overexpression decreases APP colocalization with Rab11, while 






































































































































n=62–78 cells/condition, 3 independent cultures). D) Schematic representing colocalization between anti-BACE1 
antibody (blue) and Rab11-positive recycling endosomes (red) in primary hippocampal neurons. E-F) Representative 
images and quantification of BACE1 colocalization with Rab11 in 14 DIV hippocampal neurons. Rab35 
overexpression decreases, and knockdown increases, BACE1 colocalization with Rab11 compared to mCh control 
(**P=0.001, ****P<0.0001, one-way ANOVA, Dunnett’s post-hoc analysis, n=58-66 cells/condition, 3 independent 
cultures). Scale bars: 10 µm, 1 µm for zoomed insets. G-H) Quantification of Rab11 puncta density (G) and size (H), 
showing that Rab35 overexpression reduces Rab11 puncta density but not size (**P=0.0002, one-way ANOVA with 




Lifetime stress is a precipitating factor for AD, and can accelerate the disease. Stress has 
been shown to increase Aβ production, synaptic atrophy, and cognitive and mood deficits 
(Catania et al., 2009; Lopes et al., 2017; Sotiropoulos et al., 2011). Aβ accumulation in AD and 
aging has been well-documented in humans (Fjell et al., 2014; Rodrigue et al., 2009) and rodents 
(Cisternas et al., 2018; Kimura et al., 2016), underscoring the need for investigating the 
molecular mechanisms of amyloidogenic APP processing. Previously, we showed that stress 
downregulates Rab35 and leads to increased Tau accumulation (Vaz-Silva et al., 2018), but the 
roles of stress/GCs and Rab35 in APP amyloidogenic processing remain poorly understood.  
In this chapter, I describe that Rab35 protein expression was reduced by stress, Aβ-
infusion, and aging in the rat hippocampus. I also show that Rab35 RNA transcript levels were 
reduced in aged (60-79 years of age) vs. young (20-39 years of age) humans, and in AD patients 
vs. age-matched controls. Together, these data indicate that Rab35 levels are reduced by 
conditions associated with Aβ production in rodents and humans. Furthermore, our lab identified 
Rab35 as a negative regulator of APP-BACE1 interaction, which is necessary for Aβ production. 
I show that among 16 tested Rab GTPases, Rab35 most potently reduced APP-BACE1 
interaction, and that Rab35 had these effects on endogenous APP-BACE1 interaction in 
hippocampal neurons. Moreover, we discover that this decrease in APP-BACE1 interaction has 
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functional consequences: Rab35 reduced APP CTFs in N2a cells and iPSC-derived cortical 
neurons. This is an intriguing result because β-C-terminal fragments (β-CTFs) have been shown 
to promote Tau hyperphosphorylation and accumulation (Moore et al., 2015), and to impair 
endosomal protein sorting (Moore et al., 2015; Willen et al., 2017), further contributing to the 
dysregulation of intracellular trafficking in AD. We also show that this inhibition of APP 
cleavage also reduced secreted Aβ40 and Aβ42 in iPSC-derived neurons, indicating that Rab35-
mediated decreases in APP-BACE1 interaction functionally reduce amyloidogenic cleavage and 
Aβ production. 
Because Rab35 regulates intracellular protein trafficking through the endosomal network, 
I propose that Rab35 decreases APP-BACE1 interaction by limiting the presence of APP and 
BACE1 in endosomal compartments. Indeed, we show that Rab35 reduced both APP and 
BACE1 colocalization with Rab11-positive endosomes in hippocampal neurons. Together, the 
data presented in this chapter suggest that stress downregulates Rab35 expression, thereby 




Chapter 4: Rab35 sorts APP and BACE1 into distinct trafficking 
pathways, which may be disrupted by stress/GCs 
4.1. Rationale 
In chapter 3, we learned that Rab35 reduces APP-BACE1 interaction, Aβ production, and 
APP/BACE1 presence in endosomal compartments, where amyloidogenic cleavage of APP 
occurs. These results suggest that Rab35 either promotes the degradation of APP and/or BACE1, 
or that it mediates the sorting of these proteins into pathways that reduce their residence time in 
endosomes. In previous studies, we have shown that Rab35 recruits the ESCRT pathway, 
facilitating the degradation of synaptic vesicle proteins and Tau (Sheehan et al., 2016; Vaz-Silva 
et al., 2018). Rab35 also mediates protein retrograde trafficking from endosomes to the trans-
Golgi network, such as that of the mannose-6-phosphate receptor (Cauvin et al., 2016), and fast 
protein recycling to the plasma membrane, such as that of T-cell receptors and cell adhesion 
molecules (Allaire et al., 2013; Argenzio et al., 2014; Kouranti et al., 2006; Patino-Lopez et al., 
2008). Given the multiple trafficking events regulated by Rab35, and its role in reducing APP-
BACE1 interaction, it is possible that glucocorticoid (GC)-mediated downregulation of Rab35 
impacts APP or BACE1 trafficking to modulate stress-induced Aβ production.  
In this chapter, I investigate the role of Rab35 and GCs in APP and BACE1 trafficking 
pathways. I assess whether Rab35 mediates the degradation, retrograde trafficking, or fast 
recycling of APP and BACE1 and discover that Rab35 regulates BACE1 retrograde trafficking 
to the Trans-Golgi Network through the effector OCRL, and APP recycling to the plasma 
membrane through ACAP2. Furthermore, I test whether GC administration, which mimics stress 
in cells, dysregulates Rab35-mediated trafficking pathways of APP and/or BACE1. I find that 
GCs increase APP-BACE1 interaction and slow APP and BACE1 recycling, which can be 
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blocked by Rab35 overexpression. Together, these data reveal that Rab35 serves as a molecular 




4.2.1. Rab35 promotes BACE1 trafficking through the retrograde pathway  
Given that Rab35 mediates protein degradation through the endolysosomal pathway 
(Sheehan et al., 2016; Vaz-Silva et al., 2018), we examined whether Rab35 decreases APP-
BACE1 interaction and Aβ production by stimulating the degradation of APP and/or BACE1. 
Using a previously described cycloheximide (CHX)-chase assay to measure protein degradation 
by blocking the translation of new proteins (Miranda et al., 2018; Sheehan et al., 2016), João 
Vaz-Silva and I found that Rab35 gain- or loss-of-function did not alter the degradation rate of 




Figure 15. Rab35 does not alter degradation of APP, CTFs, or BACE1 in hippocampal neurons. A-C) 
Representative immunoblots and quantification of APP and APP CTF degradation in 14 DIV hippocampal neurons 
transduced with GFP, GFP-Rab35 or shRab35. Neurons were treated with cycloheximide (CHX) for 0, 2, 4 or 8 hours, 
and probed for APP and tubulin. Values were normalized to tubulin and expressed as percent of protein levels at 0h. 
Modulation of Rab35 levels does not alter APP and/or CTF degradation (nAPP=7-8 independent samples per 
condition/timepoint, nCTFs=5-6 independent samples per condition/timepoint). D-E) Representative immunoblots and 
quantification of BACE1 degradation in 14 DIV hippocampal neurons transduced with GFP, GFP-Rab35 or shRab35, 
treated with CHX for 0, 2, 4, 8, or 24 hours, and probed for BACE1 and tubulin. Values were normalized to tubulin 
and expressed as percent of protein levels at 0h. Modulation of Rab35 levels does not alter BACE1 degradation (n=3-
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Since Rab35 also regulates the retrograde trafficking of mannose-6-phosphate receptors 
from endosomes to the trans-Golgi network (TGN) (Cauvin et al., 2016), I next examined whether 
Rab35 similarly promotes the retrograde trafficking of APP and/or BACE1. Here, I used a 
modified antibody feeding assay (Ubelmann et al., 2017; Vieira et al., 2010) in N2a cells, which 
are more amenable to trafficking assays than neurons. This assay was coupled with 
immunofluorescence microscopy to monitor the colocalization of internalized APP-GFP or 







Figure 16. Retrograde trafficking assay timecourse for APP and BACE1. A) Schematic representation of APP 
retrograde trafficking assay, in which cell-surface APP was labeled with 22C11 antibody, cells were incubated for 0, 
10, 30 or 60 minutes to allow for APP internalization, and finally, cells were immunostained with syntaxin-6 
antibodies to label the TGN. B) Representative images of APP retrograde trafficking timecourse in control cells, with 
cells outlined in gray, the TGN area outlined in blue, and white arrowheads pointing to areas of colocalization in 
insets. APP colocalization with the TGN (insets) increases up to the 30 min chase timepoint and reduces at 60 min. 
C) Schematic representation of BACE1 retrograde trafficking assay. Surface FLAG-BACE1 was labeled with FLAG 
antibody. D) Representative images of BACE1 retrograde trafficking timecourse, showing BACE1 colocalization with 
the TGN (insets) increasing over the timecourse. Scale bars: 5 µm; 1 µm for zoomed insets. ES: Endosomal structure; 
TGN: trans-Golgi network. 
 
In the case of APP, I found that Rab35 overexpression did not alter its colocalization with 
syntaxin-6 at any timepoint post-labeling compared to the control condition (Fig. 17). To verify 
that I was primarily tracking full-length APP vs. an N-terminal APP ectodomain fragment to which 
the APP antibody (22C11) is raised, I measured the colocalization between 22C11 and the C-
terminal GFP tag of APP (Fig. 18A-B). While colocalization of these signals was ~50% (Fig. 
18B), this measurement significantly underestimated the degree of colocalization due to saturating 
perinuclear levels of APP-GFP, which obscured dimmer puncta in the periphery where the 
majority of 22C11 signal was located (Fig. 18A-B). Moreover, shedding of the APP ectodomain 
is expected to occur at the plasma membrane, as evidenced by studies that enhanced APP 
ectodomain shedding by inhibiting APP internalization (Carey et al., 2005; Haass et al., 2012; 
Lichtenthaler, 2006). This APP ectodomain cleavage would lead to rapid diffusion of sAPP 
fragments into the medium rather than their recycling to the TGN. Together, these results indicate 




Figure 17. Rab35 does not affect APP retrograde trafficking in N2a cells. A-B) Representative images and 
quantification of N2a cells expressing APP-GFP and HA vector control or HA-Rab35. Internalized APP (red) and 
syntaxin-6 (blue) are shown at 0 and 60 min timepoints post-labeling. Overexpression of Rab35 does not significantly 
alter the colocalization of internalized APP with syntaxin-6 at any timepoint, indicating no change in retrograde 
trafficking (n=53-69 cells per condition/timepoint, 3 experiments). Scale bars: 5 µm, 1 µm for zoomed insets. All 
























































Figure 18. Colocalization between APP N- and C-terminus does not change throughout timecourse. A-B) 
Representative images and quantification of APP N- and C-terminus colocalization using 22C11 antibody to mark the 
N-terminus and GFP to mark the C-terminus in N2a cells expressing APP-GFP and HA control or HA-Rab35. 22C11 
antibody (blue) colocalizes with GFP (green) approximately 50% of the time across timepoints and conditions (n=53-
101 cells/condition, 4 experiments). White arrowheads in insets point to areas of colocalization. Scale bars: 5 µm; 1 
µm for zoomed insets. All numeric data represent mean ± SEM.  
 
I next performed the same assay with FLAG-BACE1 (see Fig. 19A). In contrast to its 
effect on APP, I found that Rab35 overexpression significantly increased the colocalization of 
internalized BACE1 with syntaxin-6 at the 30 and 60 min timepoints post-labeling, indicating 
that Rab35 regulates the retrograde trafficking of BACE1, but not APP. To determine whether 
this trafficking depends on Rab35 activation/GTP binding, I performed the same assay in N2a 
cells expressing dominant negative (DN) HA-Rab35. Expression of DN Rab35 either reduced or 
did not affect BACE1/syntaxin-6 colocalization at the majority of post-labeling timepoints 
compared to the control condition (Fig. 19B-C). However, DN Rab35 expression was lower than 
that of WT Rab35 (Fig. 19D), suggesting that the results likely underestimate the effects of 
Rab35 inactivation on BACE1 retrograde trafficking. Nevertheless, these results indicate that 







Figure 19. Rab35 stimulates the retrograde trafficking of BACE1. A) Schematic representation of BACE1 
internalization assay, in which cell-surface BACE1 was labeled with FLAG antibody and cells were incubated for 0, 
10, 30 or 60 minutes to allow for BACE1 internalization, followed by immunostaining with syntaxin-6 antibodies for 
TGN labeling. B-C) Representative images and quantification of BACE1 internalization in N2a cells expressing 
FLAG-BACE1 and either HA Control, HA-Rab35 wild-type (WT), or HA-Rab35 dominant negative (DN). 
Internalized BACE1 (red) and syntaxin-6 (blue) are shown at 0 and 60 min timepoints post-labeling. Compared to 
vector control, overexpression of WT Rab35 increases colocalization of internalized BACE1 with syntaxin-6 at both 
30 and 60 min timepoints, and DN Rab35 prevents this effect (*PDN-0 min=0.0392, ** PDN-10 min=0.0011, ** PWT-30 = 
0.0025, **** PWT-60 min<0.0001, 2-way ANOVA and Sidak post hoc analysis, n=45-155 cells per condition/timepoint. 
2-5 experiments. Time × Rab35 interaction F6,1253=8.002, P<0.0001, overall Rab35 effect F2,1253=10.43, P<0.0001). 
Scale bars: 5 µm; 1 µm for zoomed insets. D) Representative immunoblots and quantification of WT and DN Rab35 
expression in N2a cells expressing FLAG-BACE1 with HA control, HA-Rab35 WT, or HA-Rab35 DN. Immunoblots 
were probed for Rab35 and tubulin. Rab35 levels are normalized to tubulin and expressed as a ratio of HA control 
condition. Cells express WT Rab35 at higher levels than DN Rab35 (*P=0.0131, ***P=0.0009, ****P<0.0001 by 
one-way ANOVA with Tukey’s multiple comparisons test; n=14-16 independent samples/condition). All numeric 
data represent mean ± SEM. ES: Endosomal structure; TGN: trans-Golgi network. 
 
The Rab35 effector and lipid phosphatase OCRL (Oculocerebrorenal Syndrome of Lowe 
Inositol Polyphosphate-5-Phosphatase) is required downstream of Rab35 for the retrograde 
trafficking of mannose-6-phosphate receptors (Cauvin et al., 2016). To test whether Rab35-
mediated retrograde trafficking of BACE1 also requires OCRL, I performed the same antibody 
feeding/TGN colocalization assay in the presence of siRNAs against OCRL (siOCRL; Fig. 20A). 
While OCRL knockdown alone did not affect BACE1 colocalization with syntaxin-6 compared 
to control siRNAs, it did prevent the Rab35-mediated increase in BACE1/syntaxin-6 
colocalization (Fig. 20B-C), indicating that Rab35 stimulates the sorting of BACE1 into the 




Figure 20. Rab35-mediated retrograde trafficking of BACE1 is mediated by the effector OCRL. A) 
Representative immunoblots and quantification of OCRL knockdown in N2a cells expressing APP-GFP and either 
HA control or HA-Rab35, together with control siRNA (siCtrl) or siRNA against OCRL (siOCRL). Immunoblots 





















































































































Cells transfected with siOCRL show a ~60% reduction in OCRL, regardless of whether they co-express HA control 
or HA-Rab35 (****P<0.0001; unpaired, two-tailed t-test, n=12 samples/condition). B-C) Representative images and 
quantification of BACE1 internalization in N2a cells expressing FLAG-BACE1 and HA or HA-Rab35 together with 
siCtrl or siOCRL. Internalized BACE1 (red) and syntaxin-6 (blue) are shown at 0 and 60 min timepoints post-labeling. 
Compared to control, overexpression of Rab35 increases colocalization of internalized BACE1 with syntaxin-6 at the 
60 min timepoint, and knockdown of OCRL blocks this effect (**PHA + siCtrl vs. Rab35 + siCtrl=0.0151, 2-way ANOVA and 
Tukey’s multiple comparisons test, n=50-61 cells per condition/timepoint, 2 experiments. Time × Condition 
interaction F6,635=3.861, P=0.009, overall Condition effect F2,635=2.446, P=0.0629). Scale bars: 5 µm; 1 µm for 
zoomed insets. All numeric data represent mean ± SEM.  
 
To investigate whether Rab35 similarly alters BACE1 trafficking in hippocampal 
neurons, my colleague Mei Zhu measured endogenous APP and BACE1 colocalization with 
syntaxin-6 following Rab35 overexpression and knockdown. Consistent with my data in N2a 
cells, APP colocalization with syntaxin-6 was not affected by these manipulations (Fig. 21A-B), 
while BACE1/syntaxin-6 colocalization was significantly increased by Rab35 overexpression 
(Fig. 21C-D). This increase was not caused by Rab35-mediated alterations in TGN morphology, 
as the density and size of syntaxin-6 puncta were unchanged by Rab35 overexpression and 








































































































































Figure 21. Rab35 regulates BACE1 endosomal distribution in hippocampal neurons. A-B) Representative 
images and quantification of APP colocalization with syntaxin-6 in 14 DIV hippocampal neurons expressing mCh, 
mCh-Rab35, or shRab35. Rab35 overexpression or knockdown does not significantly alter APP colocalization with 
syntaxin-6, compared to the control condition (n=64-70 cells/condition, 3 independent cultures). C-D) Representative 
images and quantification of BACE1 colocalization with syntaxin-6 in hippocampal neurons expressing mCh, mCh-
Rab35, or shRab35. Overexpression of Rab35 increases BACE1 colocalization with syntaxin-6, while Rab35 
knockdown does not significantly alter this value (**P=0.006, one-way ANOVA, Dunnet post-hoc analysis, n=66-69 
cells/condition, 3 independent cultures). Scale bars: 10 µm; 1 µm for zoomed insets. E-F) Quantification of syntaxin-
6 puncta density (E) and size (F) in hippocampal neurons expressing mCh, mCh-Rab35, or shRab35. Rab35 
overexpression or knockdown does not affect either value (n=56-68 cells/condition, 3 independent cultures). All 
numeric data represent mean ± SEM.  
 
4.2.2. Rab35 stimulates APP recycling to the plasma membrane  
Rab35’s ability to promote the retrograde trafficking of BACE1 to the TGN could be 
sufficient for reducing APP-BACE1 interaction in the endosomal network. However, Rab35 also 
facilitates the fast endocytic recycling of proteins (i.e. T-cell receptors, β1 integrin) to the plasma 
membrane (PM) in a pathway that operates in parallel with Rab11-mediated endosomal recycling 
(Allaire et al., 2013; Argenzio et al., 2014; Kobayashi et al., 2014; Kouranti et al., 2006; Patino-
Lopez et al., 2008). Stimulating APP and/or BACE1 trafficking into this pathway could also 
reduce APP-BACE1 interactions in Rab11-positive endosomes. To determine whether Rab35 
promotes the fast recycling of APP and/or BACE1, I used another antibody feeding assay 
(Ubelmann et al., 2017) to monitor the internalization and PM recycling of APP-GFP and 
FLAG-BACE1 at several timepoints post-labeling (Fig. 22, 23A). Intriguingly, I found that 
Rab35 overexpression stimulated both APP internalization and recycling to the PM at nearly all 






Figure 22. Recycling assay timecourse for APP and BACE1. A) Schematic representation of APP recycling assay, 
in which APP internalization and recycling were assessed by labeling cell-surface APP with 22C11 antibody followed 
by cell incubation for 0, 10, 30, or 60 minutes, and fixation and immunostaining with secondary antibodies to detect 
recycled or internalized APP. B) Representative images of APP recycling assay timecourse in control cells. Cells are 
outlined in gray, and white arrows point to recycled 22C11 antibody at the cell surface. C) Schematic representation 
of BACE1 recycling assay, in which BACE1 internalization and recycling were assessed by labeling cell-surface 
BACE1 with FLAG antibody followed by cell incubation for 0, 10, 30, or 60 minutes, and fixation and 
immunostaining with secondary antibodies to detect recycled or internalized BACE1. D) Representative images of 
BACE1 recycling assay timecourse, with cells outlined in gray and white arrows pointing to recycled FLAG antibody 
around the cell surface. Scale bars: 5 µm. ES: Endosomal structure; TGN: trans-Golgi network. 
 
To determine whether APP internalization and recycling steps were dependent on Rab35 
activation, I also performed this assay in the presence of DN Rab35. As anticipated, expression 
of DN Rab35 did not stimulate APP recycling relative to the control condition (Fig. 23B, D), 
indicating the dependence of this trafficking step on Rab35 activation. Surprisingly, the DN 
construct stimulated APP internalization at the 30 and 60 min timepoints to a similar degree as 
WT Rab35 (Fig. 23B-C), suggesting that Rab35 mediates APP internalization independently of 




Figure 23. Rab35 stimulates APP recycling to the plasma membrane. A) Schematic of APP recycling assay, in 
which APP internalization and recycling were assessed by labeling cell-surface APP with 22C11 antibody, incubating 
cells for 0, 10, 30 or 60 minutes, and finally fixing and immunostaining cells with secondary antibodies to detect 
recycled or internalized APP. B-D) Representative images and quantification of APP internalization and recycling in 
N2a cells expressing APP-GFP and either HA control, HA-Rab35 WT, or HA-Rab35 DN. Internalized and recycled 
APP are shown at 0 and 60 min timepoints post-labeling. Compared to control, Rab35 overexpression increases the 
ratio of internalized (C) and recycled (D) APP over total APP-GFP at multiple timepoints (*PWT-30 min=0.0299, **PDN-
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30 min=0.0027, **PDN-60 min=0.0017, ****P<0.0001, 2-way ANOVA and Sidak post-hoc analysis, n=53-269 cells per 
condition/timepoint, 3 experiments. For C: Time × Rab35 interaction F6,1897=3.002, P=0.0064, overall Rab35 effect 
F2,1897=118.9. For D: Time × Rab35 interaction F6,1897=3.443, P=0.0022, overall Rab35 effect F2,1897=26.03). Scale 
bars: 5 µm. All numeric data represent mean ± SEM. ES: Endosomal structure; TGN: trans-Golgi network. 
 
Rab35 also stimulated BACE1 internalization at the earliest timepoint post-labeling (0 
min; Fig. 24A-C), but did not alter BACE1 internalization at later timepoints, nor its recycling to 
the PM (Fig. 24B, D).  Consistent with these findings, I observed higher cell-surface levels of 




Figure 24. Rab35 does not mediate BACE1 recycling. A) Schematic representation of BACE1 recycling assay, in 
which BACE1 internalization and recycling were assessed by labeling cell-surface BACE1 with FLAG antibody, 
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incubating cells for 0, 10, 30 or 60 minutes, and finally fixing and immunostaining cells with secondary antibodies to 
detect recycled or internalized BACE1. B-D) Representative images and quantification of BACE1 internalization and 
recycling in N2a cells expressing FLAG-BACE1 and either HA or HA-Rab35. Internalized and recycled BACE1 are 
shown at 0 and 60 min timepoints post-labeling (B), and are expressed in graphs as ratios of total BACE1, normalized 
to the 0 min timepoint (C-D). Rab35 overexpression increases BACE1 internalization at early timepoints, but has no 
effect on BACE1 recycling dynamics (***P=0.0004, *P=0.0494 (internalization); 2-way ANOVA with Sidak post 
hoc analysis, n=127-143 cells per condition/timepoint, 3 experiments). E-F) Representative images and quantification 
of steady-state cell-surface levels of APP in N2a cells transfected with APP-GFP and HA control or HA-Rab35. Rab35 
increases cell-surface APP, expressed as a ratio of cell surface to total protein (****P<0.0001; unpaired two-tailed t-
test, n=54-64 cells/condition, 3 experiments). G-H) Representative images and quantification of steady-state cell-
surface levels of BACE1 in N2a cells transfected with FLAG-BACE1 and HA control or HA-Rab35. Rab35 does not 
alter cell-surface BACE1 levels (n=46-70 cells/condition, 3 experiments). Scale bars: 5 µm. All numeric data represent 
mean ± SEM. ES: Endosomal structure; TGN: trans-Golgi network. 
 
Fast endocytic recycling has been shown to occur through two distinct pathways, 
mediated by the Rab35 effectors OCRL and ACAP2 (Mrozowska & Fukuda, 2016). I first tested 
whether Rab35-mediated APP recycling to the PM relies on OCRL, using the 
internalization/recycling assay in N2a cells transfected with siRNAs against OCRL (see Fig. 
20A). Interestingly, I found that while OCRL knockdown did not alter Rab35-induced APP 
internalization, it further increased Rab35-induced APP recycling at the 60 min timepoint (by 
~50%; Fig. 25A, C). These data suggest that Rab35-mediated APP recycling does not occur 
through OCRL, but that OCRL knockdown frees Rab35 to interact with the effector responsible 




Figure 25. Rab35 effector OCRL does not mediate APP recycling. A-C) Representative images and quantification 
of APP internalization and recycling in N2a cells expressing APP-GFP and either HA or HA-Rab35, together with 
control siRNA (siCtrl) or siRNA to knockdown OCRL (siOCRL). B) Compared to control, overexpression of Rab35 
increases APP internalization at the 60 min timepoint, and OCRL knockdown does not alter this effect (**PHA+siCtrl vs. 
Rab35+siCtrl=0.0069, ****PHA+siCtrl vs. Rab35+siOCRL<0.0001; 2-way ANOVA with Sidak’s post-hoc test, n=33-47 cells per 
condition/timepoint, 2 experiments. Time × Condition interaction F6,460=9.453, P<0.0001, overall Condition effect 
F3,460=8.431, P<0.0001). C) Compared to control, overexpression of Rab35 increases APP recycling at 60 min, and 
OCRL knockdown further increases this effect (*PHA+siCtrl vs. Rab35+siCtrl=0.0152, ****PHA+siCtrl vs. Rab35+siOCRL<0.0001, 
*PRab35+siCtrl vs. Rab35+siOCRL=0.0400; 2-way ANOVA and Tukey’s multiple comparisons test, n=33-47 cells per 
condition/timepoint, 2 experiments. Time × Condition interaction F6,460=4.537, P=0.0002, overall Condition effect 
F3,460=5.606, P=0.0009). Scale bar: 5 µm. All numeric data represent mean ± SEM. 
 
I next tested whether ACAP2 (ArfGAP with Coiled-coil, Ankyrin repeat and PH domains 
2) is the effector mediating APP recycling, again using our antibody feeding assay in the 

































































































not alter APP internalization compared to siRNA control, nor lessen the effect of Rab35 on APP 
internalization (Fig. 26A-B), as expected if this sorting step is a GTP-independent function of 
Rab35. However, ACAP2 knockdown completely abolished Rab35-enhanced APP recycling to 
the PM at the 60 min time point (Fig. 26A, C). These data demonstrate that Rab35 stimulates the 
sorting of APP into the fast recycling pathway, via GTP-independent stimulation of APP 
internalization and ACAP2-dependent stimulation of APP recycling to the PM. Together, these 
actions increase APP sorting out of endosomes and promote its accumulation at the PM, thereby 
















































































































Figure 26. Rab35 effector ACAP2 mediates APP recycling to the plasma membrane. A-C) Representative images 
and quantification of APP internalization and recycling in N2a cells expressing APP-GFP and either HA or HA-
Rab35, together with control siRNA (siCtrl) or siRNA to knockdown ACAP2 (siACAP2). Internalized and recycled 
APP are shown at 0 and 60 min timepoints post-labeling.  B) Compared to control, overexpression of Rab35 increases 
APP internalization, and ACAP2 knockdown does not alter this effect (***PHA + siCtrl vs. Rab35 + siACAP2=0.0003, ****PHA 
+ siCtrl vs. Rab35 + siCtrl<0.0001, 2-way ANOVA and Tukey’s multiple comparisons test, n=20-48 cells per 
condition/timepoint, 3 experiments. Time × Rab35 interaction F4,310=2.843, P=0.0244, overall Rab35/ACAP2 effect 
F2,310=39.12, P<0.0001). C) Compared to control, overexpression of Rab35 increases APP recycling, and ACAP2 
knockdown blocks this effect (*PHA + siCtrl vs. Rab35 + siCtrl=0.0457, 2-way ANOVA and Tukey’s multiple comparisons 
test, n=20-48 cells per condition/timepoint, 3 experiments. Time × Condition interaction F4,310=2.877, P=0.023, overall 
Condition effect F2,310=3.279, P=0.039). Scale bars: 5 µm. All numeric data represent mean ± SEM.  
 
Finally, I tested whether ACAP2, like OCRL, mediates Rab35-regulated BACE1 
retrograde trafficking. Using our antibody feeding/syntaxin-6 colocalization assay to monitor 
BACE1 retrograde trafficking, I found that knockdown of ACAP2 (siACAP2; Fig 27A) did not 
alter the Rab35-mediated increase in BACE1/syntaxin-6 colocalization (Fig. 27B-C). These 
findings reveal that Rab35 regulates APP and BACE1 trafficking via distinct mechanisms, 
stimulating the retrograde trafficking of BACE1 to the TGN through OCRL, and the fast 




Figure 27. ACAP2 does not mediate the retrograde trafficking of BACE1. A) Representative immunoblots and 
quantification of ACAP2 knockdown in N2a cells expressing FLAG-BACE1 and either HA control or HA-Rab35, 
with control siRNA (siCtrl) or siRNAs against ACAP2 (siACAP2). Immunoblots were probed for ACAP2 and tubulin, 
and represented as a ratio of the control condition. Cells expressing siACAP2 show reduced levels of ACAP2, 
regardless of whether they co-express HA control or HA-Rab35 (**P=0.0078; un-paired, two-tailed t-test. n=4 
samples/condition). B-C) Representative images and quantification of BACE1 retrograde trafficking in N2a cells 





































































































and syntaxin-6 (blue) are shown at 60 min post-labeling. Rab35 overexpression increases BACE1 colocalization with 
syntaxin-6 at 60 min, and ACAP2 knockdown does not alter this effect (**PHA+siCtrl vs HA-Rab35+siCtrl=0.0056; 2-way 
ANOVA with Tukey’s multiple comparison’s test, n=50-66 cells per condition/timepoint, 3 experiments. Time × 
Condition interaction F6,702=4.665, P=0.0001, overall Condition effect F3,702=4.417, P=0.0044). Scale bars: 5 µm; 1 
µm for zoomed insets.  All numeric data represent mean ± SEM. 
 
4.2.3. Rab35 counteracts GC-induced pro-amyloidogenic trafficking of APP and BACE1  
Although GCs are known to stimulate Aβ production both in vitro and in vivo, their 
effects on APP and BACE1 trafficking are largely unexplored. I therefore examined whether 
GCs alter the interaction between APP and BACE1 within the endosomal network, again using 
the Venus BiFC assay in N2a cells (see Fig. 11). Here, I found that 24-hour treatment with the 
synthetic GC dexamethasone significantly increased Venus intensity, indicating that GCs 
promote APP-BACE1 interaction (Fig. 28). I next examined whether overexpression of Rab35 
could block this effect, as predicted if GC-induced downregulation of Rab35 underlies the 
increased APP-BACE1 interaction. Indeed, Rab35 overexpression blocked the GC-induced 
increase in Venus intensity (Fig. 28), suggesting that Rab35 prevents this pro-amyloidogenic 




Figure 28. GC-induced APP-BACE1 interaction is blocked by Rab35 overexpression. A-B) Representative 
images and quantification of Venus fluorescence intensity in N2a cells expressing APP:VN, BACE:VC, and either 
mCh or mCh-Rab35, treated with GCs or vehicle control (CON). GCs increase Venus intensity in control cells, but 
have no effect in Rab35-expressing cells, which exhibit an overall decrease in Venus fluorescence (***PmCh CON vs mCh 
GC=0.0004, *PmCh CON vs mCh-Rab35 CON=0.028, two-way ANOVA, Tukey’s post-hoc analysis, n=3 experiments.  Rab35 
x GC interaction F1,291=5.989, P=0.015, overall Rab35 effect F1,291=41.35, P<0.0001, overall GC effect F1,291=12.19, 
P=0.0006). Scale bar: 10 µm. All numeric data represent mean ± SEM. 
 
I next tested whether GCs impact the APP and BACE1 trafficking pathways mediated by 
Rab35. Using the aforementioned antibody feeding/syntaxin-6 colocalization assay, I found that 
24h treatment with GCs did not alter BACE1 retrograde trafficking compared to vehicle control 














































Figure 29. GCs do not affect BACE1 retrograde trafficking in N2a cells. A-B) Representative images and 
quantification of BACE1 retrograde trafficking in N2a cells expressing FLAG-BACE1 and either HA or HA-Rab35, 
treated with GCs or vehicle control (CON). Internalized BACE1 (red) and syntaxin-6 (blue) are shown at the 60 min 
timepoint post-labeling. GC treatment does not alter BACE1 colocalization with the TGN at any timepoint (n=43-65 
cells per condition/timepoint, 3 experiments).  Scale bars: 5 µm; 1 µm for zoomed insets. All numeric data represent 
mean ± SEM. 
 
However, GC treatment significantly altered the kinetics of APP and BACE1 fast 
endocytic recycling as revealed by the antibody internalization/recycling assay. In particular, 
GCs stimulated APP internalization at the 0 min timepoint post-labeling, and decreased its 
recycling back to the PM at the 30 min timepoint compared to vehicle control (Fig. 30A-C). 
Remarkably, Rab35 further enhanced APP recycling compared to the control condition (Fig. 
30A, C), similar to its actions in the absence of GCs (see Fig. 23). Additionally, GCs decreased 
BACE1 internalization at multiple timepoints, as well as BACE1 recycling to the PM, and Rab35 
blocked these effects (Fig. 31A-C). Together, these findings demonstrate that GCs disrupt the 
endocytic trafficking of APP and BACE1, resulting in their increased colocalization in 
















































Figure 30. GC-induced pro-amyloidogenic APP trafficking is reversed by Rab35 overexpression. A-C) 
Representative images and quantification of APP internalization and recycling in N2a cells expressing APP-GFP and 
either HA or HA-Rab35, treated with GC or vehicle control (CON). GCs alter APP internalization (B) and recycling 
(C) kinetics, while Rab35 overexpression prevents these effects (For B: *PHA+DMSO vs HA-Rab35+GC=0.0119, ***PHA+DMSO 
vs HA-Rab35+GC=0.0009, ****P<0.0001; 2-way ANOVA with Tukey’s post hoc analysis, n=47-77 cells per 
condition/timepoint, 3 experiments. For APP internalization: Time × Condition interaction F6,780=15.81, P<0.0001. 
For C: ****PHA+DMSO vs HA-Rab35+GC<0.0001, *PHA+DMSO vs HA-Rab35+GC=0.0136, **PHA+DMSO vs HA+GC=0.0011; two-way 
ANOVA with Tukey’s post hoc analysis, n=47-77 cells per condition/timepoint, 3 experiments. For APP recycling: 
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Figure 31. GC-induced pro-amyloidogenic BACE1 trafficking is blocked by Rab35 overexpression. A-C) 
Representative images and quantification of BACE1 internalization and recycling in N2a cells expressing FLAG-
BACE1 and either HA or HA-Rab35, treated with GCs or vehicle control (CON). GC treatment decreases BACE1 
internalization (B) and recycling (C), and these effects are blocked by Rab35 overexpression (For B: *PHA+GC vs HA-
Rab35+GC=0.0491, ***PHA+DMSO vs HA-+GC=0.0003, ****P<0.0001; two-way ANOVA with Tukey’s multiple comparisons 
test, n=54-76 cells per condition/timepoint, 3 experiments. For BACE1 internalization: Time × Condition interaction 
F6,765=3.385, P=0.0027. For C: *PHA+DMSO vs HA-Rab35+GC=0.0487, ***PHA+DMSO vs HA+GC=0.0009; two-way ANOVA 
with Tukey’s multiple comparisons test, n=54-76 cells per condition/timepoint, 3 experiments. For BACE1 recycling: 










































































































Endocytic and lysosomal abnormalities are among the earliest features of AD (Nixon, 
2005), indicating that dysfunctional endosomal trafficking can trigger APP misprocessing and 
the accumulation of AD-associated proteins. Rab35 regulates the degradation, retrograde 
trafficking, and fast recycling of several membrane proteins through the endosomal network 
(Cauvin et al., 2016; Kouranti et al., 2006; Sheehan et al., 2016; Vaz-Silva et al., 2018), and this 
study is the first to investigate the role of Rab35 on APP and BACE1 trafficking pathways.  
In this chapter, I demonstrate that Rab35 does not mediate the degradation of APP, APP-
CTFs, or BACE1, but that it promotes BACE1 retrograde trafficking and APP recycling to the 
plasma membrane. I show that Rab35 overexpression increases BACE1 colocalization with the 
trans-Golgi network, and that this is mediated by the effector OCRL, similar to Rab35-mediated 
retrograde trafficking of the mannose-6-phosphate receptor (Cauvin et al., 2016; Van Rahden et 
al., 2012). Additionally, I show that APP internalization and recycling are increased by Rab35 
overexpression, and that APP recycling is mediated by the effector ACAP2, an effector 
previously documented in Rab35-mediated recycling pathways (Mrozowska & Fukuda, 2016). 
These data indicate that Rab35 decreases APP-BACE1 interactions in endocytic compartments 
by sorting them into separate pathways that are dependent on distinct effectors. 
Furthermore, the effects of chronic stress and GCs on the progression of AD and AD-
related pathology in human patients and rodent models suggest that stress/GCs affect the 
molecular pathways underlying AD. Here, I provide more definitive evidence that GCs impact 
APP and BACE1 trafficking pathways. I show that GCs increase APP-BACE1 interaction and 
slow APP and BACE1 recycling to the cell surface, and that Rab35 overexpression blocks these 
effects, suggesting that Rab35-mediated trafficking pathways are disrupted by GCs. Collectively, 
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these data support my hypothesis that stress/GCs promote conditions for Aβ production by 
reducing Rab35 levels, thereby disrupting the sorting of APP and BACE1 out of the endosomal 
network and into their distinct trafficking pathways. Under these conditions, APP and BACE1 
remain in endosomal compartments for longer time periods, enabling BACE1 to cleave APP and 




Chapter 5: Methods for isolating and measuring exosomes 
5.1. Rationale 
5.1.1. Aβ and Tau spread during AD progression 
The accumulation of Aβ peptides and hyperphosphorylated Tau are the hallmarks of AD, 
and stress/glucocorticoids (GCs) have been shown to promote both APP amyloidogenic 
processing and Tau hyperphosphorylation (Catania et al., 2009; Green et al., 2006; Jeong et al., 
2006; Sotiropoulos et al., 2011, 2019; Srivareerat et al., 2009). Furthermore, there is 
considerable evidence that Aβ and Tau enhance one other’s accumulation to exacerbate AD 
pathology. For instance, secreted Tau has been shown to increase levels of Aβ peptides (Bright et 
al., 2015), while oligomeric and fibrillar forms of Aβ promote Tau phosphorylation (Busciglio et 
al., 1995; Ferreira et al., 1997; Sackmann & Hallbeck, 2020). Aβ oligomers have also been 
shown to increase cellular uptake of Tau “seeds” (Shin et al., 2019) that spread Tau pathology in 
a prion-like manner (Clavaguera et al., 2020). Although AD is characterized by the combination 
of Aβ and Tau’s degenerative effects, Tau appears to be the ‘final executor’ of AD progression 
and pathology. Intriguingly, Tau knockout has been shown to prevent Aβ-induced excitotoxicity 
and behavioral deficits in transgenic mice expressing human APP (hAPP) with a mutation that 
causes familial AD (Roberson et al., 2007), and to block Aβ-induced axonal transport defects in 
hippocampal neurons (Vossel et al., 2010). Furthermore, Tau knockout prevented stress-induced 
dendritic and synaptic loss in mouse hippocampus and prefrontal cortex, as well as 
accompanying behavioral deficits (Lopes et al., 2017, 2016). These studies reveal that Tau 
knockout is protective against both Aβ- and stress-induced synaptotoxicity and indicate its 
essential role in AD- and stress-induced brain pathology.  
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A key characteristic of neurodegenerative diseases such as AD is their progression over 
time, driven by neuronal dysfunction that spreads throughout the brain (Przedborski et al., 2003). 
Indeed, analysis of post-mortem brains from AD patients reveals that the spreading of Tau and 
amyloid pathology between interconnected brain areas correlates with disease severity (Braak & 
Braak, 1991). Amyloid plaques and Tau tangles are observed in the hippocampus during early-
stage AD, and spread to the entorhinal cortex and frontal cortex in later disease stages. However, 
the mechanisms by which pathogenic Aβ and Tau spread between cells and across brain regions 
are unclear, and little is known about how stress/GCs affect these processes. 
 
5.1.2. Astrocytes and microglia impact AD pathology 
Though neurodegenerative disease research has historically focused on neuronal 
pathology, more recent studies have begun to uncover the contributions of glial cells in the 
progression of AD. Astrocytes and microglia support and protect neurons, often reacting quickly 
to disturbances, including injury, infection, and neurodegenerative disease (Gleichman & 
Carmichael, 2020; Jauregui-Huerta et al., 2010). Astrocytes are the most common glial cell type 
in the brain, regulating functions such as blood-brain barrier maintenance and extracellular 
homeostasis, and their dysfunction has been linked to many types of brain pathology (Siracusa et 
al., 2019). Astrocytes have been shown to take up and degrade Aβ (Mohamed & Posse De 
Chaves, 2011; Ries & Sastre, 2016), and their loss of function is linked to AD. However, 
astrocytes may also drive AD progression by promoting neuroinflammation (Garwood et al., 
2017) and potentially by producing Aβ, given that they express APP and its secretases (Frost & 
Li, 2017). Furthermore, Aβ synaptotoxicity and Tau phosphorylation in cell culture were reduced 
by the inhibition of astrocyte activation (Garwood et al., 2011), suggesting that astrocytes are 
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drivers of neuronal damage initiated by Aβ and Tau. Astrocytes may also contribute to the 
intercellular spreading of amyloid and Tau pathology through the secretion of exosomes, 
extracellular vesicles ~40-150 nm in size that mediate intercellular communication. Exosomes 
released by astrocytes have been shown to selectively target neurons (Venturini et al., 2019), and 
to carry Aβ (Winston et al., 2019). It is currently unclear whether astrocytes contribute to or 
protect from Aβ-induced neuronal deficits, and they may behave differently depending on the 
stage of disease progression.  
Microglia are the immune cells of the central nervous system, active and motile, 
patrolling the brain for pathogens, misfolded proteins, or unhealthy cells (Benarroch 2013; Bilbo 
& Stevens, 2017; Rock et al., 2004). Microglia are important for neurogenesis, trophic support of 
neurons, and response to illness and injury (Paolicelli et al., 2019). However, they can drive 
neuroinflammation when the brain is subject to chronic homeostatic perturbations (e.g. repeated 
injury, chronic stress, neurodegenerative disease), as they are the primary producers of cytokines 
and other inflammatory mediators (Hanisch, 2002; Li & Barres, 2018). Because of this feature, 
researchers have focused on neuroinflammation as the main contribution of microglia to AD 
progression. Indeed, there is ample evidence that activated microglia correlate with reduced 
functional brain activity and cognitive performance in AD patients, and that microglia activated 
by Aβ cause neuronal dysfunction and death through their release of cytokines (Leng & Edison, 
2021). However, recent research indicates that in addition to neuroinflammation, microglia play 
a more direct role in AD by internalizing and secreting Aβ and Tau. Microglia may be protective 
early in AD by phagocytosing Aβ (Gratuze et al., 2018), and detrimental in the later stages of 
AD through the spreading of Aβ or Tau pathology. Microglia have been shown to internalize 
aggregated Aβ and secrete it in a more synaptotoxic soluble form through extracellular vesicles 
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(Joshi et al., 2014), suggesting that they promote the intercellular transmission of Aβ. 
Furthermore, microglia may also spread Tau pathology through extracellular vesicles (Fruhbeis 
et al., 2013; Paolicelli et al., 2019; Vogels et al., 2019). In fact, depletion of either microglia or 
exosome production was found to reduce the spread of mutant Tau linked to human tauopathy 
(Asai et al., 2015), indicating that both microglia and exosomes drive the spreading of 
pathogenic Tau between cells. Collectively, these studies suggest that astrocytes and microglia 
are important players in the progression of AD, and likely contribute to the spreading of Aβ and 
Tau pathology via exosomes. 
Exosomes, small extracellular vesicles ~40-150nm in size, are released by most cell types 
(Deatherage & Cookson, 2012; Schorey et al., 2015), and were initially thought to be a method 
of waste disposal (Johnstone, 1991; Johnstone et al., 1987; Pan et al., 1985; Rashed et al., 2017). 
Currently, exosomes are known to function in intercellular communication, exchanging nucleic 
acids (Simpson et al., 2009; Valadi et al., 2007; Waldenstrom et al., 2012), lipids (Vidal et al., 
1989), and proteins (Simpson et al., 2009) between cells to maintain homeostasis, or as a 
response to pathological processes (Colombo et al., 2014; Lo Cicero et al., 2015; Van Niel et al., 
2018; Yanez-Mo et al., 2015). Due to their role in sharing components between cells, exosomes 
are a means by which AD pathology can spread intercellularly. Exosomal proteins have been 
shown to accumulate in amyloid plaques of AD patients (Rajendran et al., 2006), and prefibrillar 
Aβ preferentially binds to exosomes (Lim et al., 2019), linking these vesicles to AD pathology. 
Moreover, brain-derived exosomes from AD patients carry oligomeric Aβ, which can be taken 
up by cells in culture (Sinha et al., 2018). Interestingly, blocking the formation, secretion, and 
uptake of exosomes reduced the spread of Aβ oligomers (Sinha et al., 2018), indicating that they 
are an important component in the spread of Aβ.  
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Tau has also been found in purified exosomes from cerebrospinal fluid (CSF) of AD 
patients, and from Tau transgenic (P301L) mouse brain and neuroblastoma cells (Brunello et al., 
2020). Neuron-derived exosomes from AD patients promote Tau phosphorylation in wild-type 
mice (Winston et al., 2016), indicating that exosomes can spread Tau pathology. Furthermore, 
Tau-containing exosomes released by neurons can be taken up by neighboring neurons and 
microglia (Wang et al., 2017), indicating that they may spread AD pathology intercellularly, and 
that this can occur between different cell types. Together, these studies suggest that exosomes are 
important mediators of the intercellular spread of Aβ and Tau. 
 
5.1.3. Exosome generation and secretion 
Exosomes play an important role in cellular homeostasis and intercellular 
communication, by removing misfolded proteins and transferring proteins, lipids, and RNAs 
from cell to cell. Exosomes are generated through the endosomal pathway: originating as the 
intraluminal vesicles (ILVs) of multivesicular bodies (MVBs), they become exosomes when 
MVBs fuse with the plasma membrane (Luarte et al., 2017; Van Niel et al., 2006). The 
endosomal sorting complex required for transport (ESCRT) pathway is critical for the formation 
of MVBs, and the first ESCRT component, Hrs, has been shown to regulate exosome secretion 
(Tamai et al., 2010). ILVs are generated at MVB membranes through several pathways: in the 
canonical ESCRT-dependent pathway, Hrs recruits downstream ESCRT components, controlling 
the initiation and completion of membrane budding. In the non-canonical ESCRT-dependent 
pathway, the proteins syntenin, syndecan, and ALIX cluster cargoes and initiate membrane 
budding, but ESCRT-III and VPS-4 are still required for the completion of membrane budding to 
form ILVs (Teng & Fussenegger, 2021). Additionally, exosomes can form at MVB membranes 
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through two ESCRT-independent pathways: tetraspanin clustering and ceramide-induced ILV 
formation (Blanc & Vidal, 2018; Escola et al., 1998; Perez-Hernandez et al., 2013; Teng & 
Fussenegger, 2021; Trajkovic et al., 2008; Van Niel et al., 2018). Tetraspanins are 
transmembrane proteins that cluster cargo for ILV loading, and whose shape facilitates the 
budding of membranes to form ILVs (Blanc & Vidal, 2018). Ceramide can form lipid raft 
domains that induce membrane invagination to create ILVs (Teng & Fussenegger, 2021). All of 
these pathways facilitate cargo loading and the generation of exosomes from MVBs (Fig. 32). 
 
 
Figure 32. MVB biogenesis machineries. Multiple molecular mechanisms of ILV generation in MVB have been 
revealed. A) In the canonical ESCRT-dependent pathway, ubiquitinated proteins in the endosomal membrane are 
recognized by ESCRT-0, which is recruited to the endosomal membrane by PtdIns3P binding and subsequently 
clustered into microdomains via clathrin binding. Then ESCRT-0 recruits ESCRT-I, and ESCRT-I recruits ESCRT-
II. ESCRT-I and ESCRT-II coordinately induce the budding of the endosomal membrane and confine cargos within 
the buds. ESCRT-III components are dynamically recruited for membrane scission of the ILV necks and disassembled 
after ILV scission via VPS4. In a non-canonical ESCRT-dependent pathway, HD-PTP binds to ESCRT-0 and 
coordinately recruits ESCRT-I and ESCRT-III, bypassing the need for ESCRT-II. B) In the syndecan-syntenin-ALIX 
pathway, membrane budding and cargo clustering can occur independently of ubiquitin and ESCRT-0, but ESCRT-
III and VPS4 are required for the scission step. C) Ceramide, generated from sphingomyelin by mSMase2, plays a 
key role in the ESCRT-independent pathway of ILV biogenesis. Ceramide can form lipid raft microdomains, which 
might trigger the conversion of ILVs into MVBs. D) CD63 plays a vital role in the ESCRT-independent pathway of 
ILV biogenesis. CD63 can form tetraspanin-enriched microdomains, which might trigger the conversion of ILVs into 
MVBs. Abbreviations: MVB, multivesicular body; ILV, intraluminal vesicle; ESCRT, endosome sorting complex 
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required for transport; PdtIns3P, phosphatidylinositol 3-phosphate; STAM, signal transducing adaptor molecule; 
HRS, hepatocyte growth factor-regulated tyrosine kinase substrate; TSG101, tumor susceptibility gene 101 protein; 
VPS, vacuolar protein sorting; MVB12, multivesicular body subunit 12; CHMP, charged multivesicular body protein; 
HD-PTP, His domain protein tyrosine phosphatase; ALIX, ALG-2 interacting protein X; nSMase2, neutral 
sphingomyelinase 2. Copyright © 2021 The Authors, published by John Wiley & Sons, reprinted from Teng & 
Fussenegger, 2021, with permission under the terms of the Open Access Creative Commons CC BY license, provided 
as-is with no warranties or liabilities concerning this material. 
 
Previous studies indicate that Rab35 regulates exosome secretion in specific cell types  
(Abrami et al., 2013; Fruhbeis et al., 2013; Gauthier et al., 2017; Hsu et al., 2010; Yang et al., 
2019). Rab35 plays an important role in the endolysosomal sorting of proteins (Sheehan & 
Waites, 2019; Sheehan et al., 2016; Uytterhoeven et al., 2011), as well as in protein endocytosis 
and recycling with the plasma membrane (Allaire et al., 2013; Dutta & Donaldson, 2015; 
Klinkert & Echard, 2016; Kobayashi & Fukuda, 2012; Kobayashi et al., 2014; Kobayashi & 
Fukuda, 2013; Patino-Lopez et al., 2008), indicating that it could regulate both the formation and 
secretion of exosomes. Indeed, inhibition of Rab35 activity has been shown to impair exosome 
secretion (Abrami et al., 2013; Hsu et al., 2010), and the upregulation of Rab35 expression by 
the non-coding RNA HOTAIR enhances exosome secretion by promoting MVB docking (Yang 
et al., 2019). While studies to date have only examined Rab35’s role in exosome release (Abrami 
et al., 2013; Fruhbeis et al., 2013; Hsu et al., 2010), it is conceivable that Rab35 contributes to 
the ESCRT-mediated formation of MVB-derived exosomes via its recruitment of ESCRT-0 
component Hrs (Sheehan et al., 2016; Vaz-Silva et al., 2018). Our future studies will examine 
the role of Rab35 in exosome formation, cargo loading, and secretion in different brain cell types 
(neurons, microglia, and astrocytes), and in the context of Aβ and Tau intercellular transmission 
(Fig. 33). Additionally, by testing for the presence of ESCRT components, tetraspanins, and 
ceramide on Rab35-mediated exosomes, we can determine whether these exosomes are 




Figure 33. Putative role of Rab35 in exosome formation and secretion. Endocytosed proteins travel through the 
early endosome, where they can be sorted to multivesicular bodies (MVB), and loaded into intraluminal vesicles 
(ILV). Exosomes are generated when MVBs fuse with the plasma membrane and release ILVs into the extracellular 
space instead of fusing with a lysosome for degradation. ILVs can form at MVB membranes through the endosomal 
sorting complex required for transport (ESCRT) pathway (1), tetraspanin clustering (2), or ceramide-mediated ILV 
budding (3). It is unclear if Rab35 regulates the ESCRT-mediated generation of ILVs, but studies show that Rab35 
promotes MVB docking and exosome secretion (4). 
  
Exosome secretion is also modulated by stress in cells. Endoplasmic reticulum stress has 
been shown to promote MVB formation and extracellular vesicle release (Kanemoto et al., 2016; 
O’Neill et al., 2019). Furthermore, cellular stress can alter the protein and microRNA cargo of 
exosomes (Chen et al., 2018; De Jong et al., 2012; Harmati et al., 2019), indicating that stressors 
have an impact on both exosome secretion and on their contents. Interestingly, stress-regulated 
exosome release by astrocytes has been shown to reduce neuronal dendritic complexity (Luarte 
et al., 2020), providing a link between cellular stress, glial exosome secretion, and dendritic 
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damage. However, the effects of chronic stress and glucocorticoids on exosome secretion in cell 
types of the brain are not yet clear. Moreover, the connection between stress/GCs and APP 
amyloidogenic processing, Tau hyperphosphorylation and mislocalization, and their potential 
spread through exosomes remains largely unexplored.  
In the previous chapters, I described the role of Rab35 in reducing APP-BACE1 
interaction, which produces Aβ, and the impact of stress on Rab35-mediated APP and BACE1 
trafficking pathways. These data, in combination with our previous work showing that Rab35 
promotes Tau degradation, indicate that Rab35 regulates the intracellular trafficking of these 
major AD-associated proteins. In this chapter, I describe methods for investigating the roles of 
stress/GCs and Rab35 in exosome secretion, which can spread Aβ or Tau between cells. 
 
5.2. Results 
5.2.1. Size-exclusion chromatography yields more EVs than serial ultracentrifugation 
To begin our investigations, we first established and compared two techniques for 
extracellular vesicle (EV) purification from various cell types. We purified EVs from mouse 
neuroblastoma (N2a) and immortalized microglial (IMG) cells, as well as primary rodent 
astrocytes and neurons using serial ultracentrifugation (Perez-Gonzalez et al., 2017; Thery et al., 
2006) or size exclusion chromatography (Koh et al., 2018; Lobb & Moller, 2017) (Fig. 34A-C). 
Nanoparticle tracking analysis (NTA) was used to determine particle counts and sizes, which 
were calculated by ParticleMetrix ZetaView by measuring the Brownian motion of each particle 




Figure 34. Techniques used for purifying and measuring EVs. A) Conditioned medium is centrifuged to remove 
cell debris, and cells are collected for counting and western blot analysis. B) Ultracentrifugation at 20000 x g (70 min) 
and 100000 x g (70 min, 2 times) is used to isolate EVs in the serial ultracentrifugation protocol. C) Size exclusion 
chromatography requires a conditioned medium concentration step (3220 x g, 10 min) prior to EV isolation and is a 
faster purification process. D) EV samples are diluted in 1X PBS and analyzed using Nanoparticle Tracking Analysis, 




Following EV purification, we verified that our samples contained exosomes by 
immunoblotting for the commonly-used exosome markers ALIX and TSG101 (Willms et al., 
2016). Indeed, we found that our purified samples contained both markers and were enriched in 
ALIX compared to cell lysate (Fig. 35A). We then compared ultracentrifugation (UC) to size 
exclusion chromatography (SEC) by isolating EVs from primary mouse cortical neurons. By 
SEC, we were able to recover more EVs relative to the number of cells, and the particles 
measured were smaller in size than those isolated by UC, indicating a purer EV sample (Fig. 
35B-C). We concluded that SEC provides more efficient EV purification than UC, and we will 




































































Figure 35. Verification of exosome purification and comparison of ultracentrifugation versus size exclusion 
chromatography techniques. A) EVs isolated by ultracentrifugation from N2a cells, rat primary cortical neurons and 
astrocytes, and IMG cells were probed for the exosome markers ALIX and TSG101, and showed enriched expression 
of ALIX compared to cell lysate. B-C) Comparison of particle counts and particle sizes detected by NTA from mouse 
primary cortical neuron EV samples, purified using ultracentrifugation (UC) and size exclusion chromatography 
(SEC). The number of detected particles were divided by the number of cells for each collected sample, and the median 
particle sizes were recorded. SEC yields more EVs relative to the number of cells (**P=0.0065, *P=0.0367, unpaired, 
two-tailed Welch’s t-test, n=3-6 independent samples/technique), and the EVs are smaller in size, indicating purer EV 
isolation. All numeric data represent mean ± SEM. 
 
5.2.2. On-chip interferometry counts EVs and antibody binding reveals tetraspanin profiles 
Both ultracentrifugation and size exclusion chromatography isolate EVs based on size, 
but exosome identity must still be verified via immunoblot using exosome-enriched markers and 
via electron microscopy to visualize vesicle size and morphology. On-chip exosome analysis 
(ExoView R100, NanoView Biosciences) bypasses these steps by capturing EVs expressing CD9 
and CD81, tetraspanin proteins enriched on exosome membranes (Andreu & Yanez-Mo, 2014). 
With this method, conditioned medium or purified EV samples are incubated on chips containing 
antibodies against CD9 and CD81, which serve as capture probes (Fig. 36A). Following 
incubation, particle sizes are measured by interferometric imaging with an infrared wavelength 
of 405 nm, detecting extracellular vesicles in the 50-200nm range (Fig. 36B). The captured 
vesicles are also incubated with fluorescent antibodies against CD81, CD9, and CD63 (Fig. 
36C), and colocalization of these markers is measured by fluorescence on the chip (Fig. 36D) to 




Figure 36. ExoView on-chip interferometry and tetraspanin colocalization workflow. A) Samples are loaded onto 
chips containing antibodies against the exosome markers CD81 and CD9, along with two isotype controls. CD81-
positive and CD9-positive EVs bind to the antibodies on these capture probes. B) Vesicle sizes between 50-200 nm 
are determined using infrared interferometry. C) EVs bound to chip capture probes are incubated with fluorophore-
conjugated antibodies against CD81, CD9, and CD63. D) Tetraspanin profiles of each sample are determined by 
fluorescence imaging measuring the colocalization between tetraspanin antibodies. 
 
5.2.3. Microglia may secrete more exosomes than other cell types 
Microglia and astrocytes have been shown to take up Aβ and Tau from their surrounding 
environments (Asai et al., 2015; Gratuze et al., 2018; Joshi et al., 2014; Mohamed & Posse De 
Chaves, 2011; Perea et al., 2019; Wang et al., 2017), and contribute to the spread of AD 
pathology (Garwood et al., 2011; Venturini et al., 2019; Vogels et al., 2019; Winston et al., 
2019), suggesting that they may take up extracellular Tau or Aβ and secrete them through 
exosomes. To determine which brain cell types are the primary producers of exosomes, we used 
NTA to compare the number of EVs released by neurons, astrocytes, and microglial cells, 
normalized to the number of cells in each sample. Our preliminary data show that immortalized 
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microglial cells (IMG) produce more EVs than primary rodent neurons and astrocytes (Fig. 37A-
B), indicating that microglia may play a large role in exosome-mediated transmission of AD-
related proteins. Because this effect could be due to the immortalized nature of the IMG cells, we 
compared purified EV samples from IMG cells with those of another immortalized cell line, 
neuronal-derived N2a cells. We used ExoView on-chip interferometry to compare the number of 
EVs captured on CD9 and CD81 capture probes, and found that that IMG cells secreted more 
total CD9+ and CD81+ particles than N2a cells (Fig. 37C-D). These results indicate that 
microglial cells may produce substantially more exosomes than neuronal cells, and potentially 










































































Figure 37. IMG cells produce more EVs than primary cortical neurons, astrocytes, and N2a cells. A) Schematic 
of nanoparticle tracking analysis (NTA) to count the number of particles per sample. B) EVs produced by primary rat 
cortical neurons and astrocytes, as well as mouse immortalized microglial cells (IMG) were collected by serial 
ultracentrifugation, counted by NTA, and normalized to the number of cells in the sample. IMG cells trend toward 
increased particles relative to the number of cells (PNeuron vs. IMG=0.1924, PAstrocyte vs. IMG=0.1132, Brown-Forsythe 
ANOVA with Dunnett’s correction, n=9-15 samples/condition, 4-6 independent cultures). C) Schematic of ExoView 
chips with exosome capture probes containing anti-CD81 and anti-CD9 antibodies, along with isotype control capture 
probes against rat and hamster IgG. D) ExoView interferometry analysis of particles captured by CD81 and CD9 
probes, measuring the amount of CD81+ and CD9+ particles. Compared to the N2a sample, the IMG sample contained 
significantly more particles relative to the number of cells (**P=0.0079, Mann-Whitney test, n=5 capture probe 
spots/sample; 1 sample/cell type). ExoView samples in D were run by NanoView Biosciences. All numeric data 
represent mean ± SEM. 
 
Furthermore, we characterized the tetraspanin profiles of exosomes captured by CD81 
and CD9 chip capture probes (Fig. 38A). The IMG sample was enriched for CD9 compared to 
the N2a sample (Fig. 38B-E), suggesting that different cell types release exosomes with distinct 
tetraspanin profiles. In upcoming experiments, we will characterize the tetraspanin profiles of 
primary neurons, astrocytes, and microglia, which could allow us to determine which cell types 




Figure 38. Exosomes from IMG cells are enriched in CD9. A) Schematic of exosomes incubated with tetraspanin 
antibodies after binding to ExoView capture probes, followed by fluorescence imaging for tetraspanin colocalization. 
B) Representative images of capture probe spots with CD9+ (blue), CD81+ (green), and CD63+ (red) vesicles. EVs 
were purified from N2a cell conditioned media by ultracentrifugation. C) Quantification of CD9+, CD81+, and CD63+ 
EVs. The number of single-, double-, and triple-positive EVs were normalized to the number of cells and averaged 
for both CD9 and CD81 capture spots. N2a cells produce more CD9+/CD81+ and CD9+/CD81+/CD63+ vesicles than 
any other tetraspanin combination. D) Representative images of capture probe spots with CD9+ (blue), CD81+ 
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Quantification of CD9+, CD81+, and CD63+ EVs, normalized to the number of cells and averaged for both CD9 and 
CD81 capture spots. The IMG cell sample was enriched for CD9+ and CD9+/CD63+ EVs compared to the N2a cell 
sample. ExoView samples in B-E were run by NanoView Biosciences. All numeric data represent mean ± SEM. 
 
5.2.4. pHluorin-tagged CD63 and CD81 allow for the monitoring of exosome release in real time 
Our EV purifications from conditioned media provide bulk data about exosome secretion 
and tetraspanin profiles of exosomes from specific cell types, but they cannot be used to study 
exosome release dynamics at the single-cell level. Thus, in addition to NTA and on-chip analysis 
methods of measuring EV secretion, we are employing a live imaging-based approach to 
measure exosome secretion from individual cells, using the pH-sensitive GFP variant pHluorin 
fused to CD63 or CD81 (Lee et al., 2019; Pols & Klumperman, 2009). The fluorescence of these 
pHluorin-tagged exosomes is quenched in the acidic environment of MVBs, and activated when 
exosomes are released into the extracellular space (Fig. 39A). CD63-pHluorin has been used in a 
series of studies to visualize exosome secretion in vitro and in vivo with high spatial and 
temporal resolution (Messenger et al., 2018; Sinha et al., 2016; Sung et al., 2015; Sung et al., 
2020; Verweij et al., 2019; Verweij et al., 2018). In my preliminary experiments, I readily 
visualized exosome release events in N2a cells expressing mCherry-pHluorin-CD63 and 
mCherry-pHluorin-CD81 by total internal reflection fluorescence (TIRF) microscopy (Fig. 39B-
C), supporting the utility of this method. Exosome secretion was measured by timelapse image 
capture at 500 ms intervals over a period of 3 minutes. N2a cells on glass-bottom dishes were 
maintained in Normal Tyrode’s solution and a humidity chamber at 37°C with 5% CO2 for the 





Figure 39. Total Internal Reflection Fluorescence imaging of N2a cells expressing mCherry-pHluorin-CD63. 
A) Schematic of a multivesicular body (MVB) containing exosomes expressing a tetraspanin protein tagged with 
mCherry and pHluorin. At the lower MVB pH (~5), pHluorin fluorescence is quenched (gray dot) while mCherry 
fluorescence persists (red dot). When the MVB fuses with the plasma membrane, the neutral pH (~7) of the 
extracellular space causes exosomes expressing the pHluorin-tagged tetraspanin to fluoresce (green dot). B) 
Representative images of an N2a cell expressing mCh-pHluorin-CD63. mCherry fluorescence is seen most brightly 
in the center of the cell where proteins are synthesized; pHluorin fluorescence is around the cell periphery where 
vesicles fuse. Brightfield images are used to visualize the cell perimeter. The merged image provides a full view of 
the cell expressing both mCh (red) and pHluorin (green). C) Example images of EV tracking in the pHluorin channel 
during timelapse imaging. Images were acquired every 500 ms for 3 min and analyzed using ImageJ Fiji 2D/3D 
Particle Tracker, which circles any moving particles. Here, transient EV release is marked by the lower left arrow. 
The software tracks a vesicle appearing at 14 s and disappearing at 16.5 s. More sustained vesicle release is marked 
by the top right arrow, where the software tracks a vesicle appearing at 13.5 s and disappearing at 17.5 s. 
 
5.2.5. GCs may increase exosome secretion 
Stress/GCs have been shown to modulate exosome secretion and contents in cancer cells 
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determine how GCs affect exosome secretion in neurons, astrocytes, and microglia, and whether 
this contributes to the transmission of Aβ or Tau. Using ExoView on-chip exosome analysis in 
preliminary experiments, we found that treating mouse primary cortical neurons with 
dexamethasone, a synthetic glucocorticoid (GC), did not affect particle capture on CD9+ and 
CD81+ capture probes (Fig. 40A-B) or their tetraspanin profiles (Fig. 40C-F).  
Interestingly, visualization of exosome secretion by live imaging using pHluorin-tagged 
tetraspanins in N2a cells revealed that GC treatment increased the total number of CD63-positive 
exosomes released (Fig. 41A-B). Surprisingly, CD81-positive exosomes did not show the same 
trend (Fig. 41C-D). This may be due to the smaller size of CD81+ exosomes (as reported by Lee 
et al., 2019) and lower observed fluorescence of pHluorin-CD81, leading to reduced recognition 
of release events by the particle tracking software. Alternatively, GCs may have differential 
effects on specific tetraspanin-expressing exosomes, though this is contrary to our preliminary 
results on tetraspanin profiles of control and GC-treated primary cortical neurons, which showed 
no differences in exosomal CD9, CD81, and CD63 expression between conditions (see Fig. 40). 
In upcoming experiments, we will resolve this question by using primary neurons, astrocytes, 
and microglia to determine the effects of GCs on exosome secretion using both techniques: 
ExoView interferometry and tetraspanin profiling, as well as live cell imaging. In the future, our 
lab will also use proteomics and miRNAomics on purified EV samples to determine how GCs 




Figure 40. GC treatment does not affect total CD9+ and CD81+ exosome secretion or tetraspanin profiles in 
primary mouse cortical neurons. A) Schematic of ExoView chips with exosome capture probes containing anti-
CD81 and anti-CD9 antibodies, along with isotype control capture probes against rat and hamster IgG. B) ExoView 
interferometry analysis of particles captured by CD81 and CD9 probes, measuring the amount of CD81+ and CD9+ 
positive particles in SEC-purified EV samples from primary mouse cortical neurons treated with glucocorticoids (GC) 
or vehicle control (CON). C-D) Representative images and quantification of capture probe spots with CD9+ (blue), 
CD81+ (green), and CD63+ (red) EVs from control neurons. The number of single-, double-, and triple-positive EVs 
were normalized to the number of cells and averaged for both CD9 and CD81 capture spots. E-F) Representative 
images and quantification of single-, double-, and triple-positive EVs on capture probe spots from GC-treated neurons. 
The number of EVs were normalized to the number of cells and averaged for both CD9 and CD81 capture spots. 
Exosomes captured by the probes had the same tetraspanin profiles regardless of GC treatment. All numeric data 












































































































































Figure 41. GCs may impact CD63-positive but not CD81-positive exosome secretion. A) Representative images 
of N2a cells treated with GCs or vehicle control, expressing the tetraspanin protein CD63 tagged with mCherry (red) 
and pHluorin (green). Grayscale images show Fiji/ImageJ 2D/3D Particle Tracker detection of moving particles in the 
pHluorin channel. Colored circles mark each detected particle. B) Quantification of total particles detected per 3 min 
timelapse image, normalized to the number of cells in the frame, and displayed as a percent of the control condition. 
GC-treated N2a cells expressing mCh-pHluorin-CD63 produce more tracked particles relative to the number of cells 
(*P=0.0328, Mann-Whitney test, n=15 images/condition, 4 independent cultures/condition). C) Representative images 
of N2a cells treated with GCs or vehicle control, expressing mCh-pHluorin-CD81 (red/green), and Fiji/ImageJ 2D/3D 
Particle Tracker detection of moving particles (grayscale, with circles). D) Quantification of total particles detected 
per 3 min timelapse image, displayed as a percent of the control condition. GC treatment in N2a cells expressing mCh-
pHluorin-CD81 does not affect the total number of tracked particles (n=14 images/condition, 2 independent 












































































5.3. Summary  
Stress/GCs accelerate the progression of AD and the propagation of Tau and Aβ 
throughout brain regions, suggesting that stress can promote the spread of Tau and Aβ 
pathology. Nearly all brain cells release exosomes for intercellular communication (Fruhbeis et 
al., 2013), providing a mechanism by which AD proteins could spread from cell to cell. Indeed, 
exosomes have been shown to carry Tau and Aβ, which can be released and taken up by neurons, 
astrocytes, and microglia (Guix et al., 2018; Lim et al., 2019; Perez-Gonzalez et al., 2012; 
Rajendran et al., 2006; Saman et al., 2012). Both stress/GCs and Rab35 have been shown to 
modulate exosome secretion and contents (Abrami et al., 2013; Chen et al., 2018; Fruhbeis et al., 
2013; Gauthier et al., 2017; Harmati et al., 2019; Hsu et al., 2010; Yang et al., 2019), suggesting 
yet another avenue by which stress may exacerbate AD. This chapter describes methods for 
isolating extracellular vesicles (EVs) by ultracentrifugation and size exclusion chromatography, 
and measuring their release by nanoparticle tracking analysis (NTA), ExoView on-chip 
interferometry and tetraspanin profiling, as well as live cell imaging.  
 Here, we learn that size exclusion chromatography (SEC) is a more precise method for 
isolating EVs than ultracentrifugation, in agreement with Sidhom, et al., who reviewed several 
exosome purification techniques and concluded that SEC is the most accessible, reproducible, 
and easy to use. All of our future experiments will utilize SEC instead of ultracentrifugation. 
Using NTA in combination with ExoView interferometry and tetraspanin profiling, we find that 
IMG cells produce more EVs than primary neurons, astrocytes, and N2a cells, and that IMG cell 
exosomes are enriched in the tetraspanin protein CD9. These data indicate that microglia may be 
the most prolific producers of exosomes among brain cell types, with the potential to 
significantly influence exosome-mediated Tau and Aβ intercellular transmission.  
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ExoView interferometry and tetraspanin profiling allow the measurement of particle 
number, size, and tetraspanin colocalization using only a small amount of conditioned medium 
or purified EV sample. This technique will allow us to characterize the tetraspanin profiles of 
neurons, astrocytes, and microglia, from which we can develop a method to determine which cell 
types dominate exosome secretion in samples from mixed-cell cultures or brain tissues. Most 
intriguingly, the on-chip technology can be modified to capture EVs expressing other markers, 
by coating the capture probes with antibodies other than CD9 and CD81. Moreover, the 
ExoView workflow can be used to study the contents of exosomes pulled down by the capture 
probes. For this analysis, the EVs can be incubated with antibodies against proteins of interest 
(e.g. Tau, APP). We plan to use this technique for unraveling the complex interplay between 
GCs, Rab35, exosomes, and the spread of AD-related proteins in the brain. 
Finally, we observe that GC treatment in primary mouse cortical neurons does not affect 
total exosome secretion or tetraspanin profiles in purified exosome samples analyzed by 
ExoView, but that GC treatment in N2a cells increases the number of pHluorin-tagged CD63-
positive exosomes secreted. Together, these results suggest that GCs may differentially affect 
exosome secretion based on cell type and perhaps based on the tetraspanins present on these 
exosomes. Live imaging with pHluorin-tagged tetraspanins will allow us to measure how GCs 
and Rab35 expression affect exosome secretion at the single cell level. The techniques described 
in this chapter will be used to measure how stress/GCs, Rab35, and molecular pathways of 
intraluminal vesicle formation (i.e. ESCRT-mediated and ESCRT-independent ILV budding) 
impact exosome secretion and cargo in neurons, astrocytes, and microglia, and will allow our lab 
to pioneer investigations on how stress/GCs impact the intercellular spreading of AD pathology 
in the brain.   
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Chapter 6: Discussion and Future Directions 
6.1. Discussion 
Epidemiological and clinical studies indicate that lifetime stress accelerates Alzheimer’s 
Disease (AD) onset and progression (Csernansky et al., 2006; Elgh et al., 2006; Silva et al., 
2019; Vyas et al., 2016). Although stress activates cellular responses that ultimately return cells 
to homeostasis, chronic stress dysregulates these cellular mechanisms and may exacerbate 
protein trafficking deficits in neurodegenerative disease (De Kloet et al., 2005; Farley & 
Watkins, 2018). In this thesis, I demonstrate that chronic stress reduces Rab35 expression in the 
hippocampus, impacting amyloid-beta (Aβ) production via Rab35-mediated regulation of 
amyloid precursor protein (APP) endocytic recycling and the retrograde trafficking of its 
secretase BACE1 (Fig. 42). Furthermore, I show that glucocorticoids (GCs), the major stress 
hormones, disrupt Rab35-mediated APP and BACE1 trafficking pathways, and that Rab35 
overexpression blocks these effects (Fig. 42). Finally, I describe methods for measuring the 
effects of GCs and Rab35 on exosome secretion, which may contribute to AD progression by 




Figure 42. Model of how stress/GCs and Rab35 regulate APP processing. Stress/glucocorticoids (GCs) induce 
glucocorticoid receptor (GR)-mediated transcriptional downregulation of Rab35 (1). Rab35 expression also appears 
to be downregulated by aging and Aβ exposure. Our studies suggest that GCs reduce Rab35-mediated APP and 
BACE1 recycling with the plasma membrane (2), thereby increasing APP-BACE1 association in the endosomal 
network, leading to Aβ overproduction (3). On the other hand, higher levels of Rab35 expression promote APP 
internalization in a manner independent of Rab35 activation state (4) and APP recycling to the plasma membrane via 
the effector ACAP2 (5), as well as BACE1 retrograde trafficking to the trans-Golgi network via the effector OCRL 
(6). These actions decrease APP-BACE1 interaction within the endosomal network, thus reducing the production of 
Aβ and CTFs. 
 
6.1.1. Rab35 expression is reduced by stress and conditions associated with AD  
Our previous study identified 14 distinct glucocorticoid response elements (GREs) in the 
RAB35 gene, and showed that treatment with glucocorticoids (GCs) reduced hippocampal Rab35 
levels in vitro and in vivo  (Vaz-Silva et al., 2018). In this study, I found that chronic 
unpredictable stress also reduced Rab35 protein expression in the rat hippocampus, suggesting 
that the effects of chronic stress are GC- and glucocorticoid receptor (GR)-mediated. This 
finding is supported by research showing that GRs are the primary receptors involved in the 
chronic stress response (De Kloet et al., 2008). The existence of glucocorticoid response 
elements in the RAB35 gene suggests a mechanism by which stress reduces the expression of 
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Rab35 in the hippocampus: GCs activate the GR, which either binds directly to the RAB35 gene 
at one or more of the 14 GRE sites, or interacts with other transcription factors that bind RAB35 
to block or slow its transcription. Future studies can determine whether the GR directly regulates 
RAB35 through in vitro studies, by systematically mutating the 14 GREs in a cell line via 
CRISPR/Cas9 and assessing whether subsequent GC treatment affects RAB35 mRNA levels. 
Additionally, ChIP-seq and luciferase transcription assays could be used to determine which 
sequences are bound by GRs, and whether this binding causes activation or repression of these 
target genes. 
Since Rab35 mediates pathways involved in protein degradation and endosomal 
trafficking, as well as cell adhesion and migration, neurite outgrowth, and synapse formation, it 
is likely that Rab35 is target for regulation by acute stress. For instance, reducing Rab35-
mediated synaptic vesicle protein turnover might conserve cellular energy while maintaining 
synaptic function under stressful conditions. Though a brief reduction in Rab35 expression could 
allow cells to maintain their essential functions, this thesis describes how chronic stress 
downregulates Rab35 in ways that are maladaptive, leading to increased Aβ production and Tau 
accumulation. Future studies should address whether acute stress similarly downregulates Rab35 
in order to illuminate how acute versus chronic stress alter Rab35-mediated cellular processes. 
To study this, Rab35 mRNA and protein expression could be assessed following short-term GC 
treatment, and the effects of acute and chronic GC treatment on Rab35-mediated processes (e.g. 
cell cytokinesis, endocytic recycling, neuron outgrowth, and antigen cross-presentation) could be 
measured (as in Fuchs et al., 2007; Kobayashi et al., 2014; Kobayashi & Fukuda, 2013; Kouranti 
et al., 2006; Zou et al., 2009) to determine if these Rab35-mediated pathways are sensitive to 
either type of stress. If Rab35 expression and Rab35-mediated pathways are affected by acute 
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and chronic GC treatment, it is likely that Rab35’s downregulation under acute stress benefits 
cells in the short term, or helps to return them to homeostasis, while its downregulation under 
chronic stress does not. To test this concept, Rab35-mediated pathways (e.g. protein recycling 
and degradation, antigen presentation, cell division) and general cell health can be measured in 
rescue experiments wherein Rab35 is overexpressed during short- and long-term GC treatment. I 
hypothesize that Rab35 overexpression in the short term would result in disruptions to cellular 
function by blocking ‘beneficial’ acute GC effects, whereas Rab35 overexpression in the long 
term would help return the cell to homeostasis. These investigations would reveal how acute and 
chronic stress affect Rab35 expression and Rab35-mediated cellular pathways, and whether 
blocking these effects is beneficial or detrimental to cells. 
Because GR binding to DNA, and therefore gene regulation, can vary between cell types 
(Meijsing, 2015), additional investigations should determine if Rab35 is similarly downregulated 
across cell types and brain regions. Rab35 mRNA and protein levels could be measured in 
astrocyte, oligodendrocyte, and microglial cultures following treatment with GCs, as well as in 
various brain regions in GC-treated or stressed animals to determine how stress/GCs affect 
Rab35 expression across brain regions. Both neurons and astrocytes are capable of producing 
Aβ, and cellular stress has been shown to increase APP and BACE1 levels in astrocytes (Frost & 
Li, 2017). However, it is not yet known whether Rab35 controls APP and BACE1 trafficking 
pathways in astrocytes, or how stress affects Rab35 expression in these cells. Elucidating the 
effects of GCs in a cell type-specific manner will lead to a more complete understanding of how 
stress accelerates and exacerbates AD.  
An intriguing finding of this study is that Rab35 levels are decreased under conditions 
linked to APP misprocessing and AD; namely advanced age, Aβ accumulation, and exposure to 
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chronic stress and/or high levels of GCs. Aging is the greatest risk factor for AD (Querfurth & 
LaFerla, 2010), and has been linked to increased amyloidogenic APP processing (Cisternas et 
al., 2018; Jiang et al., 2010; Kimura et al., 2016), although the underlying mechanism(s) of APP 
misprocessing in the aged brain remain unknown. Here, I find that Rab35 protein levels are 
reduced in hippocampi of older vs younger rats, and that Rab35 overexpression protects against 
APP cleavage in aged animals. These results are in line with the human data, showing that Rab35 
mRNA transcripts are reduced in hippocampi and cortices from older (60-79 year old) compared 
to younger (20-39 year old) individuals, indicating a similar decrease in expression over time. 
Importantly, my findings also show that in vivo infusion of the rat brain with Aβ peptides, an 
experimental procedure that mimics early AD neuropathology and further stimulates 
amyloidogenic APP processing (Catania et al., 2009; Davis-salinas et al., 1995; Heredia et al., 
2004; Lorenzo et al., 2000), also reduces Rab35 levels. These findings are again in agreement 
with data from the human brain showing reduced Rab35 mRNA levels in hippocampi of AD 
patients compared to age-matched controls. Decreased Rab35 levels have also been observed in 
the brains of mice expressing the human ApoE4 allele (Alldred et al., 2018), the strongest 
genetic risk factor for late-onset AD (LOAD). Human studies show that ApoE4 carriers have a 
significantly increased probability of developing AD and exhibit greater accumulation of Aβ in 
their brains compared to carriers of other ApoE alleles (Huang et al., 2017). Another recent 
human study reported decreased Rab35 levels in brain-derived exosomes from athletes following 
mild traumatic brain injury (TBI) (Goetzl et al., 2019), which is known to elicit AD-like 
neuropathology and predispose individuals to AD. Together, these studies support a role for 
Rab35 in APP misprocessing precipitated by stress, aging, and AD-related conditions.  
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Interestingly, TBI and Aβ overproduction lead to the dysregulation of neural circuits, 
resulting in neuronal hyperactivity (Almeida-Suhett et al., 2015; Biegon et al., 2004; Busche & 
Konnerth, 2015; Kamenetz et al., 2003). Paradoxically, Rab35 activation also increases with 
neuronal activity (Sheehan et al., 2016), and perhaps with GC treatment (unpublished 
preliminary experiments), suggesting that Aβ generation should be downregulated by neuronal 
activity-induced activation of Rab35. However, it is unclear which effectors interact with Rab35 
under these conditions, potentially influencing specific trafficking events. For instance, 
trafficking pathways that reduce Aβ formation may not be increased by neuronal activity. Future 
experiments should explore the interplay between neuronal activity, Rab35 activation and 
downstream trafficking pathways. First, the effectors that bind Rab35 under conditions of 
increased neuronal activity can be determined by co-immunoprecipitation and mass spectrometry 
analyses. Second, the downstream targets of these effectors can be investigated to determine 
which trafficking pathways are likely impacted under these conditions. Finally, the effects of Aβ 
overproduction on these pathways could be assessed. These experiments would reveal the links 
between neuronal activity, which is enhanced by Aβ, and Rab35-mediated pathways, which tend 
to decrease Aβ generation. Together, these experiments would further elucidate the proposed 
negative feedback loop between Aβ and neuronal activity (Kamenetz et al., 2003). 
 
6.1.2. Rab GTPases are associated with AD and amyloidogenic APP cleavage 
Amyloidogenic APP processing and overproduction of Aβ are widely accepted as 
triggering events for AD pathogenesis (Mucke & Selkoe, 2012), underscoring the urgent need to 
elucidate cellular and molecular mechanisms of APP misprocessing. Importantly, previous 
studies show that Aβ is not the only pathogenic component of the amyloidogenic pathway, as 
114 
 
APP β-CTFs (the intracellular product of BACE1 cleavage), have intrinsic synaptotoxic 
properties and can promote Tau hyperphosphorylation and accumulation independently of Aβ, 
leading to synaptic degeneration and impaired cognition (Moore et al., 2015; Vaillant-Beuchot et 
al., 2021). Accordingly, and in light of the failures of clinical trials that specifically target Aβ or 
molecules involved in its cleavage (e.g. presenilin) (Huang et al., 2020), the focus of more recent 
studies has shifted to illuminating mechanisms of APP and BACE1 trafficking/interaction in the 
endosomal network (Bera et al., 2020; Tan & Gleeson, 2019), constituting the rate-limiting step 
for cleavage of APP into β-CTFs and Aβ peptides (Haass et al., 2012). Targeting the molecular 
modulators of APP and/or BACE1 intracellular trafficking could serve as a promising 
therapeutic approach against amyloidogenesis (Sun & Roy, 2017).  
Here, we show that Rab35 reduced APP cleavage and the production of Aβ40 and Aβ42 
peptides. APP amyloidogenic vs. non-amyloidogenic cleavage is determined by the intracellular 
localization of APP and its secretases (Haass et al., 2012; Yan et al., 2013), whose trafficking 
pathways are controlled by a series of Rab GTPases (Stenmark, 2009). In my screen for Rab 
GTPases that regulate APP-BACE1 interaction, I identified Rabs 6, 15 and 26 as positive 
regulators of this interaction, and Rab35 as a negative regulator. Interestingly, Rab6 levels are 
reportedly increased in brain tissue from AD patients (Scheper et al., 2007), and Rab6 was 
previously demonstrated to positively regulate Aβ but not sAPPβ production, suggesting that its 
influence on APP processing occurs via γ-secretase rather than β-secretase regulation (Udayar et 
al., 2013). However, our findings indicate a potential role for Rab6 in stimulating APP-BACE1 
interaction, indicating that it may influence more than one step of APP processing. In contrast to 
Rab6, little is known about the roles of Rabs 15 and 26 in AD etiology, although both have been 
implicated in endocytic trafficking (Chan et al., 2011; Zuk & Elferink, 2000) and Rab26 is 
115 
 
linked to autophagy (Binotti et al., 2015; Dong et al., 2018), suggesting the potential importance 
of these pathways for APP and BACE1 trafficking or interaction.  
A limitation of my approach is that overexpression of wild-type or dominant-negative 
Rab35 can act as a sink for GAPs (Rab inactivators) and GEFs (Rab activators), which are 
shared with other Rabs, thereby leading to the dysregulation of other trafficking pathways in the 
cell. However, the GC-induced decrease in Rab35 expression could also perturb these pathways 
by freeing shared GAPs, GEFs, and effectors (facilitators of trafficking events) to interact with 
other Rabs (Chaineau, et al., 2013). For instance, Rab35 shares GAPs with several Rabs, i.e. 
TBC1D13 is shared with Rabs 1, 3a and 10 (Davey et al., 2012), and TBC1D10A is shared with 
Rabs 8a and 27a (Chaineau et al., 2013; Hokanson & Bretscher, 2012; Itoh & Fukuda, 2006). 
Intriguingly, all of these Rabs have been associated with AD (Zhang et al., 2018). Rab1, which 
controls ER-to-Golgi trafficking, was shown to reduce Tau secretion in neurons (Mohamed et 
al., 2017), suggesting that Rab1-mediated trafficking pathways may be disrupted in AD. 
Hippocampal tissue from AD patients shows reduced Rab3 levels (Sze et al., 2000), suggesting 
that this Rab may function in AD-relevant trafficking pathways. Intriguingly, synaptic protein 
levels may serve as a predictor of cognitive decline (Bereczki et al., 2016), and Rab3a promotes 
synaptic vesicle transport to the active zone of neurons (Leenders et al., 2001), indicating the 
possible importance of this trafficking pathway in AD. Like Rab35, Rab8a has been shown to 
reduce amyloidogenic APP processing (Udayar et al., 2013). Investigators found that reduced 
expression of Rab8a disrupted trafficking between the trans-Golgi Network and the plasma 
membrane (Kametani et al., 2004), highlighting another protein trafficking step that may be 
important in AD. Rab8a also promotes the recycling of endocytic vesicles in concert with Arf6 
(Rahajeng, et al., 2012), a GTPase that can inhibit Rab35 activity (and reciprocally, be inhibited 
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by Rab35) (Allaire et al., 2013; Kobayashi & Fukuda, 2012; Sheehan & Waites, 2019). It is 
possible that GC/stress-mediated downregulation of Rab35 expression could lead to reduced 
Rab8a activity because their shared GAP is more available to interact with Rab8a. 
Simultaneously, Arf6 activity may be enhanced through a decrease in its Rab35-mediated 
inhibition. These modifications could result in APP misprocessing through the dysregulation of 
TGN-plasma membrane trafficking or Arf6/Rab8a-mediated endosomal recycling. Overall, these 
studies suggest that Rab35 reduction could lead to the inactivation of Rabs 1, 3, or 8 through a 
shared Rab GAP, thereby disrupting pathways mediated by these GTPases and contributing to 
endosomal protein trafficking defects in AD. 
Conversely, Rab10 protein levels were shown to be elevated in AD brains (Ridge et al., 
2018; Zhao et al., 2016), and Rab10 silencing was found to reduce Aβ secretion and Aβ42 
generation (Ridge et al., 2018; Udayar et al., 2013), indicating that Rab10 is a driver of 
amyloidogenesis. Additionally, phosphorylated Rab10 was present in hippocampal 
neurofibrillary tangles of AD patients (Yan et al., 2018), suggesting that Rab10 may regulate 
both Aβ generation and Tau trafficking. Rab10 localizes to the plasma membrane, where it 
mediates steps of the secretory pathway, possibly including neurotransmitter release (Mitra et al., 
2011), implicating these processes in AD pathomechanisms. It is conceivable that GC-induced 
downregulation of Rab35 could reduce Rab10 activation through the previously mentioned effect 
on Rab GAPs, thereby decreasing Rab10-mediated Aβ and Tau pathology. However, this effect 
is likely minimal, as loss of Rab35 has been shown to increase Aβ production (Udayar et al., 
2013), and GCs have been shown to increase Tau accumulation by disrupting Rab35-mediated 
Tau degradation (Vaz-Silva et al., 2018). 
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Together, these data suggest that numerous trafficking pathways, controlled by distinct 
Rab GTPases, are disrupted during AD. Future studies should address whether and how 
stress/GCs impact the activation of Rab GTPases linked to AD pathology, as well as those that 
share Rab35 GEFs, GAPs, or effectors. Though there are currently few assays to measure Rab 
activation, antibodies are available to detect the active/GTP-bound forms of several Rabs. 
Additionally, our lab has developed a Venus bimolecular fluorescence complementation (BiFC) 
assay for measuring Rab activation (unpublished data). In this assay, individual Rabs are tagged 
with an N-terminal fragment of Venus fluorescent protein (Rab:VN), and an effector Rab 
binding domain (RBD) is tagged with the complementary C-terminal fragment (RBD:VC). 
Using flow cytometry or fluorescence imaging to analyze the Venus fluorescence intensity in 
cells co-expressing Rab:VN and RBD:VC, we would be able to measure how GCs or Rab35 
reduction affects the activation of Rab GTPases that share GAPs, GEFs, and effectors with 
Rab35. Further analysis of the activation, expression, and localization of these Rabs in AD will 
clarify their roles in the mechanisms of amyloidogenesis and Tau pathology.  
 
6.1.3. Rab35 sorts APP and BACE1 into distinct trafficking pathways, respectively mediated by 
the effectors ACAP2 and OCRL 
Defects in the endolysosomal pathway are among the earliest cellular features of AD 
(Nixon, 2005; Orr & Oddo, 2013), suggesting that dysfunction of endosomal trafficking 
underlies AD pathogenesis. Indeed, the endosomal network is the major site of Aβ production 
(Haass et al., 2012), and Aβ accumulation is associated with enlarged multi-vesicular bodies 
(MVBs) (Willen et al., 2017), implying that amyloidogenic conditions drive APP and BACE1 
interactions in the endosomal system. Furthermore, conditions associated with decreased 
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residence of APP or BACE1 in this subcellular compartment typically inhibit Aβ generation 
(Small et al., 2017). Here, I demonstrate that Rab35 gain-of-function decreases the localization 
of both APP and BACE1 in endosomal compartments. 
For APP, this decrease occurs via Rab35-mediated stimulation of APP recycling to the 
plasma membrane (PM) through the effector ACAP2, similar to Rab35-induced fast endocytic 
recycling of other PM-associated proteins, e.g. T-cell receptors and β1 integrin (Allaire et al., 
2013; Kobayashi & Fukuda, 2013; Patino-Lopez et al., 2008). Not only does this fast recycling 
pathway decrease APP colocalization with BACE1 in endosomes, but it also boosts levels of 
APP at the PM, likely promoting cleavage by α-secretase and thus preventing amyloidogenic 
processing.  
A particularly interesting result in my experiments is that APP endocytosis from the 
plasma membrane appears to be driven by Rab35 independently of its activation state and of the 
effector ACAP2, since both wild-type (WT) and dominant-negative (DN) Rab35 increased APP 
internalization, and ACAP2 knockdown did not attenuate this effect. It is likely that the observed 
Rab35-induced APP internalization occurs via clathrin-mediated endocytosis because Rab35 
sorts proteins internalized through this pathway (Donaldson et al., 2016). DN Rab35 has been 
shown to inhibit the clathrin-dependent pathway (Dutta & Donaldson, 2015), suggesting that DN 
Rab35 might shift APP internalization to the clathrin-independent pathway without affecting the 
total rate of APP endocytosis. Follow up studies could test this concept by measuring the 
dependence of APP endocytosis on clathrin in cells expressing WT Rab35 or DN Rab35. If 
clathrin knockdown decreases APP internalization in the presence of WT Rab35 but not DN 
Rab35, this finding would indicate that APP internalization occurs through a clathrin-dependent 
pathway under conditions of increased Rab35 activation, and a clathrin-independent pathway 
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under conditions of reduced Rab35 activation. In this case, the dependence of APP 
internalization on dynamin could be tested, as dynamin-mediated endocytosis has been proposed 
as a clathrin-independent APP internalization pathway (Mayor et al., 2014; Saavedra et al., 
2007).  
Alternatively, Rab35 may be driving APP internalization in both its GTP- and GDP-
bound states. In some instances, effectors have been found to interact with GDP-bound Rabs 
(Shirane & Nakayama, 2006), suggesting that it is possible for ‘inactive’ Rabs to drive 
trafficking events. Identifying binding partners of DN Rab35 vs. WT Rab35 by co-
immunoprecipitation and mass spectrometry would help determine if there is an effector or other 
interacting protein that binds with similar affinity to active and inactive forms of Rab35. Follow-
up experiments could test whether any such protein regulates APP internalization. These studies 
would reveal not only how Rab35 controls APP internalization, but also whether inactive Rab35 
can facilitate cellular trafficking events. 
For BACE1, the decrease in endosomal localization results from its Rab35-mediated 
retrograde trafficking to the TGN through the effector OCRL, similar to Rab35/OCRL-mediated 
mannose-6-phosphate receptor retrograde trafficking (Cauvin et al., 2016). Interestingly, two 
genes identified as risk factors for LOAD, namely VPS35 and VPS26, encode protein 
components of the retromer complex that regulates the retrograde trafficking of proteins from the 
endosomal network to the TGN. Mutation of these genes is hypothesized to disrupt the 
retrograde trafficking of APP (Zhang et al., 2016), and potentially BACE1 (Wang et al., 2012), 
increasing APP-BACE1 interaction in endosomes and therefore stimulating Aβ production. 
Although I did not see any effect of Rab35 gain-of-function on the retrograde trafficking of APP, 
I did observe a significant stimulation of BACE1 retrograde trafficking, thus reducing BACE1 
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residence time within endosomes as well as its exposure to APP. Rab35 may be acting in concert 
with the retromer to promote BACE1 retrograde trafficking, or it may be mediating a parallel 
pathway. To address this question, BACE1 retrograde trafficking could be measured under 
conditions of retromer knockdown with Rab35 overexpression. If Rab35 overexpression 
counteracts the effects of retromer knockdown, then Rab35-mediated BACE1 retrograde 
trafficking likely occurs through a separate pathway. Additionally, if Rab35 mediates a parallel 
retrograde trafficking pathway, then knocking down both Rab35 and components of the retromer 
should have additive effects on blocking BACE1 retrograde trafficking compared to Rab35 or 
retromer knockdown alone. 
My finding that Rab35 sorts APP and BACE1 into separate pathways through its 
interaction with distinct effectors, ACAP2 and OCRL, encourages future examination to 
determine at which step of intracellular trafficking this Rab35 sorting occurs (e. g. protein 
internalization, exit from early/recycling/late endosomes). Since efficient recycling from 
endosomes typically requires Rab35 (Allaire et al., 2010; Marat & McPherson, 2010), and we 
provide evidence that Rab35 drives both APP and BACE1 internalization but only APP 
recycling (via ACAP2), it is likely that this sorting of APP and BACE1 occurs at the endosomal 
level. The differential intracellular localizations of ACAP2 and OCRL further support this 
concept, as ACAP2 primarily localizes to the cell periphery (Allaire et al., 2013; Jackson et al., 
2000), while OCRL localizes to the plasma membrane as well as to endosomes and the TGN, 
where it regulates receptor recycling through its hydrolysis of the lipid phosphatidylinositol 4,5-
biphosphate (PtdIns(4,5)P2) (Cauvin et al., 2016; Festa et al., 2019; Mondin et al., 2019; Sharma 
et al., 2015; Vicinanza et al., 2011). Although Rab35 typically recruits OCRL after clathrin-
coated vesicle scission (Cauvin et al., 2016), suggesting that Rab35/OCRL-mediated protein 
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sorting could occur immediately upon protein internalization, Rab35 and OCRL have been 
shown to colocalize at several endosome types (Cauvin et al., 2016), suggesting that OCRL may 
initiate BACE1 sorting into the retrograde pathway from early or recycling endosomes. Future 
experiments can utilize super-resolution microscopy to investigate where in the cell ACAP2 and 
OCRL colocalize with APP and BACE1, together with gain- and loss-of-function experiments to 
determine which distinct steps of APP and BACE1 trafficking involve Rab35-mediated sorting 
through these effectors. Together, these investigations would reveal where along these pathways 
Rab35 downregulation by GCs or other stimuli could disrupt APP and BACE1 trafficking.  
 
6.1.4. Rab35-mediated APP and BACE1 trafficking – implications for Arf6-mediated pathways 
Another important trafficking molecule that acts in concert with Rab35 is the small 
GTPase Arf6. Rab35 and Arf6 have been shown to reciprocally inhibit one another’s activation 
in a variety of cellular processes, including cell migration, vesicle secretion, and cytokinesis 
(Allaire et al., 2013; Kobayashi & Fukuda, 2012; Sheehan & Waites, 2019). Further, Rab35 and 
Arf6 have been shown to regulate clathrin-mediated and clathrin-independent endocytosis, 
respectively (Donaldson et al., 2016), suggesting that the observed effects of Rab35 on APP and 
BACE1 internalization may result from Rab35-mediated inactivation of Arf6.  
In the studies described in this thesis, I show that Rab35-regulated APP recycling is 
dependent on ACAP2, an Arf6 GAP that Rab35 recruits to the plasma membrane to facilitate 
Arf6 inactivation and reduce clathrin-independent endocytosis (Allaire et al., 2013; Donaldson et 
al., 2016; Egami et al., 2011; Jackson et al., 2000; Kobayashi & Fukuda, 2012, 2013; Mayor et 
al., 2014). Overexpression of Rab35 in my experiments may thus reduce Arf6-mediated 
internalization and recycling pathways by recruiting ACAP2 to Arf6-positive endosomes and 
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deactivating Arf6 (Allaire et al., 2013). However, to date, a role for Arf6 in APP internalization 
or recycling has not been reported, though it has been implicated in APP macropinocytosis, 
which sends APP directly to the lysosome, bypassing early and late endosomes (Tang et al., 
2015). Dominant-negative Arf6 has been shown to reduce Aβ generation by blocking lysosomal 
transport, indicating that Arf6 promotes APP amyloidogenic processing occurring in lysosomes. 
Furthermore, immunostaining for Arf6 in hippocampi of AD patients and age-matched controls 
showed that its expression increases with AD (Tang et al., 2015), providing further correlation 
between Arf6 activity and amyloidogenesis. Since Arf6 inhibits Rab35 activation, it is possible 
that increased Arf6 expression promotes amyloidogenic trafficking pathways by reducing Rab35 
activity. Manipulating Arf6 expression or activity and monitoring APP fast recycling and 
BACE1 retrograde trafficking would reveal whether Arf6 disrupts these Rab35-mediated 
trafficking pathways. Moreover, using the techniques described in Tang, et al., future studies can 
measure whether altering Rab35 expression affects APP macropinocytosis and investigate 
whether Rab35/ACAP2-mediated APP trafficking reduces Arf6-controlled macropinocytosis, 
providing an additional mechanism for reducing Aβ generation. 
It is conceivable that Rab35 also regulates BACE1 trafficking through Arf6, which has 
been reported to facilitate BACE1 endocytosis from the PM into the endosomal network 
(Sannerud et al., 2011). Thus, Rab35 overexpression could reduce BACE1 endocytosis via Arf6 
inhibition, preventing BACE1 interaction with APP in endosomes. To test this, Arf6 activation 
can be compared under our control and Rab35 overexpression conditions using an Arf6-GTP-
specific antibody. Additionally, BACE1-Arf6 colocalization could be measured when Rab35 is 
overexpressed or knocked down to determine whether Rab35 influences Arf6-mediated BACE1 
trafficking pathways. Reducing BACE1-Arf6 interactions should reduce Arf6-mediated BACE1 
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internalization, but in the current study, I found that steady-state cell-surface BACE1 levels 
remained unchanged upon Rab35 overexpression, indicating that Rab35 does not inhibit BACE1 
endocytosis. This finding suggests that Rab35 drives BACE1 retrograde trafficking without 
interfering with Arf6-mediated endocytosis. My studies show that Rab35 regulates distinct 
trafficking pathways of APP and BACE1, and studying the interplay between Rab35 and Arf6 in 
these trafficking pathways would further illuminate how these cellular mechanisms are impacted 
by conditions associated with AD.  
 
6.1.5. Stress/GCs disrupt Rab35-mediated trafficking pathways 
The studies in this thesis show that exposure to chronic stress and high levels of GCs 
reduces Rab35 levels and stimulates the pro-amyloidogenic trafficking of APP and BACE1, 
while Rab35 overexpression attenuates these effects. These findings are in line with previous 
studies demonstrating that stress and GCs trigger APP misprocessing and Aβ production 
(Catania et al., 2009; Green et al., 2006; Jeong et al., 2006; Srivareerat et al., 2009), and offer a 
novel, Rab35-driven mechanism for how stress/GCs precipitate amyloidogenesis. Combined 
with our previous work showing the critical role of Rab35 in Tau sorting and degradation (Vaz-
Silva et al., 2018), these findings suggest that Rab35 serves as a molecular link through which 
chronic stress/GCs trigger both major AD pathomechanisms: Aβ production and accumulation of 
hyperphosphorylated Tau (Carroll et al., 2011; Catania et al., 2009; Green et al., 2006; 
Sotiropoulos et al., 2008). Interestingly, the effects of Rab35 on APP and Tau are through 
distinct mechanisms, as Rab35 stimulates Tau degradation via the endolysosomal pathway (Vaz-
Silva et al., 2018), whereas it modulates the fast endocytic recycling and retrograde trafficking of 
APP and BACE1, respectively.  
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A substantial limitation of my studies is that they capture one hour of cellular trafficking 
events that occur after 24 hours of treatment with a high dose of glucocorticoids. In the human 
brain, chronic stress occurs on the timeline of months or years, suggesting that these effects may 
be more pronounced because the cellular pathways are disrupted for much longer periods of 
time. Nevertheless, these results provide a mechanism by which high levels of GCs/stress can 
lead to the generation of excess Aβ, and they provide the groundwork for investigating how 
stress/GCs affect the intercellular spread of Aβ and Tau. Recently, Rab35 and ACAP2 were 
implicated in the formation of tunneling nanotubes that connect distant cells and enable passage 
of vesicles, organelles, and molecules (Bhat et al., 2020). Tunneling nanotubes may be involved 
in the cell-to-cell spread of proteins such as APP, Aβ, or Tau, though it is unclear whether this 
would have a pathogenic or protective effect on neurons. Investigations exploring how GC-
induced changes in Rab35- and ACAP2-mediated trafficking affect neuronal health and the 
spread of these proteins could lead the way to studying the role that tunneling nanotubes play in 
the intercellular spread of AD proteins.  
 
6.2. Future Directions  
6.2.1. Stress/GCs and Rab35 in glial contributions to AD 
My studies motivate investigations of intra- and inter-cellular trafficking pathways for 
APP, BACE1, and Tau proteins in glia, which are responsible for maintaining brain homeostasis. 
Astrocytes, microglia, and oligodendrocytes express glucocorticoid receptors, and GCs have 
been shown to reduce astrocyte density and function, increase microglial activation, and 
modulate oligodendrocyte proliferation (Jauregui-Huerta et al., 2010). Glia quickly react to 
changes in the brain, including stress, infection, and injury (Jauregui-Huerta et al., 2010); and 
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there is mounting evidence that microglia, astrocytes, and oligodendrocytes undergo 
morphological and functional changes in AD (Alibhai et al., 2018; Dzamba et al., 2016), making 
them a prime suspect for accelerating and exacerbating AD in response to homeostatic 
perturbations. Indeed, microglia and astrocytes can internalize Aβ (Mohamed & Posse De 
Chaves, 2011; Wang et al., 2017) and facilitate the endolysosomal clearance of AD proteins 
(Ries & Sastre, 2016; Wong, 2020), a process that could be disrupted by stress. Furthermore, 
astrocytes may secrete Aβ (Frost & Li, 2017), increasing the spread of AD pathology. To 
determine how stress affects the endocytosis and possible clearance or spread of Aβ and Tau, 
future studies should measure Aβ production in GC-treated vs. control astrocytes; as well as Aβ 
and Tau internalization, degradation, and potential secretion by glial cells treated with GCs. 
Investigating how stress affects glial function in AD will provide a more complete understanding 
of this complex disease. Though Rab35 is not expressed at high enough levels for consistent 
detection in glial cells of the hippocampus (Thul et al., 2017; Uhlen et al., 2015; 
http://www.proteinatlas.org), its role in several glial processes has been documented. Namely, 
Rab35 regulates the integrity of glial morphology (Coutinho-Budd et al., 2017), oligodendrocyte 
differentiation and myelination (Miyamoto et al., 2014; Sawade et al., 2020), and glial exosome 
secretion (Blanc & Vidal, 2018; Hsu et al., 2010). These studies suggest that Rab35 controls 
intracellular pathways in glia, and future studies should explore Rab35’s role in Aβ clearance or 
generation pathways in glial cells.   
 
6.2.2. Stress/GC effects on exosome secretion  
Stress/GCs promote the spread of amyloid and Tau pathology (Dong & Csernansky, 
2009; Sotiropoulos et al., 2019; Vyas et al., 2016), but it is unclear which mechanisms drive this. 
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Exosomes, small extracellular vesicles (EVs), function in intercellular communication and have 
been linked to AD (Lim et al., 2019; Perez-Gonzalez et al., 2012; Rajendran et al., 2006; Saman 
et al., 2012), suggesting a method for the intercellular transmission of AD-associated proteins. 
Indeed, BIN1, a risk gene associated with late-onset AD, is involved in the spread of Tau through 
exosomes (Crotti et al., 2019). Rab35 and GCs impact exosome secretion and cargo (Abrami et 
al., 2013; Chen et al., 2018; De Jong et al., 2012; Fruhbeis et al., 2013; Gauthier et al., 2017; 
Harmati et al., 2019; Hsu et al., 2010; Luarte et al., 2020; Yang et al., 2019), and our lab plans to 
uncover how GCs and/or Rab35 influence exosome secretion and contents in brain cell types 
(neurons, astrocytes, microglia), and whether they are a means for intercellular Aβ and Tau 
transmission. 
In this thesis, I describe methods for biochemically isolating and measuring exosome 
secretion in neurons, microglial cells, and astrocytes to investigate the effects of stress/GCs on 
exosome release and the spread of AD pathology. We conclude that size exclusion 
chromatography isolates extracellular vesicles from conditioned medium more efficiently than 
ultracentrifugation, and we show the feasibility of three exosome measurement techniques: 
nanoparticle tracking analysis, ExoView on-chip interferomentry and tetraspanin profiling, and 
live cell imaging of exosome secretion using pHluorin reporters. Using these techniques in our 
preliminary data, we show that tetraspanin profiles vary among cell types, and that microglia 
may be the primary producers of extracellular vesicles among cell types of the brain. 
Furthermore, I show that GC treatment does not affect exosome production in primary cortical 
neurons, but that it increases the number pHluorin-CD63-tagged exosomes secreted by N2a cells. 
These results provide preliminary evidence that GCs may alter exosome release in a cell-type 
specific and/or tetraspanin-marker specific manner, but additional studies are needed to 
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determine how GCs affect exosome secretion in different cell types, and whether GCs 
differentially affect exosomes generated by different pathways (e.g. ESCRT-, tetraspanin-, 
ceramide-mediated).  
Our result showing that microglial cells produce more EVs than primary neurons, 
astrocytes, and N2a cells suggest that microglia may be essential in exosome-mediated 
transmission of AD pathology. Recent studies show that microglia phagocytose Tau and release 
non-degradable forms of the protein in exosomes, playing an important role in Tau propagation 
(Asai et al., 2015; Spanic et al., 2019; Vogels et al., 2019; Wang et al., 2017). Furthermore, 
microglia are capable of endocytosing Aβ, though it is unclear whether this degrades Aβ or 
packages it for transmission (Mohamed & Posse De Chaves, 2011). There is conflicting evidence 
showing both increased and decreased Aβ load with deficiency of complement proteins 
(Hemonnot et al., 2019), which signal microglia to phagocytose Aβ (Fu et al., 2012). 
Furthermore, microglia are among the first responders to homeostatic changes in the brain (Bilbo 
& Stevens, 2017), making them a particularly important target for our research on stress and AD.  
Though GCs are anti-inflammatory in many contexts (Cain & Cidlowski, 2017), stress 
and GCs can prime the brain for inflammation, leading to enhanced microglial activation and 
phagocytosis in response to immune challenges (Fonken et al., 2018). Tau and Aβ aggregates 
can serve as such challenges, activating microglia and provoking pro-inflammatory cytokine 
production (Guillot-Sestier & Town, 2013; Stancu et al., 2019). Thus, stress/GCs could 
precipitate a vicious cycle of Aβ and Tau secretion, microglial activation, and Aβ/Tau 
phagocytosis and exosomal release by microglia, accelerating the propagation of AD pathology. 
Interestingly, Rab35, ACAP2, and Arf6 are involved in protein endocytosis by microglia through 
their mutual activation/inhibition cycles (Egami et al., 2015), suggesting that stress/GC-induced 
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reduction of Rab35 could dysregulate microglial phagocytic properties. Astrocytes can also 
internalize Tau and Aβ (Mohamed & Posse De Chaves, 2011; Perea et al., 2019), and chronic 
stress has been found to alter their morphology in the hippocampus (Jauregui-Huerta et al., 2010; 
Naskar & Chattarji, 2019), suggesting that astrocytes may also play a role in AD pathology 
propagation under stress.  
In future experiments, we will characterize how GCs affect the potential spread of AD-
related proteins through exosomes by measuring the concentration of secreted exosomes from 
GC-treated neurons, astrocytes, and microglia. To delve deeper into exosome characterization, 
we will use loss-of-function and/or inhibitors against ESCRT components, nSmase2, and 
tetraspanins to determine which pathways of exosome cargo loading are most important for GC-
induced spread of AD proteins. Furthermore, we will address whether glial Tau and Aβ 
endocytosis lead to the intercellular spread of these proteins by identifying exosome contents 
using ExoView on-chip technology to probe for Aβ and Tau, and proteomics and microRNomics 
to determine other exosome cargo. Finally, we will measure Aβ and Tau concentrations in 
exosome-purified samples and exosome-depleted media to determine whether transmission of 
pathological proteins occurs through both exosomal and non-exosomal pathways, and whether 
GCs affect which pathways dominate. These experiments will reveal the contributions of 
neurons and glial cells to the intercellular propagation of Aβ and Tau, and further uncover the 
effects of stress on AD-associated protein trafficking pathways.  
 
6.2.3. Exosomes as biomarkers 
Exosomes are a prime biomarker candidate because they can carry proteins, lipids, and 
RNAs indicative of neurodegenerative diseases, are able to cross the blood-brain-barrier, are 
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resistant to proteases and RNases, and can be detected in cerebrospinal fluid, blood, and urine 
(DeLeo & Ikezu, 2018; Quek & Hill, 2017; Saman et al., 2012; Xiao et al., 2017). Indeed, 
investigators were recently able to detect AD 10 years prior to clinical onset by measuring Tau 
and Aβ levels in brain-derived exosomes isolated from plasma of AD patients (Fiandaca et al., 
2015). In another study using brain-derived exosomes isolated from plasma, the levels of Aβ and 
phosphorylated Tau in exosomes could predict the progression from mild cognitive impairment 
to AD (Winston et al., 2016). Because exosomes were recently implicated in the propagation of 
Tau and Aβ pathology in animal models (Asai et al., 2015; Sardar Sinha et al., 2018), we 
hypothesize that exosomes carrying AD proteins may reflect stress-induced brain pathology, 
offering prognostic potential. Neuron-derived exosomes have also been shown to carry RNA-
binding proteins (RBPs) and microRNAs (miRNAs) (Quek & Hill, 2017; Xiao et al., 2017; You 
& Ikezu, 2019), which are increasingly linked to neurodegenerative mechanisms (Apicco et al., 
2019; Xiao et al., 2017). Recently, a panel of 7 miRNAs from plasma exosomes has been found 
to predict AD diagnostic status with 83-89% accuracy (Lugli et al., 2015). Intriguingly, recent 
work from our collaborator’s lab indicates that stress/GCs alter the cellular machinery for RNA 
metabolism, leading to the accumulation of RBPs and the formation of  stress granules (Silva et 
al., 2019). These findings suggest that chronic stress and elevated GCs may impact the 
composition of miRNAs and RBPs in exosomes. By using proteomics and microRNomics in our 
isolated EVs to address whether exosome cargo (e.g. proteins and miRNAs) reflect brain 
pathology driven by stress/GCs, and which cell types (neurons, astrocytes, microglia) contribute 
to these differences, our studies will provide a more complete picture of how stress/GCs affect 
trafficking pathways of Aβ and Tau secretion and propagation in neurons, microglia, and 
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Collectively, the studies described in this thesis identify Rab35 as a molecular link 
between chronic stress/high levels of GCs and Aβ generation. I show that Rab35 controls APP 
and BACE1 intracellular trafficking pathways, reducing their interaction in endosomal 
compartments and subsequent Aβ production. Stress/glucocorticoids (GCs) disrupt these 
pathways, promoting amyloidogenesis, and Rab35 overexpression blocks this. Finally, I describe 
methods for studying how stress/GCs and Rab35 affect exosome secretion and intercellular 
transmission of Aβ and Tau in neurons, astrocytes, and microglia. Altogether, these findings 
support multiple roles for Rab35 in the intracellular trafficking of AD-relevant proteins and 
suggest that downregulation of Rab35 may precipitate amyloidogenesis. These studies highlight 
Rab35’s potential relevance for AD brain pathology and suggest that additional work 
investigating its roles in AD and aging-related intracellular pathways could open novel 
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